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Summary 
 
Glucocorticoids (GC) are important regulators of permissive and adaptive physiology. 
Exogenous and endogenous GC excess (Cushing’s syndrome) can lead to a range of 
metabolic complications including increased adiposity, fatty liver, high blood pressure and 
muscle wasting. This increases the risk of developing type 2 diabetes, metabolic syndrome 
and cardiovascular disease. GC levels are regulated by a number of homeostatic mechanisms. 
Importantly, intracellular GC sensitivity is controlled by the enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), which reactivates GC to increase their local availability. 
11β-HSD1 activity in adipose tissue has been shown to be deregulated in a range of metabolic 
disorders in which GC levels are generally normal. I now hypothesise that 11β-HSD1 is a 
critical regulator of  adipose tissue sensitivity to circulating GC excess, driving a fast forward 
mechanism of intracellular GC excess, and that through 11β-HSD1 depletion adipose tissue 
will be desensitised to GCs and resist metabolic deregulation.   
Using 11β-HSD1 global and adipose tissue-specific KO mice in a model of GC excess 
I demonstrated that 11β-HSD1 indeed mediates the adverse metabolic effects of GC excess on 
a global scale. Specifically, adipose tissue 11β-HSD1 activity plays a major role in 
determining the hepatic manifestation of GC excess.  
            I further investigated brown adipose tissue (BAT) in the context of GC excess. 
I demonstrate that 11β-HSD1 regulates BAT activity and mitochondrial function, possibly 
suppressing BATs thermogenic potential. I extended our studies to examine the potential for 
white adipose tissue (WAT) to assume markers of thermogenic and mitochondrial function in 
the context of 11βHSD1 and GC excess. The data suggest that 11β-HSD1 may act to suppress 
the potential of WAT to assume a ‘BAT-like’ profile, particularly in the face of GC excess.      
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These data show that 11β-HSD1 loss of function in mice confers a protective 
phenotype in the face of GC excess and highlights the important role of this enzyme in 
mediating the metabolic phenotype associated with GCs. The effects of GC excess on adipose 
tissue are profound and extend beyond the usual description of lipid and glucose regulation. 
Indeed these data support the idea that GCs can influence BAT and WAT thermogenic 
potential and may help to extend what I understand about the metabolic dysregulation in 
humans suffering from GC excess syndromes. This therefore highlights 11β-HSD1 as an 
exciting potential target for the treatment for the metabolic disease associated with GC excess. 
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1. Chapter 1 – General introduction 
1.1 The clinical problem 
The global prevalence of obesity is on the increase, leading to ever escalating costs and 
burdens on health care systems to cope with this modern day epidemic. On its own obesity 
poses a striking medical problem, however it is additionally linked to a myriad of other 
diseases. These include metabolic syndrome and type 2 diabetes; the incidences of which are 
also on the increase. It is therefore highly desirable to define novel approaches to decrease the 
incidence of obesity and its related metabolic disorders. 
1.1.1 Obesity 
Obesity is as an accumulation of adipose tissue which is of sufficient levels to impair health 
(WHO, 2014). The incidence of obesity has escalated to a global epidemic with as many as 
30% of adults in the US being obese according to the US Department for Health, with 
complications substantially contributing to health care costs and mortality, placing a huge 
financial burden on the economy (Stryjecki et al 2011). Current figures estimated by the 
World Health Organisation (WHO) place 1.6 billion adults as overweight and at least 400 
million of them clinically obese. The increasing trend in obesity is shown in figure 1-1. 
Within the US alone the cost associated with obesity is around $100 billion per year. 
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Figure 1-1 Rising incidence of obesity 
The level of obesity worldwide has been increasing over the last 50 years and this trend is 
expected to continue. Further to this the increasing incidence of obesity is not limited to one 
country or area; it is a global issue with global consequences. Cited from Drugs Today 2006, 
42(Suppl. C): 5. 
 
Obesity is the result of a greater degree of energy intake as opposed to energy expenditure 
(Rohner-Jeanrenaud et al 2015). It is a consequence of the ingestion of energy-dense foods, a 
decrease in physical expenditure, and an inability of the central nervous system (CNS) to 
correctly suppress appetite, this leads to an increase in the concentration of white adipose 
tissue (Cypress et al 2010; Wickelgrem et al 1998).  
Despite obesity being driven by environmental factors there is evidence to suggest that 
inherited factors also affect human fat mass. It has been demonstrated that genetic factors play 
a role in the development of obesity highlighting that the burden of obesity is not limited 
solely to the effects of the environment (Faroogi et al 2008). 
In addition to the direct complications of obesity, it represents a major risk factor for 
the development of insulin resistance, and has been implicated in a wide range of pathological 
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states such as hyperlipidaemia, type 2 diabetes, and cardiovascular disorders (Wickelgren et al 
1998).  These complications are more frequently attributed to central obesity, in particular at 
the visceral level, as compared with generalised obesity (Kissebah et al 1994). It has been 
demonstrated that accumulation of visceral fat strongly increases the risk of cardio metabolic 
disease, whereas peripheral fat accumulation is relatively protective (Gabriely et al 2002; 
Jensen et al 2008). Studies have shown that for a given body mass index, there is an increased 
mortality rate if adipose tissue is located centrally (visceral or omental) as opposed to general 
obesity (Bjorntrop et al 1991). 
1.1.2 Type 2 diabetes 
Type 2 diabetes is a metabolic disorder characterised by hyperglycaemia. The prevalence of 
type 2 diabetes is higher within women than men, and represents a growing disease burden 
with estimates of approximately 171 million cases worldwide in 2000, and 366 million cases 
predicted by 2030 (Wild et al 2004). Type 2 diabetes consequently has become a worldwide 
epidemic and is closely associated with the metabolic syndrome (MS). 
Initial treatment for type 2 diabetes is an increase in exercise and dietary modifications; 
however, if this does not produce a clinical improvement then medications may be required. 
However the current medications available come with selection of associated negative side 
effects. Metformin is the first-line treatment choice for the majority of patients with type 2 
diabetes, however it does not improve glycaemic control in all patients and can cause 
gastrointestinal upset (Bolen et al 2007). Thiazolidinedione’s such as rosiglitazone are good 
insulin sensitises but can lead to an increase in body weight, cause fluid retention and induce 
congestive heart failure (Bolen et al 2007). In addition sulphonylureas such as gliclazide can 
lead to weight gain and are prone to causing hypoglycaemia (Bolen et al 2007). Due to this 
improved medications with decreased levels of side effects are highly desirable. 
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1.2 Adipose tissue 
Adipose tissue represents an active endocrine organ (Rosen et al 2006). There are three 
separate types of adipose tissue within the body: white, brown and brite. Within the body 
adipocytes maintain lipid homeostasis and energy balance, this is achieved by storing 
triglycerides and releasing free fatty acids as a response to fluctuating energy needs. In 
addition, adipocytes produce and secrete signalling molecules, such as leptin and TNFα. 
(Halaas et al 1995; Hotamisligil et al 1994). 
White adipose tissue (WAT) is located primarily within three anatomically distinct 
areas; subcutaneous, dermal and intraperitoneal. WAT stores energy in the form of 
triglycerides during times of energy excess and releases fatty acids in times of need, thereby 
regulating whole body energy homeostasis. Brown adipose tissue (BAT) is located primarily 
perinatally within humans but has also been found in the interscapular, subclavicular, cervical, 
auxiliary and paravertebral regions (Sacks et al 2013). BAT releases energy in the form of 
heat in response to a given stimulus. Brite adipocytes are located within WAT and are 
induced by a variety of environmental stimuli such as cold exposure, or β-adrenergic receptor 
agonists. Brite adipocytes exhibit similar molecular and functional features to brown 
adipocytes, are multi-ocular and express uncoupling protein 1 (UCP1). 
1.2.1 Adipose cell lineage 
It has recently been demonstrated that brown and white adipocytes originate from separate 
cell lineages, where primary brown cell cultures are phenotypically distinct from white 
preadipocytes, and a number of developmental genes are differentially expressed between the 
two adipocyte depots (Timmons et al 2007). 
A selection of experiments have shown that brown and white adipose cells are not 
sister cells, and that brown adipocytes are in fact more closely related to myocytes where both 
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originate from a common precursor (Seale et al 2008; Atit et al 2006). This relationship 
includes a common early transcriptional programme, which is suppressed early in 
differentiation (Timmons et al. 2007). 
Myogenic genes including Myf5 have been shown to be expressed within brown 
preadipocytes and skeletal muscle, but are absent from white adipose cells (Seale et al 2008). 
In addition distinct expression patterns have been shown for several developmental genes, 
including tbx15, hoxc8, and hox7 between brown and white preadipocytes. Further, white 
adipocytes and not brown adipocytes or skeletal muscle express Tcf21, which suppresses 
myogenesis. (Timmons et al 2007). 
The link between brown adipocytes and myocytes occurs early in differentiation 
where the expression of MyoD is lost one day into differentiation in brown adipocytes. This 
could provide an explanation for the decreased expression of myogenin leading to the down-
regulation of the skeletal muscle gene expression pattern within brown adipocytes. This 
decrease in MyoD has been shown to be a consequence of the action of SIRT1 which 
deacetylates MyoD (Timmons et al 2007). 
The similarities between the myocyte and the brown preadipocyte demonstrate the 
distinct origin for BAT compared to WAT and provides an explanation as to why brown 
adipocytes ultimately specialise in lipid catabolism rather than storage, similar to oxidative 
skeletal muscle tissue (Timmons et al 2007). 
Further studies have shown that classical white adipocytes contain two types of cells, 
pure white adipocytes and a more brown-like cell type, named brite cells which have the 
ability to express UCP1 which until recently was believed to be a unique marker for brown 
adipocytes. However the full the molecular characteristics of brown adipocytes are not shared 
with brite cells (Petrovic et al 2009; Guerra et al 1998; Seale et al 2008). Brite cells are not 
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derived from the Myf-5 lineage like traditional brown adipocytes. They have been shown to 
have a related but distinct gene expression profile from brown adipose cells (Long et al 2014; 
Petrovic et al 2009). 
Brite cells are most commonly seen following cold acclimatisation, which induces 
neither an increase in DNA content nor an increase in adipocyte number (Petrovic et al 2009). 
This supports the notion that a distinct pool of progenitors in the white adipose tissue depot 
can give rise to beige cells that are similar but not identical to brown fat cells (Wu et al 2012). 
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Figure 1-2 Adipose tissue cell lineage 
From mesenchymal stem cells there is the production of either Myf
+
 or Myf
-
 precursor cells. 
Myf+ precursor cells proceed to either a brown pre adipocyte or a myoblast, which become 
brown adipocytes or myocytes respectively. The Myf
-
 precursor cells become white pre 
adipocytes which can go on to develop into white adipocytes or brite adipocytes. There is also 
the possibility given the correct stimulus for the inter conversion of white adipocytes and brite 
adipocytes. 
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1.2.2 Key adipocyte genes 
There are a selection of key adipocyte genes which play central roles in the development and 
function of adipose tissue. 
1.2.2.1 PRDM16 
PRDM16 is cold inducible, and plays a crucial role within the biology of adipocytes 
(Murholm et al 2009). It primes and triggers brown adipocyte differentiation and is involved 
in the expression of key brown adipocyte markers (Murholm et al 2009). Silencing of 
PRDM16 within brown precursor cells has been shown to blunt the induction of typical 
brown fat marker genes, like UCP1, and PGC-1α (Murholm et al 2009). PRDM16 also acts as 
a co-regulator to activate PGC-1α and together they drive the molecular phenotype of brown 
fat cells (Seale et al 2007). Furthermore, expression of PRDM16 is correlated with 
mitochondrial biogenesis, and uncoupled cellular respiration (Seale et al 2007).  
Over-expression of PRDM16 leads to protection from obesity on a high-fat diet due to 
an increase in energy expenditure which is not related to physical activity, demonstrating a 
key role for PRDM16 in energy expenditure (Seale et al 2014). Further these mice also 
demonstrate an increased glucose tolerance and improved insulin sensitivity, in addition they 
expressed greater levels of brown fat selective genes compared to wild-type (WT) when 
exposed to a high fat diet (HFD) (Seale et al 2014). Overall this demonstrates that the action 
of PRDM16 in adipose tissue increases energy expenditure to oppose weight gain and 
increase the disposal of glucose (Seale et al 2014). 
1.2.2.2 PPARγ 
The transcription factor PPARγ is highly expressed in both BAT and WAT and its expression 
is further induced upon cold exposure (Kelly et al 1998; Murholm et al 2009). PPARγ is 
crucial to the differentiation and function of brown and white adipocytes, and expression of 
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PRDM16 within WAT triggers the formation of brown adipose like cells (Tzu-Ann et al 
1996; Guerra et al 1998; Seale et al 2007). Expression of PRDM16 induces a dramatic 
increase in the volume of interscapular BAT within depots (Tzu-Ann et al 1996). Further to 
this PPARγ cooperates with PGC1-α to induce the expression of UCP1 and other typical 
brown adipose markers (Tzu-Ann et al 1996; Tiraby et al 2003; Pisani et al 2011; Watanabe et 
al 2008; Murholm et al 2009).  
1.2.2.3 PGC-1α 
PGC-1α is a cold inducible co-activator of nuclear receptors (Wu et al 1998; Puigserver et al 
1998). PGC-1α is crucial to brown adipogenesis, where it is involved in UCP1 expression and 
mitochondrial biogenesis (Murholm et al 2009). Adipocytes which express PGC-1α 
demonstrate an elevated expression of key genes pivotal to mitochondrial function and 
adaptive thermogenesis, which includes an elevation in the expression of genes central to 
oxidative phosphorylation (Puigserver et al 1998; Tiraby et al 2003; Wu et al 1998; Uldry et 
al 2006). 
It has been demonstrated that with insulin resistant states there is a decrease in both 
PPARγ and PGC-1α and a resultant reduction in adipose tissue mitochondrial content (Tiraby 
et al 2003). PGC-1α is also reduced by high fat feeding, indicating PGC-1α’s involvement in 
mediating high-fat diet-induced decreases in adipose tissue mitochondrial proteins 
(Sutherland et al 2008). 
Therefore an increase in expression of PGC-1α could lead to both adaptive 
thermogenesis and fatty acid oxidation. These increases could consequently lead to desirable 
decrease in adipose mass (Tiraby et al 2003). 
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1.2.3 Brown adipose tissue (BAT) 
 
In rodents and humans, brown adipose is predominantly found in the interscapular and 
paraspinal regions, and the quantity of BAT shows a decrease as mammals go from the 
neonatal to adult stage (Himms-Hagen et al 2001; Rohner-Jeanrenaud et al 2015). Brown 
adipocytes are multi-ocular adipocytes rich in iron containing mitochondria with densely 
packed cristae expressing UCP1, which gives brown adipose its characteristic brown colour. 
BAT also contains a high number of capillaries due to its need for oxygen, and is critical for 
energy equilibria (Nicjolls et al 1984; Cypress et al 2010). The structure of the brown 
adipocyte is shown in figure 1-3. 
 
 
Figure 1-3 Brown adipocyte 
Brown adipocytes contain a nucleus and multiple small lipid droplets, encased with 
cytoplasm. They also have a vast number of mitochondria and are highly vascularised. 
 
BAT utilises lipids and carbohydrates to generate heat by using UCP1 to uncouple electron 
transport from oxidative phosphorylation, thus playing an active role in energy expenditure 
and fatty acid oxidation (Nicjolls et al 1984; Cannon et al 2008; Stier et al 2014). Being 
located in the mitochondrial inner membrane, UCP1 acts as a proton transporter to abolish the 
proton gradient, the driving force of adenosine triphosphate (ATP) synthesis (Watanabe et al 
2008). Thus the free energy conserved in the proton gradient is dissipated as heat (Watanabe 
et al 2008). This is the mechanism utilised to produce heat in BAT, and is referred to as non-
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shivering thermogenesis, which is in contrast to shivering thermogenesis in muscle tissues 
(Watanabe et al 2008). This non-shivering thermogenesis is highly important in neonatals and 
small rodents, whose muscle tissues are not well developed (Watanabe et al 2008). It is also 
utilised in hibernating animals. 
BAT plays a pivotal role in the modulation of body fat stores due to its role in energy 
expenditure. Because of this BAT has potential in combating obesity and diabetes. Further 
evidence to support this is that mice deficient in BAT develop obesity with insulin resistance 
and other metabolic abnormalities linked to obesity (Enerback et al 2010; Lowell et al 1993; 
Hamann et al 1995). 
Recent studies using non-invasive imaging technologies such as 
18
fluoro-labeled 2-
deoxy-glucose positron emission tomography (
18
FDG-PET) scanning and magnetic resonance 
imagery (MRI) scanning show adult humans possess significant amounts of active brown fat 
deposits (Cypress et al 2009).  
1.2.4 Incidence of brown adipose tissue in humans 
BAT is found mostly in new-borns and hibernating animals. It was initially thought that BAT 
was only evident within new-borns and that its presence decreases with age as a consequence 
of a decreased need for thermogenesis. However recent studies have conflicted with this 
initial thought and have shown the existence of BAT within adult humans, Cypress et al 2009 
demonstrated this using 18F-FDG PET-CT scans, and showed that BAT was most commonly 
located in the cervical-suprasclavicular depot. Estimates of BAT mass and activity from FDG-
PET studies suggest that humans have, on average, 50–80 g of BAT (Peirce et al, 2014). In 
addition Sharp et al 2012 have shown that these UCP1-positive brown fat cells located within 
adult humans have molecular characteristics more common to murine beige cells rather than 
classical brown adipose cells. This therefore demonstrates conflicting opinions on the true 
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nature of the UCP1 positive cells discovered, with some sources claiming them to be true 
BAT cells whereas other sources claiming they are brite cells. It may well transpire that there 
are detectable levels of BAT within adult humans and that the presence of brite cells can be 
induced either environmentally or experimentally. 
Recent studies have demonstrated that chronic cold acclimation in human subjects 
increased the quantity of metabolically active BAT, thus leading to an increase in the 
oxidative capacity of the BAT (Blondin et al 2014; Lichtenbelt et al 2015). Further to this it 
has been shown that cold-induced increases in thermogenesis have been accompanied by a 
decrease in body weight (Yoneshiro et al 2013). These results are in keeping with data 
showing a physiological role of BAT in whole-body energy expenditure, glucose 
homeostasis, and insulin sensitivity in humans during prolonged cold exposure 
(Chondronikola et al 2014). This leads brown adipose tissue to have a potential in protecting 
against obesity (Cypress et al 2009). 
1.2.5 Thermogenesis 
BAT represents the main site for adaptive thermogenesis. BAT responds to changes in 
environmental factors, for example diet and cold temperatures, where it increases energy 
expenditure.  An increase in diet is sensed by the brain, which, to avoid excessive weight gain 
triggers a decrease in food intake and an increase in energy expenditure (Lowell et al 2000). 
When exposed to a cold environment there is uncoupling of ATP synthesis and the production 
of heat. 
The two most common forms of thermogenesis seen within BAT are non-shivering 
thermogenesis and diet-induced thermogenesis, which are induced initially by the sympathetic 
nervous system (SNS) (Rothwell et al 1979). BAT requires ATP for cell maintenance, 
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therefore thermogenesis in BAT must be controlled in response to necessity (Watanabe et al 
2008). 
1.2.6 Non-shivering thermogenesis 
The action of non-shivering thermogenesis occurs within thermogenically active target 
tissues, and is initiated by exposure to cold temperatures (Landsberg et al 1984; Himms-
Hagen et al 1984; McMillian et al 2015). During active thermogenesis BAT becomes highly 
vascularised, due to the increased need for blood supply (Timmons et al 2007). The initial 
stimulus of the cold activates the sympathetic nervous system (SNS) which leads to the 
release of catecholamines including neural-derived noradrenaline which stimulates the 
predominantly fat specific β3-adrenergic receptor, and α2 adrenergic receptors (Himms-
Hagen et al, 1991; Collins et al 1997; Cannon et al 2004). These receptors signal through 
cyclic-AMP (cAMP), which is produced via adenylate cyclase, leading to activation of 
protein kinase A (PKA) (Watanabe et al 2008; Valente et al 2014). PKA up regulates the 
expression of PGC1-α, which is highly expressed in brown adipose and activates the adaptive 
thermogenic gene programme which includes up regulation of UCP1, genes in the 
mitochondrial transport chain, mitochondrial biogenesis, inhibition of apoptosis, fatty acid 
oxidation, and increased oxygen consumption through co-activation of transcription factors 
such as PPARγ and NRF1, and an overall increase in thermogenic capacity of the animal 
(Puigserver et al 1998; Himms-Hagen et al 1990; Cannon et al 2004; Wu et al 1999; Collins 
et al 1997). Further to this, activation of PKA also leads to the activation of lipolysis and the 
release of free fatty acids (FFAs) which enter the mitochondria where they act as an energy 
source. FFAs are used as fuel to supply free energy for thermogenesis and also to activate the 
function of UCP1 (Krauss et al 2005).  
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Early on following cold exposure, mobilisation of fatty acids from WAT is used as a 
primary source for activation of BAT as opposed to the breakdown of fat depots within BAT 
(Deiuliis et al 2010). Under conditions of long-term cold exposure where there is limited 
dietary glucose and circulating fatty acids, the TAG in BAT will likely be hydrolysed by 
ATGL to generate the required energy substrate for non-shivering thermogenesis (Deiuliis et 
al 2010). 
 
Figure 1-4 Non-shivering thermogenesis 
When exposed to cold or following a meal there is activation of the sympathetic nervous 
system. This leads to the release of noradrenaline which is able to bind to the B-adrenergic 
receptor. This binding stimulates the production of cAMP via adenylate cyclase. cAMP then 
activates protein kinase A which is able to activate lipolysis and result in the release of free 
fatty acids which are transported into the mitochondria, or increase the expression of UCP1. 
 
In non-shivering thermogenesis there is also an increase in BAT cell proliferation and 
differentiation following cold stimulation (Cannon et al 2004; Himms-Hagen et al 1990; 
Bukowiecki et al 1982). Several reports demonstrate that enlargement of BAT induced by 
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cold exposure is caused by an increase in the number of mature brown adipocytes, these 
results indicate that cold stimulation induces a series of gene expression changes that are 
needed for proliferation and differentiation of brown adipocytes precursor cells in BAT 
(Bukowiecki et al 1982). 
The mitochondrial UCP1 expressed in adaptive thermogenesis is a proton channel 
protein in the inner mitochondrial membrane which functions to uncouple electron transport 
from oxidative phosphorylation by promoting a proton leak across the mitochondrial 
membrane, and utilising lipids and carbohydrates to generate heat by converting the 
electrochemical potential of the mitochondria into heat instead of ATP (Houstek et al 1978; 
Rousset et al 2004; Nicjolls et al 1984). When BAT generates heat it leads to unrestrained 
oxidation by drawing lipids and carbohydrates from outside the cell (Watanabe et al 2008). 
The idea that UCP1 might be involved in regulating energy balance and the abnormalities in 
brown fat might result in obesity was first proposed by Rothwell and Stock in 1979 (Rothwell 
et al 1979). 
Reflecting the physiological uncoupling of oxidative phosphorylation BAT 
mitochondria have a high oxidative capacity, a high content of cytochrome oxidase, but a low 
content of ATP synthetase (Houstek et al 1978). 
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Figure 1-5 Uncoupling of ATP synthesis by UCP1 
UCP1 is able to uncouple ATP production via ATP synthase into the production of heat. In 
doing so it utilises the proton gradient set up by the mitochondrial electron transport chain to 
produce heat. 
 
The key role of PGC1-α in adaptive thermogenesis has been shown in PGC-1α 
deficient mice that cold sensitive with poor expression of UCP1 (Lin. J et al 2004). In 
addition the BAT appears morphologically abnormal, with abundant accumulation of large 
lipid droplets, reminiscent of WAT (Lin et al 2004). 
An important issue which is often overlooked is that normal animal house conditions 
(18-22ᵒC) are a chronic thermal stress to mice (Golozoubova et al 2004). To maintain their 
body temperature in these conditions the mice increase their metabolism and thus their food 
intake to around 50%-60% above basal levels. It is hypothesised that this thermal stress 
induced by standard animal house conditions may influence the outcome of metabolic studies 
(Golozoubova et al 2004). 
Many studies have been conducted over the past three years on BAT which have led to 
vast increase in our understanding of the role of BAT in adult humans. This has led to a 
substantial increase in belief for the possible use, or manipulation of BAT to increase energy 
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expenditure and thereby aid in regulating body weight and ameliorating metabolic diseases 
(Tam et al 2012). 
1.2.7 Effect of age on brown adipose tissue 
It is not disputed that ageing is strongly negatively correlated with BAT mass. Using 
immunohistochemistry or PET/CT it can be seen that there is a decrease in BAT following 
adolescence and a vast decrease after 80 years of age (Sacks et al 2013). However whether 
BAT function deteriorates with age is an area of debate. It has been proposed that with 
increasing age there is a decline in the metabolic effect of BAT (Tam et al 2012). This has 
been further demonstrated by Saito et al 2009, who showed that there is a higher incidence of 
BAT following cold exposure in a younger cohort. The decrease in mitochondrial biogenesis 
and function with age has been linked to a decrease in BAT activity (Graja et al 2015). 
Contradictory to these findings is a study by Van Marken Lichtenbelt et al 2009, who showed 
that there was no correlation between BAT activity and age, the study showed that the 
decrease in BAT activity which is seen with increased age is related to a decrease in the 
quantity of BAT rather than a decrease in activity. It is clear that with age there is a marked 
decrease in BAT and this will consequentially lead to a decrease in BAT activity, however 
there is conflict as to whether the decrease in BAT activity seen with age is solely attributable 
to a decrease in BAT mass or whether there are other factors which play a part. This is an area 
which requires further investigation and offers up the potential of a therapeutic if it transpires 
that BAT function is impaired with age, as preventing this may prove metabolically 
beneficial. 
1.2.8 Potential role of brown adipose tissue in obesity prevention/therapeutic target 
BAT has emerged as a possible therapeutic target in the prevention and treatment of obesity, 
type 2 diabetes and the MS. This is due to its role within energy expenditure, where it utilises 
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fatty acids for the production of heat. In support of this Vijgen et al 2001 reported an increase 
in BAT activity after weight loss in obese patients given gastric banding surgery, suggesting 
the effectiveness of successful recruitment of BAT in body fat reduction in humans.  
Within rodent studies an increase in BAT has been shown to promote energy expenditure, 
reduce adiposity, and protect mice from diet-induced obesity (Almind et al 2007). 
Furthermore BAT ablation leads to obesity in response to a HFD (Tateishi et al 2009). The 
interest in BAT is of further importance due to the recent discovery of its presence within 
adult humans, although there is conflicting data as to whether it is true BAT within humans or 
brite cells. 
1.3 White adipose tissue (WAT) 
WAT represents the majority of the adipose tissue in the human body, within humans it 
constitutes up to 20% of the body weight in men and around 25% of the body weight in 
women. White adipocytes consist of a large lipid droplet surrounded by a thin layer of 
cytoplasm and the nucleus, thus demonstrating uni-ocular morphology. The primary use of 
WAT is in the storage of energy where it stores triglycerides within individual adipocytes for 
use in times of nutrient shortage, this has evolutionary enabled humans to survive for longer 
periods between meals, where energy is stored mainly as triglycerides and released as fatty 
acids during fasting periods (Rohner-Jeanrenaud et al 2015).  Further WAT contributes to 
whole body insulation, and is also an active endocrine organ where it releases FFAs and 
adipokines such as leptin, resistin and adiponectin. 
There are many white adipose depots within the body, which can be separated into two 
areas with highly varying biology; visceral and subcutaneous adipose. An increase in visceral 
adipose tissue leads to an increased potential for cardiometabolic disease, conversely 
accumulation of peripheral adipose offers relative protection (Wamill et al 2011). Further 
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visceral adipose tissue is likely to contribute most strongly to the metabolic consequences of 
obesity and has a higher density of GC receptors, which may contribute to visceral adipose 
tissue being less insulin sensitive (Morton et al 2004; Wamil et al 2011; Jensen et al 2008). 
There are also differences between these two locations in their response to GCs where 
visceral adipose has an increased expansion in response to increased plasma cortisol or 
adipose 11β-HSD1 (Wamill et al 2011). 
1.3.1 Differences between white adipose tissue depots 
Studies have shown that there are profound differences between subcutaneous and visceral 
adipose, in both the functioning of these depots and also the metabolic consequences of their 
accumulation. There is a different expression of genes in subcutaneous and mesenteric fat 
depots, showing differences between the depots on a molecular scale (Wamil et al 2011). 
After the initial observations of Vague et al in 1947, it is well known that the distribution of 
adipose tissue is central in determining the risk of developing metabolic complications, more 
so than the degree of excess adipose tissue. This is supported by Fujioka et al 1991 who 
showed that reduction of visceral adiposity is accompanied by improvements in intermediary 
metabolism. 
Studies by Gabriely et al 2002 showed that the removal of two intra-abdominal 
adipose depots prevents age-dependent insulin resistance and substantially delays the onset of 
glucose intolerance and diabetes, whereas removal of subcutaneous adipose tissue does not 
demonstrate this effect. 
When compared to subcutaneous adipocytes, visceral adipocytes have higher basal 
and adrenaline-stimulated levels of intracellular cAMP (Ostman et al 1979; Wahrenberg et al 
1989; Richelseon et al 1991). In addition to classical white cells described earlier WAT also 
Chapter 1 – General introduction 
 
37 
 
contains cells which have a brown-like characteristic and have been termed brite cells. These 
cells have been shown to be up regulated following exposure to cold. 
1.4 Brite adipose tissue 
The term brite (brown in white) adipose tissue has been coined to describe a subset of cells 
situated within classical WAT depots that show a genetic fingerprint similar to that of classic 
brown adipocytes. These multi-ocular brown fat-like cells are detectable at low numbers 
within subcutaneous and visceral WAT depots of primary cultures of mice maintained at 
ambient temperatures with no prior cold exposure, and show levels of mRNA encoding 
UCP1, Cidea, Cox7a1 and PGC1-α, although their expression is at lower levels than that seen 
in classical BAT tissue (Wu et al 2012), this has also been demonstrated in humans (Tiraby et 
al 2003). However once stimulated via cAMP stimulation, brite significantly increases its 
levels of thermogenic genes including; UCP1, mitochondrial genes Cox7a1 and Cox8b, and 
transcriptional regulators PRDM16 and PGC-1α, to similar levels as that seen in classical 
brown fat cells (Wu et al 2012; Barbatelli et al 2010; Walden et al 2012; Cousin et al 1992). 
This change is more prominent in subcutaneous adipose compared to visceral adipose 
following cold exposure (Barbatelli et al 2010; Lee et al 2012). This ability of cells within 
classical WAT depots to express UCP1 has been recognised for 30 years as first demonstrated 
by Young et al in 1984. 
Cold-acclimatised pre-adipocytes in WAT have slightly more pronounced brown 
characteristics often with large mitochondria (Barbatelli et al 2010). This demonstrates that 
brite cells have the capacity to switch between an energy storage and energy dissipation 
phenotype (Wu et al 2012). Further Young et al 1984 showed similar changes in brite cells 
following cold acclimatisation, and also that in mice maintained at standard animal house 
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conditions (23°C) there was existence of brown fat cells in traditional white fat cell pads in 
mice, due to chronic stimulation by cold exposure (Young et al 1984; Seale et al 2014). 
Brite cells however differ from classical BAT cells in that they are not derived from a 
myf5-positive lineage, and their appearance is through a process known as browning, and are 
termed beige or brown-in-white (brite) cells (Seale et al 2011). 
A strong characteristic of brite cells is its high levels of UCP1 expression, where the 
induction of UCP1 mRNA upon browning can be up to 100-fold increase (Nedergaard and 
Cannon et al 2013). Despite this strong induction of UCP1 expression the expression levels 
are still <20% of those found within classical brown depots (Nedergaard and Cannon et al 
2013; Walden et al 2012). It has therefore been questioned whether there will be sufficient 
UCP1 within brite depots to mediate significant thermogenesis as the amount of UCP1 is the 
rate-limiting for thermogenesis as studied in brown-fat mitochondria (Shabalina et al 2010). 
However Nedergaard et al 2013 demonstrated that the UCP1 was thermogenically functional, 
however the contribution from inguinal mitochondria was one-third that of interscapular 
brown-fat mitochondria, indicating that classical BAT would still predominate in 
thermogenesis. 
The expression of certain genes is also influential in the development of brite 
adipocytes. Firstly in the absence of PRDM16 the differentiation of most brown fat-selective 
genes, including UCP1, Cidea and Cox8b are decreased (Seale et al 2011). These results 
indicate that PRDM16 is required in mature adipocytes for the full activation of the brown fat-
like gene program (Seale et al 2011). Further PPARγ activation enables white preadipocyte 
cultures to acquire brown adipocyte-like characteristics. (Petrovic et al 2010). This activation 
is achieved through PGC-1α which coactivates the PPARγ2/RXRa heterodimer to stimulate 
Chapter 1 – General introduction 
 
39 
 
UCP1, cytochrome c, fatty acid oxidation enzyme and other brown adipocyte marker 
expression (Tiraby et al 2003). 
These brite cells have been clearly distinguished from classical brown cells: their 
expression pattern of various genes, including the absence of myogenic factors, clearly 
distinguishes them from the classic brown adipocytes where they have a molecular signature 
distinct from those of genuine brown adipocytes (Petrovic et al 2010; Pisani et al 2011). 
Due to their gene expression pattern varying from that of classical brown adipocytes, 
it is clear that brite cells do not emanate from a few precursors of classic brown adipocytes 
resident in the precursor population, (Tiraby et al 2003), it has been shown that cold 
acclimatisation favours direct transformation of white to brown adipocytes in WT, a process 
termed trans differentiation (Barbatelli et al 2010). However only a subset of cells within 
WAT can attain brown characteristics (Petrovic et al 2010). This has led to the hypothesis that 
brite cells are the result of precursor cells within WAT which are able to differentiate 
following a given stimulus (Tiraby et al 2003). 
1.4.1 Potential role of brite as a therapeutic target 
The white/brown plasticity of adipose tissues may have considerable medical implications, 
since the brown-like phenotype seems to correlate with a reduction in the development of 
obesity and diabetes in rodent models (Murano et al 2009; Bachman et al 2002). Further an 
increase in expression of PGC-1α within white adipose may lead to expression of UCP1 and 
fatty acid oxidation (Tiraby et al 2003). This may consequently lead to a desirable decrease in 
adipose mass. Further Tsukiyama-Kohora et al 2001 have shown that there is an increase in 
brite cells within WAT in KO strains. These strains also demonstrate resistance to diet 
induced obesity and also an improvement in their glucose metabolism. Similar studies by 
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Hansen et al 2004; Christian et al 2005; Wang et al 2008; Romanatto et al 2009 have shown 
much the same. 
Glucocorticoids (GC) have also been demonstrated to have a role in obesity where when 
in excess they have been shown to contribute towards metabolic syndrome, Cushing’s disease 
and insulin resistance. 
1.5 Glucocorticoids 
Since their elucidation (Nobel Prize 1950) as potent anti-inflammatory agents (Hench et al 
1950), GCs have become one of the most widely prescribed drugs in medical practice for 
many conditions including asthma, chronic obstructive pulmonary disease and inflammatory 
disease. Further, GCs have also been exploited for their antiproliferative and antiangiogenic 
actions for the treatment of cancers (Vilasco et al 2011). GCs also perform a regulatory role 
within metabolic and homeostatic processes where they are central in the stress response. 
However GCs also have many diverse side effects such as contribution to obesity, Cushing’s 
syndrome, metabolic syndrome and insulin resistance.  
GCs are an important class of adrenocorticosteroids that effect their action by binding 
to the GR. Within humans cortisol represents the active GC with cortisone its inactive 
precursor. Both cortisol and cortisone are synthesised from cholesterol within the Zona 
fasciculate (zF) of the adrenal cortex, where cortisol is released in circadian and ultradian 
rhythms (Russell et al 2010). The release of cortisol from the adrenal glands is regulated by 
the hypothalamic-pituitary-adrenal (HPA) axis. The availability of natural GCs in tissues is 
also regulated locally by the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme, 
which was first discovered by Amelung et al 1953. 
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1.5.1 Cushing’s syndrome 
Cushing’s syndrome (CS) is named after Harvey Cushing, who documented a patient with an 
excess of GC in 1912. Greater than 99% of the cases of CS that are diagnosed are a 
consequence of the prescription of excessive quantities of exogenous therapeutic GC. Classic 
signs and symptoms of CS include weight gain, menstrual irregularity, depression, decreased 
memory, bruising, facial plethora, abdominal striate, and increased centripidal, 
supraclavicular, or dorsocervical fat.  
1.5.2 Therapeutic use of glucocorticoids 
Synthetic GCs are frequently prescribed to treat a myriad of ailments and resemble natural 
GCs. Prednisolone, dexamethasone, and budesonide are among the commonly prescribed 
GCs within medical practice. Synthetic GCs differ from natural GCs by both their potency 
and metabolic clearance, furthermore unlike natural GCs, synthetic GCs do not bind 
corticosteroid-binding globulin and are thereby not susceptible to their regulation of available 
levels, further they are not susceptible to inactivation by 11β-HSD2, therefore there is an 
increase in GC availability (Krasner et al 1999; Clark et al 2012). 
Adverse effects of long-term GC therapy in supraphysiological doses include 
suppression of the HPA axis, and GCs represent the most common cause of drug-induced 
diabetes (Krasner et al 1999; Lansang et al 2011).  The mechanism by which GCs cause 
diabetes is predominantly through insulin resistance rather than decreased insulin production 
(Lansang et al 2011). 
1.5.3 Adrenal glands and glucocorticoid production 
The adrenal glands are an endocrine gland located at the top of the kidneys, and weigh about 
10-15g in humans (Mitani et al 2014). The first report on the physiological role of the adrenal 
gland was presented by Thomas Addison in 1855 (Addison et al 1855).  Their primary 
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function is in the production of hormones in response to stress where they release 
corticosteroids such as cortisol, and catecholamine’s such as adrenaline and noradrenaline. 
Further to this they also produce androgens within their innermost cortical layer.  
Both of the adrenal glands have a distinct structure composing of two structurally and 
functionally distinct endocrine tissues, the outer adrenal cortex and the inner medulla (Orth et 
al 1992). The adrenal cortex is mainly responsible for the production of corticosteroids while 
the medulla is mainly responsible for the production of adrenaline and noradrenaline. The 
cortex is further subdivided into concentric zones, the Zona glomerulosa (zG), the zone 
fasiculate (zF) and the Zona reticularis (zR), the zG is responsible for the secretion of 
mineralocorticoids, the zF for glucocorticoids, and the zR for androgens (Arnold et al 1866; 
Mitani et al 2014). The structure of the adrenal gland is shown in figure 1-6. 
 
Figure 1-6 Structure of the adrenal gland 
The adrenal gland is split into two distinct sections, the adrenal cortex and the adrenal 
medulla. The adrenal cortex can be further subdivided into the Zone Reticularis, the Zona 
Fasiculate and the Zona Glomerulosa. The Zona Reticularis is primarily responsible for the 
production of androgens, the Zona Fasiculate for the production of glucocorticoids and the 
Zona Glomerulosa for the production of miaralocorticoid. The adrenal medulla is responsible 
for the production of catecholamines. Adapted from medicalook.com. 
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1.5.4 Cortisol and cortisone 
Cortisol and cortisone are central GCs within humans where they impact a variety of 
cardiovascular, metabolic, immunologic, and homeostatic functions. Cortisol is released 
following stimulation of the HPA axis and also via the oxo-reductase action of 11β-HSD1. 
Cortisone is primarily generated within the kidneys by 11β-HSD2 from active cortisol. 
Cortisol is secreted at levels of around 15 mg/day into the blood stream, when in the 
blood stream 96% of cortisol exists bound to plasma proteins; 90% to corticosteroid binding 
protein (CBP) and 6% to serum albumin, with only a small amount being unbound and 
therefore biologically active (Koteleytsev et al 1997; Lepsin et al 2011). The levels of cortisol 
are highest in the morning and following a meal and are at their lowest in the evening 
(Rosmond et al 1998).  Cortisone and 11-DHC have low affinities to bind to CBG and 
albumin, and therefore exist mostly in the free form. This enables them to enter target cells 
and undergo conversion to their active 11b-hydroxy forms via 11β-HSD1 (Lepsin et al 2011; 
Slaunwhite and Sandberg et al 1959; Cope and Black et al 1958). 
1.5.5 Hypothalamic-pituitary-adrenal axis 
The hypothalamic-pituitary-adrenal (HPA) axis is a complex set of interactions between the 
hypothalamus, the pituitary gland and adrenal glands, controlled via ultradian and circadian 
rhythms, with the purpose of regulating the levels of cortisol within the body (Russell et al 
2010; Carnes et al 1989). 
Central regulation of the HPA axis occurs within the hypothalamus where a given 
stressor initiates the release of corticotrophin-releasing factor (CRF) and arginine vasopressin 
(AVP), which are produced within the paravocellular neurons of the hypothalamic 
periventricular nucleus (PVN). These act upon the corticotrophs of the anterior pituitary gland 
(Warne et al 2009) to initiate the secretion of adrenocorticotrophic hormone (ACTH) into the 
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adrenal circulation (Carnes et al 1989). ACTH acts on the adrenal cortex to promote the 
biosynthesis of cortisol from cholesterol, and its subsequent release into the circulation 
(Chrousos et al 1995). The HPA axis is shown is figure 1.7. 
The HPA axis is tightly regulated by negative feedback mechanisms. Binding of GCs 
to central GRs, leads to inhibition of the HPA axis (Rosmond et al 1998). This inhibition 
involves signalling networks at the pituitary, hypothalamus and hippocampus, resulting in 
inhibition of CRH, AVP, and ACTH secretion in a negative feedback loop by which the HPA 
axis inhibits its own secretion (Watts et al 2005; Eijsbouts and Murphy et al 1999). The 
importance of this negative feedback loop is highlighted in patients treated with exogenous 
GCs, where there is inhibition of endogenous GC release resulting in atrophy of the adrenal 
cortex (Rang et al 2001). 
Obesity leads to dysregulation of the HPA axis, resulting in lower morning cortisol 
levels (Wajchenberg. B. L. 2000; Rosmond. R. 1998). This is due to an increase in output of 
cortisol due to central obesity which activates the negative feedback loop. 
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Figure 1-7 The hypothalamic-pituitary-adrenal axis 
The hypothalamus produces CRH and AVP in response to a given stimulus. These induce the 
production of ACTH from the anterior pituitary. ACTH then stimulates the adrenal cortex to 
release glucocorticoids. These glucocorticoids produced act as part of a negative feedback 
loop to inhibit the hypothalamic-pituitary-adrenal axis and thus prevent the over production 
of glucocorticoids. 
 
1.5.6 Glucocorticoid receptor 
The biological action of GCs is mediated through intracellular glucocorticoid receptors (GR). 
The GR is expressed in almost every cell and regulates genes controlling development, 
metabolism, and the immune response (Pujols et al 2002). Therefore appropriate control of 
GR expression is critical for maintenance of cellular and organismic homeostasis. 
The GR is the product of a single gene; nuclear receptor superfamily 3, group C, 
member 1 (nr3c1), which is located on chromosome 5q31-32 in humans (Kadmiel et al 2013). 
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Two human isoforms of the GR have been identified, termed GR-α and GR-β, which 
originate from the same gene by alternative splicing of the GR primary transcript. GR-α is the 
predominant isoform of the receptor and the one that shows steroid biding activity, GR-β is 
located within inflammatory cells (Hollenberg et al 1985; Pujols et al 2002). 
Unbound GR is located within the cytoplasm of the cell, where it is bound to 
chaperone proteins such as heat shock protein 90 (Kadmiel et al 2013). Upon the binding of 
GC to the receptor the GR undergoes a conformational change and the GR-GC complex is 
translocated to the nucleus. Within the nucleus the GR-GC complex mediates either 
transactivation or transrepression of target genes, by binding to specific DNA motifs termed 
glucocorticoid response elements (GREs) (Pujols et al 2002). Once bound to GREs the 
GC/GR complex is able to recruit and activate transcriptional co-activator molecules such as 
CREB binding protein (CBP), steroid receptor coactivator-1 (SRC-1) and other factors, 
allowing for the transcription of GC responsive genes (Adcock et al 2004). The mechanistic 
action of the GR is shown in figure 1-8. 
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Figure 1-8 Action of the glucocorticoid receptor 
Upon the binding of glucocorticoid to the glucocorticoid receptor there is dissociation of 
hsp90 and the glucocorticoid: glucocorticoid receptor complex is then translocated into the 
nucleus. Once within the nucleus the GR-GC complex binds to GREs. From here it recruits an 
array of transcriptional co activators including SRC-1 and CBP which aid leads to gene 
transcription. 
 
1.5.7 Action of glucocorticoids 
GCs may exert their effects by increasing the expression of anti-inflammatory genes, 
including interleukin-10 and interleukin-1 receptor antagonist. This increase in transcription is 
likely to be the result of an inhibitory relationship between activated transcription factors and 
activated GRs (Barnes et al 1998). 
GCs are catabolic in nature, they release energy in response to stress in order to 
service the increase in metabolic demand (Peckett et al 2011; Hermanowski-Vosatka et al 
2005). GCs exert multiple effects on lipid metabolism within adipose tissue, where they 
enhance adipose lipolysis. GCs lead to an increase the quantity of fatty acids in circulation by 
increasing caloric and dietary fat intake and the hydrolysis of circulating lipids via lipoprotein 
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lipase activity. This leads to patients with CS demonstrating elevated serum free fatty acids, 
triglycerides, and cholesterol. The increase in fatty acid content that results is then available 
for ectopic fat distribution (Hermanowski-Vosatka et al 2005; Peckett et al 2011).  
In addition GCs increase hepatic gluconeogenesis and antagonise the effects of 
insulin. This is achieved by directly inhibiting β-cell insulin secretion in the pancreas and 
peripheral glucose uptake in muscle. This results in a decrease in glucose utilisation by cells 
and leads to elevated circulating levels of glucose, and insulin resistance (Andrew et al 1999; 
Lepsin et al 2011; Hermanowski-Vosatka et al 2005). Further to this GCs promote pre 
adipocyte conversion to mature adipocytes, resulting in hyperplasia of the adipose tissue 
(Peckett et al 2011). 
1.5.8 Glucocorticoids in disease 
GC excess confers a negative phenotype, including the manifestation of central obesity and 
type 2 diabetes. GCs lead to an increase in lipolysis and therefore an increase in circulating 
fatty acids. These fatty acids are therefore available for deposition around the body leading to 
an increase in adiposity (Peckett et al 2011). There is a preference for deposition centrally 
leading to central obesity, which is metabolically less favourable. This is due to their being an 
increased level of GC receptors within visceral adipose (Lee et al 2014). In addition to this an 
increase in GCs leads to an increase in hepatic gluconeogenesis and antagonistic effects on 
insulin secretion. This leads to a decrease in glucose utilisation, an increase in the circulatory 
levels of glucose and ultimately the potential for the development of type 2 diabetes (Londero 
et al 2015). 
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Figure 1-9 Effects of glucocorticoids on the body 
An excess of glucocorticoids affects the liver by increasing gluconeogenesis and lipogenesis, 
in addition it leads to an increase in proteolysis and lipolysis in skeletal muscle with a 
decrease in glucose uptake. Within adipose an increase in glucocorticoids leads to increases 
in glucose uptake, lipolysis, preadipocyte differentiation and adipogenesis. 
 
1.6 Pre-receptor glucocorticoid metabolism 
Biochemical evidence indicates the existence of two distinct forms of 11β-HSD, one with a 
higher Km for GC substrates and a preference for NADP
+
 as a cofactor (11β-HSD1) and a 
second (11β-HSD2) with a lower Km and preference for NAD+ as a cofactor (Naray-Fejes-
Toth et al 1991). Studies have revealed that certain human tissues were able to inter-convert 
cortisol and cortisone utilising the 11β-HSD enzymes, including the kidney, placenta and liver 
(Amelung et al 1953; Bush et al 1968). Continuing observation revealed that the direction of 
GC inter-conversion varied between tissues, with kidney and placenta possessing greater 
dehydrogenase (cortisol to cortisone) activity, whilst the liver presented greater reductive 
(cortisone to cortisol) activity (Tomlinson et al 2004). The inter-conversion of active and 
inactive GCs by 11β-HSD1 and 11β-HSD2 are shown in figure 1-9. 
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Figure 1-10 11β-HSD1 and 11β-HSD2 activity 
11β-HSD1 is a bi-directional enzyme which functions to interconvert inactive cortisone to 
active cortisol and is located in glucocorticoid receptor rich tissues. It primary functions as 
an oxo reductase, where it produces active glucocorticoid cortisol in the presence of NADPH. 
11β-HSD2 is a uni-directional enzyme which functions to convert active cortisol to inactive 
corticosterone and is located within mineralocorticoid rich tissues. 
 
1.6.1 11β-hydroxysteroid dehydrogenase type 1 
Intracellular GC metabolism is regulated at the pre-receptor level by 11β-HSD1 (Rabbitt et al 
2002). 11β-HSD1 mRNA is highly expressed in mouse liver, kidney and lung, with lower 
expression in brain sub regions and gonads (Rejan et al 1995). It is a 34kD NADPH 
dependent bi-directional enzyme anchored in the endoplasmic reticulum (ER) membrane, 
with its catalytic domain projecting into the ER lumen. 11β-HSD1 is a member of the short-
chain dehydrogenase/reductase (SDR) super-family, possessing both oxo reductase and 
dehydrogenase activity. 
11β-HSD1 can be divided into four functionally important regions (Hosfield et al 
2005). The trans-membrane domain (residues 1-23 in humans), which allows the enzyme to 
attach to the ER lumen, the nucleotide binding domain (Rossmann fold), which represents the 
catalytic site, and the c-terminal domain which is involved in the oligomerisation of the 
enzyme (Hosfield et al 2005).  
Chapter 1 – General introduction 
 
51 
 
11β-HSD1 acts predominantly as an oxo reductase, thus increasing intracellular GC 
levels by converting circulating inert 11-dehydrocorticosterone (11-DHC) (Cortisone in man 
(Seckl et al 2001)) into active corticosterone (Cortisol in man (Seckl et al 2001)) through oxo-
reductase activity in most intact cells, thus amplifying intracellular GC levels in select tissues 
and increasing local GC action (Tomlinson et al 2001; Napolitano et al 1998). 
11β-HSD1 activity requires a supply of NADPH which acts as a rate limiting cofactor, 
and thus the direction of catalysis is primarily driven by the intraluminal concentration of 
NADP
+
 and NADPH. The NADPH utilised by 11β-HSD1 is supplied by Hexose-6-phosphate 
dehydrogenase (H6PDH), therefore the functional direction of 11β-HSD1 is dependent on the 
action of H6PDH that supplies the reduced cofactor, driving the oxo reductase activity of 11β-
HSD1 (Atanasov et al. 2004b). Figure 1-10 illustrates the control of 11β-HSD1 activity. 
 
Figure 1-11 Pre-receptor glucocorticoid metabolism 
Glucose-6-phosphate (G6P) is translocated into the ER by the Glucose-6-phosphate 
transporter (G6PT). This G6P is then utilised along with NADP
+
 by H6PDH to produce 6-
phosphoglutante (6-PG) and NADPH. This NADPH is then used as a cofactor by 11β-HSD1 
to perform its oxo reductase action by converting inactive cortisone into active cortisol, along 
with the production of NADP
+
. 
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1.6.2 Transcriptional control of 11β-hydroxysteroid dehydrogenase type 1 
Transcription of 11β-HSD1 is directly regulated by members of the CCAAT/enhancer 
binding protein (C/EBP) family of transcription factors: C/EBPa, b, c, d, e, and f (or CHOP) 
(Williams et al 2000) (Gout et al 2006; Cao et al 1991). C/EBP a and b each occur as distinct 
isoforms arising from differential translation initiation or proteolysis (Ossipow et al 1993). 
C.EBPa produces 42kDa and 30kDa isoforms, and C/EBPb exists as three major isoforms; the 
38kDa liver-enriched activator protein (LAP*), 35kDa liver-enriched activator protein (LAP), 
which stimulate transcription, and 20kDa liver-enriched inhibitor protein (LIP) (Calkhoven et 
al 2000). LIP lacks the transcription activation domain of C.EBPb and is typically a 
dominant-negative regulator of C/EBP function (Calkhoven et al 2000). The LIP:LAP ratio is 
thus an important determinant of C/EBPb action (Duong et al 2002). It has since been shown 
that C/EBPa and C/EBPb play central roles in regulating the expression of 11β-HSD1 
(Esteves et al 2012). Both C/EBPa and C/EBPb play a direct and positive role in regulation of 
11β-HSD1 transcription and differentiation in adipocytes, but C/EBPb alone is crucial for 
differentiating cells by activating PPARγ and also functions synergistically with PPARγ to 
promote the expression of genes found in both brown and white adipocytes (Esteves et al 
2012; Tanaka et al 1997; Wu et al 1999). Conversely in liver C/EBPa is the major known 
inducer of 11β-HSD1 transcription within the liver, where C/EBPb acts as a repressor 
(Williams et al 2000). 
1.6.3 11β-hydroxysteroid dehydrogenase type 1 in disease 
11β-HSD1 has been implicated in the pathogenesis of several human diseases. This is due to 
the physiological role played by 11β-HSD1 where it converts inactive cortisone to active 
cortisol thereby increasing the intra-cellular concentration of GC (Koteleytsev et al 1997). 
Increased 11β-HSD1 activity and expression are closely associated with fasting plasma 
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glucose, adiposity, insulin resistance and hyperglycaemia (Lindsay et al 2003; Kannisto et al 
2004; Baudrand et al 2010). Further, adipose tissue 11β-HSD1 expression is higher in 
metabolic disease prone mice than in metabolic disease resistant mice, and conversely to this 
metabolic disease resistant mice have lower basal adipose tissue 11β-HSD1 levels than 
disease prone mice, showing that an increase in 11β-HSD1 may be responsible for the 
metabolic complications (Morton et al 2004). 
1.6.4 Metabolic syndrome 
The metabolic syndrome (MS) is characterised by visceral obesity, insulin resistance, type 2 
diabetes mellitus, dyslipidaemia, hypertension, and an increased cardiovascular risk profile 
(Walker et al 2000). Chronic exposure to increased circulating GCs is causative of CS, 
however there is no evidence that plasma cortisol excess leads to MS. However there is an 
increase in 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) levels within the adipose 
of patients suffering with MS, which will lead increases in the regeneration of active GC 
(Rosmond et al 1998; Walker et al 2000).  
It is therefore hypothesised that reducing the local activity of GC within the liver and 
adipose tissue may offer protection against the development of MS. Therefore 11β-HSD1 has 
developed into a major target for pharmaceutical research as a viable target for the treatment 
of MS. 
1.6.5 Effect of 11β-hydroxysteroid dehydrogenase type 1 on adipose tissue 
11β-HSD1 located within adipose tissue is involved in modulating metabolism and function. 
An increase in 11β-HSD1 activity within adipose tissue results in MS, visceral obesity, 
diabetes, dyslipidaemia and hypertension (Masuzaki et al 2001). Following an increase in  
11β-HSD1 expression the effects are seen strongest within visceral adipose depots. This is 
because visceral adipose possesses high levels of GC receptor.  
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There is an increase in the expression of 11β-HSD1 within the adipose tissue of obese 
humans and rodents, however hepatic expression is reduced or remains constant (Masuzaki et 
al 2001; Paulmyer-Lacroix et al 2002). This increase in 11β-HSD1 expression causes an 
increase in the concentration of corticosterone within adipose despite no change in plasma 
levels (Masuzaki et al 2001). This is likely to have a pivotal role in the pathogenesis of MS 
suggesting that an increase in GC action in adipose mediated by 11β-HSD1 activity may offer 
an explanation as to the resemblances seen with both CS and MS. 
Overexpression of 11β-HSD1 selectively within adipose leads to obesity, 
hypertension, and insulin-resistance; however transgenic mice overexpressing 11β-HSD1 
within liver do not demonstrate obesity, but still show other side effects (Masuzaki et al 
2001). It is therefore hypothesised that increased 11β-HSD1 in adipose increases intra-adipose 
GC action which has causative effects on; MS, visceral obesity, insulin resistance, and 
cardiovascular disease. 
Overexpression of 11β-HSD1 has stronger effects in the visceral adipose tissue due to 
it possessing a higher quantity of GR (Bonnegard et al 1995; Masuzaki et al 2001). This 
observation adds further weight to the hypothesis that GCs possess a pivotal role in the 
pathogenesis of central obesity. 
In contrast, mice lacking 11β-HSD1 expression are insulin sensitised and demonstrate a 
resistance to the undesirable metabolic effects of a HFD, showing a cardio-protective 
phenotype (Morton et al 2004). This has been demonstrated in various transgenic models 
(Kotelevtsev et al 1997; Morton et al 2001, 2004). These 11β-HSD1 deficient mice oppose 
diet-induced obesity and diabetes via an improvement in adipose and liver function. This is a 
consequence of a decrease in both the production and secretion of triglycerides and by 
increasing the rate of fatty acid oxidation. Transgenic 11β-HSD1 KO mice maintained on a 
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HFD accumulate adipose within peripheral areas preferentially to visceral depots. This is of 
benefit to health as peripheral areas are metabolically safer. Overall a decrease in 11β-HSD1 
expression within adipose tissue leads to a preferential metabolic phenotype. This supports 
the role of 11β-HSD1 as a potential target for the treatment of MS. 
1.7 Manipulation of the 11β-hydroxysteroid dehydrogenase type 1 enzyme 
Transgenic mouse models involving genetic manipulations of the 11β-HSD1 gene have 
allowed for a greater understanding into the effects of this enzyme on whole body 
functioning. Thus allowing for the potential development of novel ways to target and 
manipulate the workings of the enzyme in the treatment of metabolic diseases. 
1.7.1 11β-hydroxysteroid dehydrogenase type 1 knock-out 
Various rodent studies involving mice with 11β-HSD1 GKO have shown that they have 
favourable metabolic profiles (Morton et al 2001). In the absence of 11β-HSD1 inert 11-keto 
corticosteroids cannot be reduced to active 11-hydroxy forms (Kotelevtsev et al 1997). 
Knock-out of 11β-HSD1 leads to protection against diet-induced visceral obesity and its 
metabolic consequences, probably via a decrease in the regeneration of intracellular GC and 
in part through insulin sensitisation and redistribution of adipose tissue to metabolically safer 
sites (Morton et al 2001, 2004).  
Further 11β-HSD1 GKO mice demonstrate improved insulin sensitivity, lipid profiles, 
lower fasting plasma glucose and lipid levels, protection from hyperglycaemia, lower plasma 
triglyceride levels, increased hepatic insulin sensitivity, reduced fat mass, higher oxygen 
consumption rate, increased hepatic lipid catabolism, while synthesis is normal, resulting in 
reduced serum triglycerides and total cholesterol, higher PPARγ expression and higher energy 
dissipation (Wamil et al 2011; Liu et al 2013). 
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Knock-down of 11β-HSD1 has profound effects on the functioning of adipose tissue. 
There is reduced subcutaneous adipocyte hypertrophy in 11β-HSD1 GKO mice, which may 
be explained by enhanced β3-adrenergenic remodelling (Wamil et al 2011; Ataab et al 2010). 
A decrease in lipid accumulation within adipocytes decreases expression of lipoprotein lipase 
(LPL) and fatty acid synthetase, a decrease in visceral adipose preadipocyte differentiation, 
and increased glucose uptake, suggesting greater insulin sensitivity (Liu et al 2007; De Sousa 
Peixoto et al 2008; Wamil et al 2011; Morton et al 2004). Further a decrease in adipose 11β-
HSD1 is linked to a favourable distribution of adipose tissue and opposition to metabolic 
disease caused by a high fat diet, including insulin sensitivity, this involves an increase in 
subcutaneous adipose which demonstrates higher insulin sensitivity than visceral adipose 
(Morton et al. 2004; Wamil et al 2011). 
Knockdown of 11β-HSD1 aids brown adipocyte function, and there is an inverse 
relationship between mRNA expression of 11β-HSD1 and BAT signature genes UCP1, 
Cidea, Cox7a1 and Cox8b in brown adipocyte differentiation. This suggests that 11β-HSD1 is 
detrimental to brown adipocyte differentiation (Liu et al 2013). In addition11β-HSD1 
knockdown cells possess smaller lipid droplets than control cells.  This decreased lipid droplet 
size is linked to an increase in lipid oxidation and energy expenditure (Liu et al 2013). 
Overall these studies demonstrate that the pharmacologic inhibition of 11β-HSD1 is a 
promising strategy to treat metabolic diseases.  
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Figure 1-12  Effect of 11β-HSD1 knock-out 
In the absence of 11β-HSD1 there is no tissue specific regeneration of cortisol from cortisone. 
This has effects on the hypothalamus, the liver, and adipose tissue, leading to an overall 
decrease in glucose and body weight. 
1.7.2 11β-hydroxysteroid dehydrogenase type 1 over expression 
As a contrast to 11β-HSD1 GKO experiments, models of 11β-HSD1 over expression have 
also been generated. Over expression of 11β-HSD1 leads to increased weight gain 
(predominantly visceral), dyslipidaemia, hyperglycaemia, hypertension and insulin resistance 
(Masuzaki et al 2003). It is hypothesised that this is due to increased FFA draining from 
visceral adipose tissue into the portal circulation, adding weight to this is that FFA levels were 
shown to be increased in 11β-HSD1-over-expressing mice (Masuzaki et al 2001). Further the 
adipose tissue accumulation is located at the more therapeutically damaging visceral sites are 
as opposed to the more favourable subcutaneous depots. This could be due to GR mRNA 
expression being higher in visceral than subcutaneous adipose  and therefore the increase in 
GC levels would have a more prominent effect on this adipose depot, due to GCs promoting 
adipocyte differentiation (Masuzaki et al 2001). 
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In addition to this, the mRNA levels of BAT specific genes are down regulated with 
11β-HSD1 overexpression, and BAT cells contain larger lipid droplets (Liu et al 2013). In 
addition UCP1 expression in BAT has been shown to be significantly decreased in 11β-HSD1 
over-expressing mice, indicating a possible role for decreased BAT function in energy 
dyshomeostasis (Masuzaki et al 2001). 
1.7.3 11β-hydroxysteroid dehydrogenase type 1 inhibitors 
11β-HSD1 has been demonstrated as a potential novel drug target in the suppression of the 
action of GCs. This would offer a potential therapy to combat the disorders linked with 
cortisol excess, for example obesity, insulin resistance, and type 2 diabetes. 
Inhibitors of 11β-HSD1 decrease the level of cortisol generated in the liver and 
adipose tissue, and decrease tissue-specific gluconeogenesis and fatty acid metabolism (Harno 
et al 2010). The potential adverse effects linked to up regulation of the HPA axis are 
characterised by osteoporosis, immunosuppression, hypertension and glucose intolerance. 
Therefore the selectivity of inhibitors is crucial to ameliorating the negative effects linked 
with non-selective binding to 11β-HSD2, leading to over activation of MRs, thus causing 
hypokalemia and hypernatremia, which in turn would lead to hypertension (Lepsin et al 
2011). 
Administration of 11β-HSD1 inhibitors results in a lower body mass, fasting glucose, 
insulin, and cholesterol in diet-induced obese mice (Vaeniant et al 2010). Further non-
selective 11β-HSD1 inhibitors result in a decrease in human adipocyte differentiation and 
cellular lipid content (Bujalska et al 1999; Bujalska et al 1998; Walker et al 1995). In 
addition, inhibition of 11β-HSD1 activity by BVT.2733 results in an increase in brown 
adipocyte function (Liu et al 2013). 
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1.8 Hypothesis 
GCs play a key role within the body and can be reactivated at the tissue specific level by 11β-
HSD1, thus giving a high available concentration of active GC within the body. I hypothesise 
that a genetic depletion of 11β-HSD1 activity in adipose will alleviate the negative effects of 
exposure to exogenous GC excess. This includes an improvement in the functioning of 
adipose tissue, inducing an increased capacity for non-shivering thermogenesis, which can 
lead to an improved metabolic and physiological phenotype. 
1.9 Aims 
 To generate and characterise a mouse model of 11β-HSD1 knock-out specifically 
within adipose tissue and to assess the effects of administration of exogenous 
glucocorticoids. 
 To assess the effect of exogenous 11β-HSD1 on BAT and WAT tissue in a mouse 
model of ageing. 
 To assess the effects of administration of exogenous glucocorticoids on BAT and 
WAT thermogenic programmes. 
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2. Chapter 2 - Materials and Methods 
2.1 RNA extraction 
2.1.1 Method 
Around 20 mg of tissue was homogenised in 1 ml of TRI reagent, or 1 ml of TRI reagent was 
added to each well of cells and the cells manually dislodged from the wells. Samples were left 
at room temperature for 5 minutes. 200 µl of chloroform was added and the solution vortexed 
and placed at room temperature for 10 minutes. The solution was centrifuged at 4°C, at 
14,000g for 15 minutes and the aqueous phase was transferred to a fresh 2 ml micro 
centrifuge tube. 500 µl of isopropanol was added and the solution vortexed and left at room 
temperature for 15 minutes. The samples were then centrifuged at 4°C, at 14,000g for 15 
minutes. The RNA pellet was then washed with 75 % ethanol, the ethanol was then aspirated 
and the RNA pellet left to air-dry at room temperature. The pellet was then re-suspended in 20 
µl of nuclease free water and stored at -80°C. 
2.2 RNA quantification 
2.2.1 Method 
 
RNA concentration was determined using the Nano Drop ND-1000 UV-Vis 
Spectrophotometer (Thermofisher, Surrey, UK). The OD260/280 ratio was used as an 
indication of the RNA purity, and only samples whose ratio fell between 1.8 and 2.0 were 
used. Measurements used nuclease free water as a blank and were made using 1.5 µl of RNA 
sample. 
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2.3 Reverse transcription of RNA 
2.3.1 Method 
This method leads to the generation of stable complementary DNA (cDNA) from RNA 
previously extracted from tissues.  
Reverse transcriptase reactions were undertaken using Applied Biosystems High-Capacity 
Reverse Transcription Kit (Applied Biosystems, Warrington, UK). 1ug of RNA was added to 
a reaction mix with a final volume 25 µl. The reaction mix consists of:  2.0 µl 10x reaction 
buffer,0.8 µl 25x dNTPs (100mM), 2.0 µl 10x RT Random Primers, 1.0 µl RNase inhibitor, 
1.0 µl Multiscribe Reverse transcriptase and made up to 25 µl with RNA free water. The 
reaction was carried out using a thermal cycler (Applied Biosystems, Warrington, UK) as 
follows: 25°C for 10 minutes, 37°C for 120 minutes, and 85°C for 5 minutes. The cDNA 
generated was stored at -20°C. 
2.4 DNA extraction 
2.4.1 Method 
Around 20 mg of tissue was digested in 100 µl of digestion buffer at 56°C overnight. 400 µl 
of nuclease free water and 500 µl of phenol was added and the solution vortexed. The solution 
was centrifuged at 4°C, at 14,000g for 15 minutes and the aqueous phase was transferred to a 
fresh 2ml micro centrifuge tube. 500 µl of 50:50 phenol/chloroform was added and the 
solution vortexed. The samples were then centrifuged at 4°C, at 14,000g for 15 minutes and 
the aqueous phase was transferred to a fresh 2ml micro centrifuge tube. 10 µl of sodium 
acetate was added along with 300 µl of 100% ethanol. The samples were then vortexed and 
left on ice for 30 minutes. The solution was then centrifuged at 4°C, at 14,000g for 15 
minutes. The supernatant was then removed and the DNA pellet was then washed with 75 % 
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ethanol, the ethanol was then aspirated and the DNA pellet left to air-dry at room temperature. 
The pellet was then re-suspended in 100 µl of nuclease free water. The extracted DNA was 
stored at -20C. 
2.5 DNA quantification 
 
DNA concentration was determined using the NanoDrop ND-1000 UV-Vis 
Spectrophotometer (Thermofisher, Surrey, UK).  
2.6 Polymerase chain reaction (PCR) 
2.6.1 Method 
Polymerase chain reactions (PCR) is used to amplify specific regions of DNA or cDNA, 
using oligonucleotide primers which are complementary to the 3’ and 5’ regions of the target 
sequence. PCR was carried out using New England Biolabs reagents (Biotaq, NEB, Herts, 
UK). A 20 µl reaction was carried out using the following reagents: 10 µl Master Mix, 0.5 µl 
forward and reverse primer, 8 µl nuclease free water and 1 µl of DNA template (200 ng/ml). 
The samples were run using a thermal cycler with the following reaction: 94°C 2 minutes then 
cycled 35 times at 94°C for 30 seconds, 57°C for 30 seconds, then 72°C for 1 minute. Finally 
samples were incubated at 72°C for 5 minutes. DNA product was visulaised under UV 
conditions using a 2% agarose gel containing SYBRSAFE Dye (x10,000) (Invitrogen). 
2.7 Quantitative polymerase chain reaction 
2.7.1 Method 
Relative quantification real-time polymerase chain reaction (RT-PCR) enables the accurate 
measurement of selected DNA sequences from cell and tissue samples. Real-time quantitative 
PCR was performed using ABI Prism 7,500 Sequence Detection System (Applied 
Biosystems, Warrington, UK). Primers were ordered pre-designed and optimised from 
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Applied Biosystems, Warrington, UK. Reactions were carried out in duplicate in 96-well 
plates (Applied Biosystems, Warrington, UK). The reactions contained the following 
reagents: 10 µl 2x Master mix, 1 µl of 18S or 20x expression assay, 100 ng of cDNA and 
nuclease free water to give a final volume of 20 µl. The plates were sealed using a clear 
adhesive film (Applied Biosystems, Warrington, UK). The results were given as Ct values 
and the ΔCt values were calculated (Ct of gene of interest-Ct of 18S) and given as a fold 
change (2
-ΔΔCt
). 
 
Figure 2-1 Relative quantification polymerase chain reaction 
Once reaching the exponential phase the cycle threshold (Ct) value is recorded. This value is 
inversely proportional to the copy number of the target DNA template. 
 
2.7.2 Validation and calibration 
To ensure that the 18S internal reference primers did not interfere with the target gene primers 
in multiplex reactions, both target gene and 18S primer and probes were run in singleplex. All 
TaqMan Gene Expression Assays have been designed using a validated bioinformatics 
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pipeline, and run with the same PCR protocol, eliminating the need for primer design or PCR 
optimisation. 
2.7.3 Primer and probe sequences and details 
All primers used in Taqman Gene Expression Assays were provided by Applied Biosystems, 
California, USA. 
11β-HSD1 Assay ID Details:Mm00476182_m1 TaqMan Gene Expression Assay 
UCP1 Assay ID Details:Mm01244861_m1 TaqMan Gene Expression Assay 
Cox8b Assay ID Details:Mm00432648_m1 TaqMan Gene Expression Assay 
Cox7a1 Assay ID Details:Mm00438297_m1 TaqMan Gene Expression Assay 
Nr3c1 Assay ID Details:Mm00433832_m1 TaqMan Gene Expression Assay 
PPARγ Assay ID Details:Mm01184322_m1 TaqMan Gene Expression Assay 
PRDM16 Assay ID Details:Mm01184322_m1 TaqMan Gene Expression Assay 
PGC-1α Assay ID Details:Mm01208835_m1 TaqMan Gene Expression Assay 
NRF1 Assay ID Details:Mm00548493m1 TaqMan Gene Expression Assay 
TFAM Assay ID Details:Mm00235765m1 TaqMan Gene Expression Assay 
CoxIV Assay ID Details:Mm01250094m1 TaqMan Gene Expression Assay 
 
Table 2-1 Primer and probe sequences 
Table showing the primers and probes used for polymerase chain reaction experiments. 
2.8 3H labelled 11β-HSD1 activity assays 
2.8.1 Method 
This technique is used to measure the inter conversion of active and inactive glucocorticoids 
by 11β-HSD1. Extracted tissue samples (~20 mg/well) were incubated in serum free media 
enriched with 20,000 cpm/reaction of 
3
H-11-DHC to allow for the assessment of 11β-HSD1 
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activity. During glucocorticoid substrate metabolism by 11β-HSD1 there was a proportional 
amount of the labelled tracer metabolised also. Following incubation the steroids were 
extracted using dichloromethane and separated via TLC. The percentage of active and 
inactive tracer labelled glucocorticoids was determined and from this the quantity of steroid 
conversion in pmoles per g of sample can be calculated. 
To measure the oxo-reductase activity of 11β-HSD1, 100 nM of 11-DHC was added 
to the serum free media along with 20,000 cpm/reaction of 
3
H-11-DHC. Samples were 
incubated at 37°C in air/5 % CO2 for 4 hours (adipose) and 30 minutes (liver). The media was 
transferred into 10ml glass tubes and 5 ml of dichloromethane was added. The remaining 
tissue samples were weighed and the weights recorded. The media was vortexed for 15 
minutes at 15,000 rpm to separate the organic and aqueous phase. The aqueous phase 
containing proteins was aspirated, leaving the steroid containing organic phase. The steroids 
were concentrated by the evaporation of the dichloromethane at 50°C for 30 minutes under an 
air blowing sample concentrator (Techne, New Jersey, US). The remaining steroids were re-
suspended in 70 µl of dichloromethane and spotted onto pre-labelled silica thin layer 
chromatography plates (thermofisher, Surrey, UK). 1 µl of standard steroid solution (10 mM 
of 11-DHC or corticosterone) was also spotted on the plates. The steroids were separated by 
TLC in ethanol: chloroform (8:92) as the mobile phase for 1.5 hours. The TLC plates were 
then analysed using Bioscan imaging detector (LabLogic, Sheffield, UK) and the conversion 
of inactive to active steroid was determined. Results were expressed as pmol of steroid 
converted per g of tissue per hour (pmol/g/h), and experiments were carried out in triplicate. 
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Figure 2-2 
3H labelled 11β-HSD1 activity assay data read out 
Region 1 represents the amount of radio-active corticosterone present and region 2 
represents the amount of 11-dehydrcorticosterone present. From the peak size the % 
conversion of 11-dehydrocorticosterone to corticosterone can be calculated. 
 
2.9 Generation of 3H-11-dehydrocorticosterone 
For the 11β-HSD1 conversion assays, inactive tritium labelled tracer substrate of 11-DHC 
was required, however this is not commercially available. This technique provides a means by 
which 
3
H-11-DHC was produced in-house through the conversion of 3H-corticosrterone (GE 
healthcare, Bucks, UK) by the 11β-HSD2 enzyme. 
20µl of 
3
H-corticosterone (1mCi/mL) was incubated with 250 mg of human placenta in 
500 µl of 0.1 M potassium phosphate buffer (pH7.4) containing 500 µM NAD
+
, at 37°C for 
18 hours in 1 ml glass tubes in a shaking water bath. 
3
H-GC were extracted by addition of 
5mL dichloromethane and vortexed for 10 seconds to extract the steroids. The solution was 
then centrifuged for 15 minutes at 15,000 rpm to separate the organic and aqueous phase. The 
steroids were concentrated by evaporating the dichloromethane at 50°C for 30 minutes using 
an air blowing sample concentrator (Techne, New Jersey, US). Steroids were then re-
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suspended into 70 µl of dichloromethane and spotted onto silica coated thin layer 
chromatography plates (Thermofisher, Surrey, UK), using a Pasteur pipette. The steroids were 
separated by thin-layer chromatography (TLC) using ethanol: chloroform (8:92) as the mobile 
phase along with 1 mg/ml of 11-DHC and corticosterone. TLC plates were analysed using 
Bioscan imaging detector (Bioscan, Washington, DC, USA). The 11-DHC and corticosterone 
fluoresce under UV light which allows for the localisation of the labelled steroid on the TLC 
plate (+/- 0.5 cm). The silica is then scraped into a fresh 10 ml tube and the steroids are eluted 
in 300ul of ethanol overnight at 4°C. The tube was spun at 15,000 rpm for 10 minutes and the 
liquid phase was transferred to a fresh tube. The remaining silica was re-suspended into 300 
µl of ethanol and the elution process repeated. The 
3
H-11-DHC was tested for purity by 
running 1 µl on a TLC plate and analysed for 1 minute. The number of counts recorded was 
analysed and the level of ethanol was altered by either addition or evaporation to give a 
concentration of 1,000 counts/µl. 
2.10 Protein extraction 
2.10.1 Methods 
For tissue samples the tissue was homogenised in 100 µl of RIPA buffer (50 mmol/l Tris-HCl 
pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l, 
0.1 % SDS, and protease inhibitor cocktail (Roche, Lewes, UK), and placed at -80°C for 1 
hour. The tissue was then further homogenised at left at -80°C for a further hour. The samples 
were then centrifuged at 4°C for 5 minutes at 14,000 rpm. For primary cell culture, 100 µl of 
RIPA buffer was added to the well and the protein manually removed from the surface of the 
well. 
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2.11 Protein estimation 
2.11.1 Method 
The soluble protein concentrations of tissue homogenates or primary cell culture were 
measured using Bio-Rad protein assay dye (Bio-Rad Laboratories, GmbH, Germany) using 
varying concentrations of BSA standards. Protein assays were performed using BIO-RAD 
protein assay kit (BIO-RAD laboratories, USA), according to the manufactures protocol. 
Samples were run in parallel with a range of concentrations of BSA standard (0, 0.25, 0.5, 1, 
1.5, 2, 4, 6, 8 mg/ml) in 96 well plates. To these 25 µl of reagent A containing Coomassie 
Brilliant Blue G-250 dye were added, followed by 200 µl of reagent B. Plates were incubated 
at room temperature for 15 minutes and their optical density read at 595 nm (OD595 nm). A 
standard curve of mg protein/ml against OD595 nm was then plotted. From this curve a line of 
best fit is added. From this line of best fit, protein concentration of samples can be determined 
for sample OD595 nm values. As all sample concentrations are taken from the same graph any 
fluctuations from the line of best fit are consistent throughout the samples and therefore do 
not affect the results. 
 
Figure 2-3 Protein assay standard curve 
Protein samples of known concentration were used to produce a standard curve with a line of 
best fit. This allowed for the concentration of the proteins with unknown concentration to be 
elucidated. 
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2.12 Western Blot analysis 
2.12.1 Principles 
Western blotting allows for target proteins from cell or tissue homogenate to be visualised as 
a band on a nitrocellulose membrane. Proteins are denatured and separated by electrophoresis 
on an SDS PAGE gel. The proteins are then transferred to a nitrocellulose membrane which is 
incubated with a primary antibody targeted to the protein of interest and then secondary 
antibody which is targeted to the primary antibody. The secondary antibody is horseradish 
peroxidase-linked and used together with a chemiluminesent agent to produce luminescence 
in proportion to the quantity of protein. A sheet of photographic film is placed against the 
membrane, and exposure to the light creates an image of the antibodies present on the blot. 
2.12.2 Solutions 
Stacking gel 625 µl Acrylamide, 1.25 ml stacking buffer, 25 µl 20 % SDS, 250 
µl 1.5% ammonium persulphate, 2.8 ml dH2O, 5 µL TEMED. 
Resolving gel 2.08 ml Acrylamide, 0.625 ml resolving buffer, 25 µl 20% SDS, 
250 µl 1.5% ammonium persulphate, 2 ml dH2O, 5 µl TEMED. 
SDS PAGE running 
buffer 
25 ml Tris base pH 7.4, 14 g glyceine, 1 g SDS, 975 ml dH2O 
 
Table 2-2 Solutions used in Western Blot analysis 
Table showing solutions used during Western Blot analysis. Staking gel and resolving gel 
were used when running the proteins and SDS PAGE running buffer was used as the solution. 
2.12.3 Method 
25 µg of protein solution (protein, LB and nuclease free water) was loaded into a 10 % SDS 
PAGE gel containing a resolving gel and a stacking gel, and run at 130 volts for 2 hours, 
covered by SDS PAGE running buffer. Proteins were then transferred onto a nitrocellulose 
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membrane (Amersham, Buckinghamshire, UK) using an iBLOT. The membrane was blocked 
for 1 hour in 5 % milk in PBS at room temperature on a shaker. The membrane was washed 4 
times in PBST for 15 minutes each. The membrane was then incubated with primary antibody 
overnight at 4°C on a shaker. The membrane was then washed 4 times in PBST for 15 
minutes each. The membrane was then incubated with secondary antibody for 1 hour at room 
temperature on a shaker. Finally the membrane was incubated with ECL for 5 minutes and the 
luminescence measured using a light sensitive Kodak MXB photographic film, in a dark 
room. Membranes were re-probed using antibodies against β-actin, which was used as an 
internal reference control. The bands were quantified using imageJ and expressed relative to 
β-actin to normalise for gel loading.  
All primary antibodies used were obtained from abcam; all secondary antibodies were 
obtained from Dako. 
2.12.4 Primary and secondary antibody details 
 
Antibody Order reference 
UCP1 Ab23841 
β-actin Ab8227 
11β-HSD1 Ab39364 
Polyclonal Goat Anti-rabbit immunoglobulins HRP P0448 
Polyclonal Goat Anti-mouse immunoglobulins HRP P0447 
 
Table 2-3 Primary and secondary antibodies 
I tested UCP1 and 11β-HSD1 protein expression and utilised β-actin as a control when 
performing Western Blot analysis. Anti-goat and anti-rabbit immunoglobulins were used as 
secondary antibodies. 
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2.13 Primary adipose tissue culture 
White adipose tissue (Subcutaneous, Mesenteric, and Gonadal), and brown adipose tissue 
(Intrascapluar) was extracted from wild-type and 11β-HSD1 global knock-out mice. The 
extracted tissue was manually digested, placed in 10ml of collagenase, and incubated in a 
37°C water bath for 1 hour (WAT) or 30 minutes (BAT). Following incubation the sample 
was vortexed for 10 minutes at 10,000 rpm and the supernatant discarded. The pellet was then 
re-suspended in 8 mls (WAT) or 4 mls (BAT) of proliferation media (DMEM/F12 culture 
media supplemented with 10% FCS and 1% penstrep) and 1ml aliquots were placed in a 12-
well plate. The cells were incubated at 37°C and 5% CO2 for 24 hours. The proliferation 
media was removed and the cells washed with 1 ml of proliferation media. 1 ml of 
proliferation media was then added to each well and the cells were placed in the incubator to 
proliferate for 2 days with the proliferation media changed daily. The proliferation media was 
then replaced with 1ml of differentiation media (DMEM/F12 culture media supplemented 
with 17 µM D-panthotenic acid, 33 µM biotin, 1 nM triiodothyronine, 166 nM human insulin, 
and 1 µM dexamethasone). The cells were placed in the incubator for 9 days to differentiate 
with the differentiation media changed daily. 
2.13.1 Statistical analysis 
Statistical analysis was used to test the significance levels of the data produced. A paired 
student T-test was used predominantly throughout the work to test for statistical significance. 
In addition, densitometry was used when assessing the significance levels of a Western blot 
analysis, this involved a quantitative measurement of optical density on photographic paper. 
Two-way ANOVA followed by Bonferroni’s multiple comparison post hoc test was used. 
Data are presented as mean ± SEM and data was deemed statistically significance if the p 
value was <0.05.  
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3. Chapter 3 – Role of adipose 11β-hydroxysteroid dehydrogenase type 1 and metabolic 
phenotype in glucocorticoid excess 
3.1 Methods 
3.1.1 Histological analysis of tissues 
3.1.1.1 Tissue preparation 
Samples were kept in 4 % formalin for at least 24 hours at room temperature to ensure the 
tissue is fixed. The sample is then placed into a cassette and immersed in 99 % industrial 
methylated spirits (IMS) (Leica biosystems, Peterborough, UK) for 1 hour. This was repeated 
two further times. The cassette containing the sample was then placed into xylene (Leica 
biosystems, Peterborough, UK) for 30 minutes and this was repeated a further two times. The 
cassettes were then removed from the xylene and placed in molten paraffin wax (Leica 
biosystems, Peterborough, UK) in a 65°C oven for 1 hour. This was repeated for a further 
hour and then again to be left in molten paraffin wax overnight. The tissue was then 
embedded in a mould with the use of molten paraffin wax, once the wax has set the cassette 
was separated from the base and the tissue was sectioned. The paraffin block was clamped 
into the microtome (Leica RM2125 RTS, Germany) and a mechanical blade (Leica DB80 LS, 
Germany) was used to cut 5 µm sections. These sections were then transferred to a 45°C 
water bath for 1 minute and collected onto Superfrost plus slides (Surgipath, Peterborough, 
UK). The slides were then placed into an incubator set at 40°C for 1 hour. 
3.1.1.2 Haematoxylin and Eosin (H & E) staining 
Slides were placed in clearene for 2 minutes, and this was repeated two further times. The 
slides were then transferred to 99 % IMS for two separate 2 minute intervals. Following this 
slides were placed in dH2O for two sets of 2 minutes and then placed into Haematoxylin stain 
for 5 minutes. The slides were then transferred to Scott’s tap water substitute (Leica 
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Biosystems) for 2 minutes and then dipped for 2 seconds in acid alcohol and transferred to 
Eosin stain for 5 minutes. Following this the slides were dipped in 99 % IMS for 2 seconds 
and then transferred to 99 % IMS for two sets of two minutes, before being transferred to 
clearene for three sets of 2 minutes. The slides were then mounted using duplex and covered 
with a cover slip. 
3.1.2 Hepatic TAG quantification 
Hepatic TAG content was measured using a colorimetric assay (Bio Vision, Inc.). 100mg of 
liver tissue was homogenised in 1 mL of 5% Nonidet P-40 in water. The samples were then 
heated to 80°C in a water bath for 5 minutes. The samples were then left to cool to room 
temperature. This heating step was then repeated to ensure all TAGs were solubilised. The 
samples were then centrifuged for 2 minutes to remove any insoluble material. The samples 
were then diluted 10-fold with distilled water. The TAG assay was then performed. 10 µl of 
standard was added to designated wells. The standards were diluted to known concentrations. 
10 µl of the sample was added to three wells and the reaction was initiated by adding 150 µl 
of diluted Enzyme Buffer solution to each well. The plate was then gently shaken for 5 
seconds in order to mix the solution. The plate was then incubated for 15 minutes at room 
temperature. The absorbance was then read at 530-550 nm. The average absorbance of each 
sample was then calculated. A graph of the standard absorbances was produced, the values of 
the samples were then calculated using the equation obtained from the linear regression of the 
standard curve. Triglycerides (mg/dl) = ((corrected absorbance – y-intercept)/slope). 
3.1.3 Free Fatty Acid quantification 
A standard curve was generated using 0, 2, 4, 6, 8, 10 µl Palmitic Acid Standards which were 
adjusted to give a total volume of 50 µl per well. Test samples were added in triplicate to the 
wells. 50 µl of reaction mix was added to each well (44 µl assay buffer, 2 µl fatty acid probe, 
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2 µl enzyme mix, 2 µl enhancer). The OD570nm was measured and the results averaged for 
each sample. A standard curve was plotted using the standard values and this was used to read 
off the values of the samples. 
3.1.4 11β-HSD1 adipose specific knock-out allele 
The 11β-HSD1 adipose specific knockout mice were purchased from Jackson labs. The 
following primers were used to confirm the presence of the Cre allele: 
 
Table 3-1 Cre primers 
A Cre forward and Cre reverse primer pair, giving a product size of 402bp were used to 
identify the presence of the Cre allele. 
 
PCR reactions were carried as described previously. The samples underwent gel 
electrophoresis on a 2 % agarose gel containing 2,000x GelRed (Cambridge BioScience, 
Cambridge, UK) at 120 volts for 1 hour. 10 µl of hyper ladder 1 was used. The gel was 
analysed for the presence of amplified genetic products (Syngene, Cambridge, UK). 
3.1.5 11β-HSD1 adipose knockout 
 
Cre/LoxP technology was used to delete loxP flanked chromosomal DNA sequences within 
the transgenic mice. I purchased a transgenic mouse which expresses cre recombinase under 
the control of the adiponectin promoter. The following primers were used to confirm the 
presence of loxP flanked chromosomal DNA: 
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Primers Sequence 
P1 GGGAGCTTGCTTACAGCATC 
P2 CATTCTCAAGGTAGATTGAACTCTG 
P3 TCCATGCAATCAACTTCTCG 
 
Table 3-2 LoxP primers 
Three primers were used to confirm the presence of loxP flanked chromosomal DNA. 
Recombination of P2 and P3 gave a 138bp product and represented WT and recombination of 
P1 and P3 gave a 172bp product and represented KO. 
 
Recombination of P2 and P3 primers yields a 138bp WT product, recombination of P1 and P3 
primers yield a 172bp KO product when P2 has been deleted. The production of two bands 
represents a heterozygote. 
3.1.6 Breeding scheme 
 
Figure 2-4 demonstrates the breeding scheme used to establish an 11β-HSD1 adipose 
knockout mice. 
  
Figure 3-1 Breeding scheme to generate adipose specific knock-out of 11β-HSD1 
Initially cre positive mice were crossed with heterozygous floxed mice. From the litters 
produced a cre positive and heterozygous floxed mouse was crossed with a cre negative and 
heterozygous floxed mouse. This allowed for the generation of a target adipose specific 11β-
HSD1 knock-out animal. 
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3.1.7 Genotyping 
 
Mouse ear clippings were collected from each animal and a single ear clip was transferred to a 
2ml micro centrifuge tube. 100 µl of Proteinase K buffer (96 µl of 10x PCR buffer (Bioline, 
London, UK), 4 µl of 50 nM MgCl2 (Bioline, London, UK), 5 µl of Tween-20, 885 µl of H2O 
and 100 µl of proteinase K (10 mg/ml) (Promega, Southampton, UK)) was added to each 
tissue sample and incubated in a hot block at 56°C overnight or until the tissue had digested. 
The samples were vortexed and placed in a hot block at 99°C for 20 minutes to denature the 
proteinase K enzyme. The samples were then left at room temperature to cool and centrifuged 
for 1 minute at 14,000g on a desk top centrifuge. The concentration of the sample was found 
using Nanodrop ND-1000 spectrophotometer (Wilmington, Delaware, USA). A working 
concentration of around 200 ng/ml was obtained by appropriate dilution in nuclease free 
water. The DNA was then stored at 4°C until required. 
3.1.8 Administration of glucocorticoids 
3.1.8.1 Methods 
Three week old male adipose specific 11β-HSDS1 knock out mice (FKO) and wild type mice 
were given drinking water supplemented with either corticosterone (CORT: 100 µg/mL, 0.66 
% ethanol), 11-dehydrocorticosteone (11-DHC: 100 µg/mL, 0.66 % ethanol) or vehicle (0.66 
% ethanol) for 5 weeks. The supplemented drinking water was changed twice weekly. 
Following the completion of the experiment, animals were sacrificed by cervical dislocation 
(schedule 1 procedure) and tissue extracted, weighed and snap frozen in liquid N2 for future 
analysis. 
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3.1.9 Glucose tolerance test 
A glucose tolerance test is commonly used to diagnose diabetes and insulin resistance. A dose 
of glucose is given based on body weight, and blood glucose measurements are taken at set 
time points up to 2 hours post-administration. This allows for a measure of the rate of glucose 
clearance by the subject. 
The mice were fasted for 5 hours prior to the procedure and glucose was measured from 
tail vein nicks using a glucometer (Accu-Chek, Roche, Hertfordshire, UK) at 0, 15, 30, 60, 
90, and 120 minutes following an IP injection of glucose (2 g/kg). 
3.1.10 Insulin tolerance test 
An insulin tolerance test is commonly used to assess adrenal and pituitary function and insulin 
sensitivity. A dose of insulin is administered with the aim of inducing hypoglycaemia. In 
response to this adrenocorticotrophic hormone (ACTH) and growth hormone (GH) are 
released. ACTH elevation causes the adrenal cortex to release cortisol to oppose the action of 
insulin. 
The mice were fasted overnight and glucose was measured from tail vein nicks using a 
glucometer (Accu-Chek, Roche, Hertfordshire, UK) at 0, 15, 30, 60, 90, and 120 minutes 
following an IP injection of insulin ( 0.75 U/kg). 
3.1.11 Animals 
All animal experiments and procedures were approved under the British Home Office 
Guidance (Animals Scientific Procedures) Act 1986 (Project Licence PIL 30/9815). Mice 
were housed in standard pathogen-free conditions on a 12 hour light/ 12 hour dark cycle with 
access to standard rodent chow and water. 
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3.1.12 Tissue collection 
Mice were sacrificed by neck dislocation (schedule 1 method). Tissue explants were removed 
and snap frozen in liquid N2, and stored at -80°C for future use. The mice were pinned onto a 
cork board to enable accurate dissections. Ethanol was then sprayed onto the animal to protect 
the tissues from contamination. Scissors were used to cut along the ventral midline and the 
skin was pealed back to enable a clear view of the tissues to be removed. The tissues were cut 
away from the animal using scissors and then trimmed of any excess artefacts. 
3.1.13 Blood collection 
Blood samples were obtained from the Saphenous Vein. The mouse was placed in a 
restraining tube, and hair was removed from the area with the use of clippers. A 25 gauge 
needle was used to collect the drops of blood as they appeared and collection tubes with 
capillary action were used to facilitate blood collection. 
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3.2 Introduction 
GCs have become one of the mostly widely prescribed drugs in medical practice due to their 
potent anti-inflammatory (Hench et al 1950), antiproliferatie and antiangiogenic properties 
(Vilasco et al 2011). However GC excess can lead to adverse metabolic effects including; 
Cushing’s syndrome, and type 2 diabetes (Fardet et al 2007). GCs can also be regenerated at a 
tissue specific level by the 11β-HSD1 enzyme (Koteleytsev et al 1997), and these reactivated 
GCs can play a critical role in the development of metabolic syndrome (Walker et al 2000).  
The key role of 11β-HSD1 has been highlighted through the use of animal models. It 
has been shown that a global KO of 11β-HSD1 confers protection from glucose intolerance, 
hyperinsulinemia, hepatic steotosis, adiposity, and hypertension, therefore showing the 
potential role of 11β-HSD1 as a therapeutic target (Morton et al 2001). 
Increased 11β-HSD1 activity selectively within adipose tissue results in the 
development of full metabolic syndrome with visceral obesity, diabetes, and hypertension 
(Masuzaki et al 2001) conversely transgenic mice with increased expression of 11β-HSD1 
within the liver resist obesity, but have insulin resistance, dyslipidaemia, and fatty liver 
(Mariniello et al 2006). An important observation in these models was that they both had no 
change in circulating corticosterone levels, which suggests that the increase in intracellular 
GC regeneration is key to the observed phenotype. These studies provide further weight to the 
role of adipose 11β-HSD1 in the GC excess phenotype. In addition to animal studies a key 
study by Tomlinson et al 2002 reported a patient with Cushing’s syndrome who was protected 
from the classic Cushing’s phenotype due to a decrease in 11β-HSD1 activity. Here a case of 
CS was presented lacking the classical central obese and metabolic phenotype and it was 
hypothesised that this was due to a lack of 11β-HSD1 enzyme content. The consequential 
decrease in local conversion of inactive cortisone to active cortisol served to highlight to role 
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of 11β-HSD1 within the development of obesity, particularly within the Cushingoid 
phenotype. 
Based on previous studies showing the link between GCs and the metabolic syndrome I 
hypothesise that tissue specific regeneration of GC via 11β-HSD1 is the major determinant of 
the phenotype of GC excess and that deletion of 11β-HSD1 specifically within adipose will 
protect from metabolic abnormalities. In this chapter I present data demonstrating the effect of 
11β-HSD1 global KO, and also the generation of an adipose specific KO of 11β-HSD1. 
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3.3 Results 
3.3.1 Metabolic consequences of glucocorticoid excess in 11β-HSD1 global 
knock-out 
Studies within our lab led by Dr Stuart Morgan have investigated 11β-HSD1 (GKO) global 
knock-out mice. Mice were treated with corticosterone (100ug/ml) or vehicle via drinking 
water for 5 weeks. I initially verified that there was an effect from the glucocorticoid excess 
(Figure 3-2). I showed that following corticosterone (CORT) treatment there was a significant 
increase in serum corticosterone levels and also adrenal atrophy in both WT and GKO mice. 
This therefore suggests that further effects seen are independent of circulating active GC 
concentrations. 
 
Figure 3-2 Validation of glucocorticoid excess 
Treatment with corticosterone led to a significant increase in serum corticosterone levels of 
both WT and GKO mice. Treatment with corticosterone also led to significant adrenal 
atrophy in both WT and GKO mice. Data was analysed using two way ANOVA. ***P < 0.001 
vs. WT vehicle; $$$P < 0.01 vs. WT CORT. Error bars represent SEM. N=6 for all mice. 
Cited from Morgan  et al 2014. 
 
By the fourth week of treatment WT mice treated with corticosterone were glucose-intolerant 
(Figure 3-3) hyperinsulinemic and hyperglycaemic following a 5-h fast (Figure 3-4), and had 
increased systolic blood pressure (Figure 3-5) when compared to those treated with vehicle. In 
contrast to this it was found that corticosterone-treated GKO mice remained relatively 
glucose-tolerant (Figure 3-2), had lower fasting insulin and glucose levels (Figure 3-3), and 
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showed no change in systolic blood pressure (Figure 3-4). The GKO mice were therefore 
protected from the adverse effects of systemic GC excess. This therefore demonstrates that 
global deletion of 11β-HSD1 can protect against the adverse metabolic effect of exogenous 
corticosterone (CORT) treatment. 
 
 
Figure 3-3 Effect of CORT treatment on glucose tolerance of WT and GKO mice 
Glucose tolerance was calculated as area under the curve, and shows improved glucose 
tolerance in CORT-treated GKO mice compared with CORT-treated WTs. There is also a 
significant decrease in glucose tolerance in WT mice following CORT treatment. Data 
analysed using a two way ANOVA. ***P < 0.001 vs. WT vehicle; ∅∅P < 0.01 vs. WT CORT. 
Error bars represent SEM. Cited from Morgan et al 2014. 
 
 
Figure 3-4 Effect of CORT treatment on insulin and glucose levels of WT and GKO mice 
Fasting insulin and fasting glucose levels are improved in CORT-treated GKO mice 
compared with CORT-treated WTs.  There is a significant detrimental effect on fasting insulin 
and fasting glucose levels following CORT treatment in the WTs. Data analysed using a two 
way ANOVA. ***P < 0.001 vs. WT vehicle; ∅P < 0.05, ∅∅P < 0.01 vs. WT CORT. Error bars 
represent SEM. Cited from Morgan et al 2014. 
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Figure 3-5 Effect of CORT treatment on systolic blood pressure in WT and GKO mice. 
Systolic blood pressure is improved in CORT-treated GKO mice compared with CORT-
treated WTs.  There is a significant increase in systolic blood pressure in the CORT-treated 
WTs compared to WT vehicle treated mice. Data analysed using a two way ANOVA. **P < 
0.01 vs. WT vehicle; ∅∅P < 0.01 vs. WT CORT. Error bars represent SEM. Cited from 
Morgan et al 2014. 
 
I also investigated the effect of GC excess on adipose tissue as GCs have been shown to 
increase adiposity. I found that within all fat beds tested there was a significant increase in 
adipose weight in CORT treated WT mice however GKO mice were protected from this 
increase in adipose weight (Figure 3-6). Thus indicating that GKO of 11β-HSD1 leads to 
protection from obesity associated with GC excess. 
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Figure 3-6 Effect of GKO of 11β-HSD1 on adipose tissue 
There is significant protection from obesity provided by global knock-out of 11β-HSD1 in all 
adipose depots studied. There is a significant increase in obesity in all adipose depots studied 
following CORT treatment in WT mice compared with vehicle treated WT mice. Data was 
analysed using a students T-test. **P < 0.01 vs. WT vehicle; ∅∅P < 0.01 vs. WT CORT ; ∅P 
< 0.05 vs. WT CORT. Error bars represent SEM. Cited from Morgan et al 2014. 
 
Adipocyte size was also investigated. Adipocyte size was increased in both gonadal and 
subcutaneous adipose depots in both WT and GKO corticosterone treated mice. This is also 
demonstrated histologically for the gonadal adipose depot (Figure 3-7). This shows that the 
decrease in adipose depot weight shown in figure 3-5 is due to decrease in adipocyte number. 
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Figure 3-7 Effect of GKO of 11β-HSD1 on adipocyte size 
There is a significant increase in adipocyte size following CORT treatment in both WT and 
GKO mice in both gonadal and subcutaneous adipose. Data was analysed using a two way 
ANOVA. *P < 0.05 vs. WT vehicle; $P<0.05, $$P<0.01 vs GKO vehicle. Error bars 
represent SEM. Cited from Morgan et al 2014. 
 
Within humans non-alcoholic fatty liver disease is commonly associated with GC excess due 
to GCs increasing lipolysis. In keeping with this I showed that there was a significant increase 
in hepatic triglyceride (TAG) and serum free fatty acid content in WT mice following 
corticosterone treatment (Figure 3-8). In contrast GKO provided protection from hepatic TAG 
accumulation and increased serum free fatty acids (Figure 3-8). 
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Figure 3-8 Global knock-out of 11β-HSD1 provided protection from TAG accumulation, 
serum free fatty acid accumulation and hepatic steatosis following CORT treatment 
GKO provided protection from an increase in TAG content following treatment with 
corticosterone and also provided protection from an increase in serum free fatty acid 
accumulation following treatment with corticosterone. In addition to this there is protection 
from hepatic steotosis. There is a significant increase in TAG content and serum free fatty 
acids following CORT treatment in WT mice. ***P < 0.001 **P < 0.01 vs. WT vehicle; ∅∅∅P 
< 0.001 ∅P < 0.05 vs. WT CORT. Error bars represent SEM. Cited from Morgan et al 2014. 
 
This data demonstrates that global deletion of 11β-HSD1 confers a beneficial phenotype on 
mice following excess CORT exposure. In order to elucidate the tissues responsible for this 
benefit I generated an adipose 11β-HSD1 specific knock-out mouse model. 
3.3.2 Validation of adipose specific knock-out of 11β-HSD1 
To examine the role of adipose 11β-HSD1 and its potential role in GC and insulin sensitivity I 
generated 11β-HSD1 adipose specific knock-out (FKO) mice. These mice were generated 
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using a previously determined floxed allele and adiponectin-cre line (JAX lab, B6;FVB-
Tg(Adipoq-cre)1Evdr/J) as the adipose specific promoter (Figure 3-9). I used both 11β-HSD1 
and cre primers to ascertain the genotypes of the mice using ear clip genotyping, which 
allowed us to identify target animals and corresponding litter matched controls. 
 
Figure 3-9 Targeting strategy and identification of adipose specific 11β-HSD1 knock-outs 
I used a previously determined floxed allele of 11β-HSD1 and cre recombinase expressed 
from an adiponectin adipose specific promoter. Knock-out mice were identified by having the 
floxed allele for 11β-HSD1 and being cre positive. Cre primers were used to identify mice 
which had expression of cre recombinase as shown in lanes 1, 2 and 8. 11β-HSD1 primers 
were used to identify mice which contained the recombined KO allele, as shown in lanes 1 
and 4. Mice which had both expression of cre recombinase and the recombined KO allele of 
11β-HSD1 were designated as being 11β-HSD1 adipose specific KO (FKO) as shown in lane 
1. Cited from Morgan et al 2014. 
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I assessed the genotype of the mice using ear clips from new born litters. I used cre primers to 
confirm the presence of cre recombinase within the mice and 11β-HSD1 primers to determine 
which mice contained the floxed 11β-HSD1 allele as shown in figure 3-9. The mice which 
contained both the cre allele and the floxed allele were designated as knock-out mice as seen 
in lane 1.  
Once these knock-out mice were identified I confirmed that the knock-out of the 11β-
HSD1 gene was specific to the adipose tissue. This was achieved by PCR amplification using 
11β-HSD1 primer sets on specific tissues from the FKO mice following DNA isolation and 
used to confirm the presence of the recombined knock-out allele is located specifically within 
the adipose tissue depots (Figure 3-10). This demonstrated that the recombined KO allele for 
11β-HSD1 was present only within the adipose tissue of the mice. 
 
Figure 3-10 Adipose specific knock-out of 11β-HSD1 on tissue samples 
Genomic DNA PCR using 11β-HSD1 primers demonstrates that the recombination is specific 
to adipose tissue. The recombined knock-out allele is shown to be present in the adipose 
tissues depots (BAT, Subcutaneous and Gonadal) of the FKO mice but absent in the other 
tissues of the FKO mice (Heart, Kidney, Liver, Lung, and Muscle). Cited from Morgan et al 
2014. 
 
Having confirmed the knock-out of 11β-HSD1 specifically within the adipose tissue of the 
mice at the genomic level I continued my validation by undertaking tissue specific mRNA 
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analysis on the expression of 11β-HSD1 as shown in figure 3-11. I found that there was no 
change in the mRNA expression level when comparing WT to FKO in the liver, lung, heart, 
kidney or muscle, however I showed a significant decrease in the mRNA expression of 11β-
HSD1 within the adipose tissue depots (BAT, Gonadal, Subcutaneous) (P<0.0001). 
 
 Figure 3-11 Confirmation of adipose tissue specific knock-out of 11β-HSD1 using mRNA 
analysis 
The fold change in 11β-HSD1 mRNA expression is significantly lower in the adipose tissues 
of the FKO mice compared to the WT. There is no difference in the mRNA expression of 11β-
HSD1 within other tissues of the FKO mice compared to the WT. Data was analysed using 
student T-test. n=3. ****P<0.0001. Error bars represent SEM. Cited from Morgan S. A et al 
2014. 
 
Having demonstrated a tissue specific knock-out of 11β-HSD1 specifically within the adipose 
tissue of the FKO mice at both the DNA and RNA level I continued the validation of my 
model by measuring the oxo-reductase activity of 11β-HSD1 within BAT, subcutaneous and 
liver tissue shown in figure 3-12. I found a significant decrease in 11β-HSD1 oxo-reductase 
activity in BAT (P<0.001) and subcutaneous adipose tissue (P<0.0001) in the FKO compared 
to the WT. I also found no change in the 11β-HSD1 oxo-reductase activity within the liver 
when comparing the WT to FKOs. 
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Figure 3-12 11β-HSD1 oxo-reductase activity of explant adipose tissue and liver 
The 11β-HSD1 oxo-reductase was significantly lower in the FKO mice within the BAT and 
subcutaneous adipose explants when compared to WT. There is no difference in the 11β-
HSD1 oxo-reductase activity in the liver explants between FKO and WT. Data was analysed 
using the student T-test. n=3. ***P<0.001, ****P<0.0001. The error bars represent the 
SEM. Cited from Morgan S. A et al 2014. 
 
Despite having shown a significant decrease in 11β-HSD1 activity in the adipose tissue 
explants of the FKO mice there was higher activity than I would have expected in the knock-
out mice despite there being a significant decrease. I hypothesise that this activity could be 
due to the presence of macrophages and/or preadipocytes present which constitute 30% of the 
adipose tissue and do not express the adiponectin gene and therefore do not have a knock-out 
of 11β-HSD1. I tested this hypothesis by separating the mature adipocyte and stromal 
vascular fractions and testing the 11β-HSD1 oxo-reductase activity present in the different 
fractions so to ascertain which area is responsible for the level of activity seen (Figure 3-13). I 
found that there was no change in 11β-HSD1 oxo-reductase activity in the stromal vascular 
fraction, however I showed a significant decrease in the oxo-reductase activity of 11β-HSD1 
within BAT (P<0.001), subcutaneous (P<0.0001) and gonadal (P<0.001) depots within the 
mature adipocytes. 
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Figure 3-13 Oxo-reductase activity of mature adipocytes and stromal vascular fraction 
There is no change in 11β-HSD1 oxo-reductase activity in any of the adipose depots in the 
stromal vascular fraction between WT and FKO. There is a significant decrease in the 11β-
HSD1 oxo-reductase activity within the BAT, subcutaneous and gonadal with the FKO 
compared to the WT, where the FKO demonstrated almost undetectable activity. Data was 
analysed using the student T-test. n=3. ***P<0.001, ****P<0.0001. The error bars represent 
the SEM. Cited from Morgan S. A et al 2014. 
 
3.3.3 Metabolic assessment of glucocorticoid supplementation in FKO mice 
I utilised this FKO model generated to investigate if GCs reactivated by 11β-HSD1 within 
adipose tissue contribute to the adverse effects of GC excess, and if adipose specific KO of 
11β-HSD1 can recapitulate the beneficial phenotype previously shown with GKO of 11β-
HSD1. This aims to highlight the tissue responsible for the beneficial phenotype confirmed 
following global deletion of 11β-HSD1.  
To investigate this I treated FKO mice with CORT (100 μg/mL), or vehicle via 
drinking water for 5 weeks. In contrast to GKO mice, FKO mice were not protected from 
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increased adiposity or a decrease in lean mass following CORT treatment. I found increases in 
the weight of all fat pads tested (Gonadal, mesenteric, retroperitoneal and subcutaneous) and 
decreases in the weight of muscle beds tested (quadriceps, tibialis anterior, and soleus). This 
overall led to an increase in total body weight following treatment with CORT. This data is 
summarised in table 3-3. 
 
Table 3-3 Effect of CORT treatment on adiposity and lean mass 
FKO mice were not protected from increased adiposity and decreased lean mass following 
treatment with CORT. Data was analysed using two-way ANOVA. n = 6–7 in each group. *P 
< 0.01 †P < 0.001 vs. WT vehicle; §P < 0.05, ‡P < 0.01, ¶P < 0.01 vs. FKO vehicle. Cited 
from Morgan 2014. 
 
Glucose tolerance testing was conducted on WT and FKO mice, I found that there was no 
change in glucose intolerance (Figure 3-14) following CORT treatment between the controls 
and the FKOs. 
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Figure 3-14 Effect of CORT treatment on glucose tolerance 
FKO mice were not protected from glucose intolerance following treatment with CORT. 
Values are calculated as area under the curve. Data were analysed using a two-way ANOVA. 
n = 6–7 in each group. Cited from Morgan et al 2014. 
 
Fasting insulin levels were not changed in WT and FKO mice (Figure 3-15) following CORT 
treatment, the FKOs were not protected from hyperinsulinemia where they showed a 
significant increase (<0.01) in fasting insulin levels following CORT treatment. 
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Figure 3-15 Effect of CORT treatment on insulin tolerance 
FKO mice were not protected from hyperinsulinemia when treated with CORT. There was a 
significant increase in the fasting insulin levels following CORT treatment in the WTs 
compared to vehicle treated, and there was a significant increase in the fasting insulin levels 
following CORT treatment in the FKOs compared to vehicle treated. Data were analysed 
using two-way ANOVA. n = 6–7 in each group. **P < 0.01, vs. WT vehicle; $P < 0.05, $$P < 
0.01, vs. FKO vehicle. Error bars represent SEM. Cited from Morgan S. A et al 2014. 
 
FKO mice showed protection from CORT induced hepatic steotosis and increased expression 
of key lipolytic mediators. This was shown using oil red O staining on frozen liver sections 
and hepatic TAG quantification. However FKO mice were not protected from CORT induced 
increased expression of the hepatic fatty acid transporter CD36 (figure 3-16). 
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Figure 3-16 WAT-specific 11β-HSD1 KO mice, and not liver-specific 11β-HSD1 KO mice, 
are protected from the development of CORT-induced hepatic steatosis.  
Oil red O staining showed that FKO mice were protected from CORT induced hepatic 
steotosis compared with CORT treated controls (wildtype). Hepatic TAG quantification also 
showed that FKO mice were protected from CORT induced hepatic steotosis compared with 
CORT treated controls (wildtype). In addition FKO mice, were protected from increased 
serum free fatty acids and increased mRNA expression of key lipolytic mediators in adipose 
tissue following CORT treatment. However FKO mice were not protected from increased 
expression of the hepatic free fatty acid transporter CD36 following CORT treatment. Data 
were analysed using two-way ANOVA (n = 6–7 in each group). *P < 0.05, ***P < 0.001 vs. 
WT vehicle; ∅P < 0.05, ∅∅P < 0.01 vs. WT CORT. C, CORT; V, vehicle. Error bars represent 
SEM. Cited from Morgan et al 2014. 
 
Taken together, these data suggest intracellular GC excess in adipose tissue is influential in 
the regulation of lipid metabolism.  
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3.4 Discussion 
Since their discovery as potent anti-inflammatory agents (Hench et al 1950) GCs have 
become one of the most widely prescribed drugs in medical practice. GCs however have 
many adverse effects and long term GC therapy can lead to suppression of the HPA axis 
(Krasner et al 1999), insulin resistance (Lansang et al 2011) and diabetes (Lansang et al 
2011). This effect of GCs is amplified by 11β-HSD1 which regulates intracellular GC 
metabolism at the pre-receptor level (Rabbitt et al 2002), via its oxo-reductase activity 
increasing intracellular GC levels by converting circulating inert GC to active GC (Tomlinson 
et al 2001) (Napolitano et al 1998). These negative effects of GC excess therefore are an 
active area of research in an attempt to establish a mechanism to control their adverse effects. 
The data shows that GKO of 11β-HSD1 protects from the adverse effects of GC 
excess, and the mice showed less of an increase in adipose mass following GC treatment. This 
has demonstrated that reactivation of GCs by 11β-HSD1 is the major determinant of the 
phenotype seen with GC excess as opposed to circulating GC levels. This leads to the 
possibility of 11βHSD1 acting as a potential target for the therapeutic treatment of patients 
with Cushing’s syndrome, and to limit the adverse effects seen following the prescription of 
GCs. 
In order to further examine the role of 11β-HSD1 within the body, I generated an 11β-
HSD1 adipose specific knock-out mouse model (FKO), in order to try to elucidate the tissue 
responsible for the protective affects seen following global knock-out of 11β-HSD1.  
FKO mice were generated by utilising cre-lox technology. I found a significant 
decrease in expression of 11β-HSD1 within the adipose of the FKO mice, and normal levels 
of 11β-HSD1 mRNA expression within the other tissue depots of the FKO mice when 
compared to WT. I further confirmed the adipose specific knock-out of 11β-HSD1 by 
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performing an 11β-HSD1 oxo-reductase activity assay. This showed a significant decrease in 
11β-HSD1 activity within the adipose depots and normal 11β-HSD1 activity within the liver 
of the FKO mice compared to the WTs. Despite this significant decrease in expression I did 
however find a higher level of 11β-HSD1 activity than would be expected in a knock-out 
model. This could have been due to the presence of other factors within adipose tissue, for 
example immune and endothelial cells (Dani et al 2012). In order to ascertain what was 
responsible for this activity I performed 11β-HSD1 oxo-reductase activity assays on the 
stromal vascular fraction and also mature adipocytes. I found that within the stromal vascular 
fraction there was a change in the 11β-HSD1 activity between the WT and FKO mice. 
However within the mature adipocytes I found that there was a significant decrease in 11β-
HSD1 expression in the FKO compared to the WT, and that the level of activity seen was the 
level to be expected from a knock-out model. These experiments allowed me to confirm that I 
had successfully generated an adipose specific 11β-HSD1 knock out model. This means that 
the model will be devoid of local GC regeneration within mature adipose tissue cells. 
It has been shown that GKO mice are protected from CS when mice are exposed to 
excess GC. These mice showed improved glucose tolerance, insulin sensitivity, improved 
systolic blood pressure, liver, muscle and skin. I utilised my generated 11β-HSD1 adipose 
specific 11β-HSD1 KO model (FKO) to ascertain the contribution of adipose 11β-HSD1 to 
this protective phenotype. I showed that these mice were not protected from adiposity, 
decreased lean body mass, glucose intolerance, hyperimsulinemia, increased expression of 
CD36 or reduced grip strength following CORT treatment  
Due to not being protected from an increase in the expression of the fatty acid 
transporter CD36, the FKO mice hepatic fatty acid uptake is unaffected by FKO of 11β-HSD1 
within adipose tissue. In addition the failure of the mice to be protected from adiposity 
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decreased lean body mass, glucose intolerance, hyperimsulinemia, or reduced grip strength 
following CORT treatment suggests the role played by 11β-HSD1 within other tissues, such 
as skeletal muscle. 
However these mice were protected from hepatic TAG accumulation, increased serum 
free fatty acids, and hepatic steotosis, and increased adipose expression of hormone sensitive 
lipase (HSL), adipose triglyceride lipase (ATGL), liver X receptor a (LXRa), and liver X 
receptor b (LXRb). In contrast to this LKO mice were not protected from these adverse 
effects of GC treatment, which suggests that increased intracellular GC availability within 
adipose tissue as opposed to the liver is central to the beneficial effects seen in the GKO. 
Triglycerides located within adipose tissue are the main form of energy storage within 
animals (Herada et al 2003). These energy stores are realised in times of need and this process 
is advantages to survival. However the balance between storage and release needs to be 
controlled as dysregulation of these processes may result in metabolic disorders, such as 
obesity and insulin resistance (Herada et al 2003). The classical enzyme, HSL, hydrolyses 
TG, diglycerides (DG), and monoglycerides (MG), with the highest specific activity against 
DG (Belfrage et al. 1978).  
HSL is primarily involved in the mobilisation of stored fats and is stimulated by 
catecholamines and ACTH and inhibited by insulin and has traditionally been considered the 
key lipolytic enzyme in adipocytes (Holm et al 2003). Its hormonal activation occurs via 
cAMP dependent PKA which phosphorylates HSL (Yeaman et al 1990). It hydrolyses the 
first fatty acid from the triglyceride molecule resulting in the release of a fatty acid and 
diglyceride and plays a pivotal role in providing the major source of energy for most tissues, 
and HSL KO mice have been shown to be resistant to obesity (Kraemer et al 2002; Herada. K. 
2003). ATGL has triglyceride-specific lipase activity, and catalyzes the initial step in 
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triglyceride hydrolysis (Kershaw et al 2006; Zimmermann et al 2004). ATGL specifically 
removes the first fatty acid from the TG molecule generating FFA and DG. LXRs are 
regulators of cholesterol, fatty acid and glucose homeostasis and are involved in the 
stimulation of lipogenesis. LXR KO mice have been shown to have decreased adiposity with 
decreased lipid size (Gerin et al 2005). LXRa and LXRb have been identified as key 
regulators of lipid homeostasis in multiple cell types (Repa et al 2000). 
Therefore the control of their expression shown in the FKO mice in my study 
demonstrated a beneficial effect of 11β-HSD1 KO within adipose tissue, as an increase in 
HSL, ATGL. LXRa or LXRb expression would lead to an increase in the breakdown of stored 
triglycerides, and a consequential increase in free fatty acids. 
Our GKO and FKO models demonstrate how knock-out of the 11β-HSD1 gene can go 
some way to ameliorate the negative effects of excess. Although the FKO mice did not show 
the striking protection seen with the GKO mice, they still demonstrated protection from some 
of the adverse effects of GC excess. This theory that KO of 11β-HSD1 will be beneficial is 
based on 11β-HSD1s role in the regeneration of active GC from 11-DHC. In addition to this 
when there is an increase in CORT there is an increase in the production of 11β-HSD1, 
leading to an increased potential for the production of CORT. Also an increase in CORT leads 
to an increase in the regeneration of 11-DHC by 11β-HSD2. This activated CORT can enter 
the cell by binding to the GR within the cytoplasm. Therefore knock-out of 11β-HSD1 can 
have far reaching benefits on the overall effect of CORT on the body. This relationship is 
demonstrated in figure 3-17. 
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Figure 3-17 The relationship between 11β-HSD1, 11-DHC and CORT 
11β-HSD1 converts 11-DHC into CORT. An increase in the concentration of cort leads to an 
increase in the production of 11-DHC by 11β-HSD2 and also an increase in the production of 
the 11β-HSD1 enzyme. Cited from Morgan et al 2014. 
 
Due to the increasing prevalence of obesity on a global scale and its consequential detrimental 
effect on health and the economy where is represents a major risk factor for the development 
of insulin resistance, hyperlipidaemia, type 2 diabetes, and cardiovascular disorders, 
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mechanisms to combat its rise are the centre of much interest. Due to GCs role within the 
development of obesity there is a potential for 11β-HSD1 as a potential target (Bjorntrop et al 
1999). 
Despite the negative side effects of GC excess their action as anti-inflammatory agents 
is still required. Therefore therapy would be required to maintain the anti-inflammatory effect 
yet eliminate the undesirable metabolic side effects.  
The data presented suggests that 11β-HSD1 may offer a novel target to limit the side 
affects seen with exogenous GC administration. I have shown that GKO of 11β-HSD1 
ameliorates the side effects seen with an excess of GC administration and that the adipose 
tissue 11β-HSD1 is partially responsible for the effects seen. This therefore highlights adipose 
11β-HSD1 as a potential tissue for targeting. 
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4. Chapter 4 - 11β-hydroxysteroid dehydrogenase type 1 and brown adipose tissue 
phenotype 
4.1 Methods 
4.1.1 Mitochondrial copy number analysis 
4.1.1.1 Method 
Mitochondrial copy number was assessed using an mtDNA/nDNA ratio on extracted DNA. 
Real-time quantitative PCR was performed using ABI Prism 7,500 Sequence Detection 
System (Applied Biosystems, Warrington, UK). A NovaQUANT™ Human Mitochondrial to 
Nuclear DNA Ratio Kit was used to compare the levels of nuclear to mitochondrial DNA 
(mtDNA). Each well individually tested for one of the four target genes. Nuclear gene 1 was 
compared to mitochondrial gene 1 and nuclear gene 2 was compared to mitochondrial gene 2. 
Ratios between the two genes were calculated and average for each sample to represent the 
mtDNA copy number per cell. The reactions contained: 10 µl of DNA template (2 ng) diluted 
using the appropriate amount of nuclease free water, and 10 µl of 2X RT2 Fast SYBR Green 
Mastermix. The plates were sealed using a clear adhesive film (Applied biosystems, 
Warrington, UK). The results were given as Ct values and the ΔCt values were calculated (Ct 
of gene of interest-Ct of 18S) and given as a fold change (2
-ΔΔCt
). 
4.1.1.2 Probe and primer sequences and details 
A NovaQUANT™ Human Mitochondrial to Nuclear DNA Ratio Kit was used, and was 
supplied by Novagen, this kit composes qPCR plates and PCR primer pairs. The kit has been 
verified to not amplify mitochondrial pseudogenes and to effectively amplify target 
sequences. 
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4.2 Introduction 
Brown adipose tissue (BAT) has emerged as a target for potential exploitation in the treatment 
of obesity and its related metabolic complications. BAT is predominantly localised in the 
intrascapular and paraspinal areas of both humans and rodents, however the concentration of 
BAT shows a decrease with increasing age (Almind et al 2007).  
BAT is the main site for adaptive thermogenesis and responds to fluctuations in 
environmental factors, for example cold and diet, by increasing energy expenditure. 
Following exposure to cold BAT utilises lipids and carbohydrates to generate heat by using 
UCP1 to uncouple electron transport from oxidative phosphorylation, thus playing an active 
role in energy expenditure and fatty acid oxidation (Cannon et al 2008). Being located in the 
mitochondrial inner membrane UCP1 acts as a proton transporter to abolish the proton 
gradient, the driving force of ATP synthesis, allowing the free energy conserved in the proton 
gradient to be dissipated as heat (Watanabe et al 2008). 
With its role in energy expenditure BAT has a central role in the regulation of adipose 
stores within the body, and as such has potential in battling both obesity and diabetes due to 
its striking metabolic capacity, further evidence to support this is that mice deficient in BAT 
develop obesity, insulin resistance and other metabolic abnormalities (Mirbolooki et al 2011; 
Enerback et al 2010). BAT has recently been shown to be present within adult humans using 
18F-FDG PET-CT scans (Cypress et al 2009). This therefore identifies BAT as possible 
therapeutic target within humans. 
Many factors have a negative impact on BAT; two main players are glucocorticoids 
and ageing. With an increase in GC exposure and an increase in ageing there is a decrease in 
BAT function. 
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Excess GCs appear to suppress BAT thermogenesis in both mice and rats, this is 
hypothesised to be due to a central action suppressing BAT thermogenesis (Walker et al 1992; 
Soumano et al 2000). Due to their high rate of administration the side effects of GCs are 
highly prevalent, and therefore there is a need for the development of a mechanism of 
treatment for GC excess. The effect of GC is further increased via the 11β-HSD1 enzyme, 
which converts inactive cortisone to active cortisol. Exposure of adipose cells to GCs 
significantly increases 11β-HSD1 expression and activity, further contributing to GC excess 
(Bujalska et al 1997).  
Increasing age has been shown to have negative effects on BAT and may contribute to 
thermal dysregulation and energy imbalance. Increasing age shows a strongly negative 
correlation with BAT mass and BAT’s metabolic effect, further there is a higher incidence of 
BAT activation following cold exposure in a young rather than an aged cohort (Pfannenberg 
et al; Saito et al 2009). This however has been contradicted by Van Marken Lichenbelt et al 
2009, who showed that there was no correlation between BAT activity and age. Further 
ageing also affects the architecture and distribution of adipose tissue where there is a positive 
correlation between age and lipid size. 
I hypothesised that with increased exposure to GCs and with increasing age there 
would be a detrimental effect on the functioning of BAT. I also hypothesised that with a 
knock-out of 11β-HSD1 and the consequential decrease in tissue regeneration of GC there 
would be a beneficial effect on the functioning of BAT and a possible delay or prevention of 
the negative affects on BAT associated with increasing age. 
To test this hypothesis I analysed BAT samples from young (10 weeks) and aged (100 
weeks) wild-type or global 11β-HSD1 knock-out (GKO) mice. Further separate cohorts have 
been treated with exogenous GC (corticosterone). This allowed me to test the effects of 
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ageing, GC excess and possible beneficial effects of 11β-HSD1 global knock-out on BAT. 
Further to this I generated primary cultures of BAT from young (10 weeks) mice, and 
assessed the effects of GC administration on overall markers of BAT function. 
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4.3 Results 
4.3.1 Effect of ageing on brown adipose tissue in vivo 
I wanted to investigate the effect of ageing on BAT. To do this I obtained tissue samples from 
young (10 weeks) and aged (100 weeks) cohorts, of both wild-type (WT) black 6 and 11β-
HSD1 global knock-out (GKO) mice. I initially analysed the base line effect of ageing on 
these tissues by comparing WT young and aged tissues. Potential changes in gene expression, 
mitochondrial copy number analysis, protein blot analysis, histological analysis and tissue 
weight were assessed. 
To begin I analysed the tissue weight data (Figure 4-1) to see if ageing resulted in a 
change in BAT mass. I found that there was a significant increase in the tissue weight/body 
weight ratio with ageing (p<0.001). This was a combination of an increase in body weight and 
an increase in BAT weight within the aged cohort (Figure 4-1). 
 
 
Figure 4-1 Effect of ageing on brown adipose tissue weight in wild-type mice 
Ageing leads to a significant increase in BAT tissue weight/body weight ratio within WT mice. 
Aged mice showed a significantly higher tissue weight/body weight ration than the young 
mice. Data was analysed using student T-test. ***P<0.001. n=11 (young) n=10 (aged). Error 
bars represent SEM. 
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Having noted an increase in tissue weight with age I investigated potential mechanisms which 
may be responsible for this change and also if the increase in BAT tissue weight led to a 
potential improvement in BAT function. I initially analysed potential age related changes in 
11β-HSD1 expression, as the 11β-HSD1 enzyme has previously been shown to be a mediator 
of BAT function. I found that there was a significant increase in 11β-HSD1 expression in the 
aged mice compared to the young (P<0.0001) as shown in figure 4-2. Having seen this 
striking increase in 11β-HSD1 expression with age, and the consequential potential for an 
increase in local GC reactivation I wanted to see if there was also an increase in 
glucocorticoid receptor expression (nr3c1). I again measured mRNA expression via RT-PCR. 
I found that there were no changes in nr3c1 expression (figure 4-2) with age and therefore 
infer that there is no change in glucocorticoid receptor content. 
 
Figure 4-2 Effect of ageing on 11β-HSD1 and nr3c1 mRNA expression in brown adipose 
tissue 
Ageing leads to a significant increase in 11β-HSD1 mRNA expression in WT mice. Aged mice 
showed significantly higher 11β-HSD1 mRNA expression than the young mice. Error bars 
represent SEM. Ageing leads to no change in the mRNA expression of nr3c1. Aged and young 
mice showed the same level of nr3c1 expression. Data was analysed using student T-test. ***. 
P<0.001. ****P<0.0001. n=11 (young) n=10 (aged). Error bars represent SEM. 
 
Due to BAT being central to non-shivering thermogenesis and this process involving the 
utilisation of mitochondria, I continued my investigations by analysing potential effects of 
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ageing on markers of mitochondrial function in an attempt to ascertain its effects on the 
potential for non-shivering thermogenesis. I began by performing RT-PCR analysis on 
mitochondrial transcription factors which are related to potential improvements in 
mitochondrial function. I analysed changes in the expression of PGC-1α, PRDM16 and 
PPARγ with age (Figure 4-3) and found a significant (p<0.05) increase in the expression of 
PRDM16 and PPARγ with age. 
 
Figure 4-3 Effect of ageing on PGC-1α, PRDM16 and PPARγ mRNA expression in brown 
adipose tissue 
Ageing leads to a significant increase in the mRNA expression of PRDM16 and PPARγ. Aged 
mice showed a significantly higher mRNA expression of PRDM16 and PPARγ than the young 
mice. There was no significant change in the mRNA levels of PGC-1α between young and 
aged mice. Data was analysed using student T-test. * P<0.05. n=11 (young) n=10 (aged). 
Error bars represent SEM. 
 
Having noted increases in mitochondrial transcription factors I proceeded to see if there were 
age related changes in the expression of genes located within the electron transport chain and 
non-shivering thermogenesis. I analysed the expression of UCP1 (Figure 4-4), Cox7a1, 
Cox8b, and CoxIV (Figure 4-5). Further to this I analysed changes in protein concentration of 
UCP1 via western blot analysis (Figure 4-4). I found a significant increase in the mRNA 
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(p<0.001) and protein (p<0.05) of UCP1, and also a significant increase in both Cox7a1 and 
Cox8b mRNA expression (p<0.05) with age. 
 
 
 
Figure 4-4 Effect of ageing on UCP1 mRNA and protein expression in brown adipose tissue 
Ageing leads to a significant increase in the mRNA expression of UCP1. Aged mice showed a 
significantly higher mRNA and protein expression of UCP1 than the young mice. Data was 
analysed using student T-test. *** P<0.001. n=11 (young) n=10 (aged). Data was analysed 
using densitometry. * P<0.05. n=3. Error bars represent SEM. 
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Figure 4-5 Effect of ageing on Cox7a1, Cox8b and CoxIV mRNA expression in brown 
adipose tissue 
Ageing leads to a significant increase in the mRNA expression of Cox7a1 and Cox8b. Aged 
mice showed a significantly higher mRNA expression of Cox7a1 and Cox8b than the young 
mice. There was no significant difference in the mRNA expression of CoxIV between the 
young and aged mice. Data was analysed using student T-test. * P<0.05. n=11 (young) n=10 
(aged). Error bars represent SEM. 
 
Having seen that there are increases in the concentration of BAT markers with age I then went 
on to see if there were age related changes in the expression of genes involved in the 
enhancement of mitochondrial biogenesis. I analysed the expression of NRF1 and TFAM 
(Figure 4-6). I found significant increases in the expression of TFAM (p<0.05) and NRF1 
(p<0.01) in the aged cohort compared to the young cohort. 
Chapter 4 - 11β-hydroxysteroid dehydrogenase type 1 and brown adipose tissue phenotype 
 
111 
 
 
Figure 4-6 Effect of ageing on expression of TFAM and NRF1 in brown adipose tissue 
Ageing leads to a significant increase in the mRNA expression of NRF1 and TFAM. Aged 
mice showed a significantly higher mRNA expression of NRF1 and TFAM than the young 
mice. Data was analysed using student T-test. * P<0.05, **P<0.01. n=11 (young) n=10 
(aged). Error bars represent SEM. 
 
Having noted increases in genes involved in mitochondrial function and biogenesis I 
investigated possible effects on mitochondrial copy number. I assessed changes in 
mitochondrial copy number and also changes in the protein concentration of mitochondrial 
complexes (Figure 4-7). I found a significant increase in mitochondrial copy number with age 
(p<0.05) and also a significant increase in the protein expression of complex 2 (p<0.05) with 
age. 
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Figure 4-7 Effect of ageing on mitochondrial copy number and mitochondrial complex 
protein expression in brown adipose tissue 
Ageing leads to a significant increase in mitochondrial copy number and protein expression 
of CIV-MTCO1. There was no significant change in the protein expression of CII-SDHB 
between the young (Y) and aged (A) mice. Data was analysed using student T-test. * P<0.05. 
n=6. Error bars represent SEM. Data was analysed using densitometry. * P<0.05. n=3. 
4.3.2 Effect of exposure to exogenous glucocorticoid on brown adipose tissue in 
vivo 
Previous studies have demonstrated the negative effects of GCs on BAT function. I wished to 
test the effect of exogenous GC treatment on BAT in an attempt to mimic the effect of 
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prescribed GCs. To test this I obtained archived tissue samples from young (10 weeks) mice, 
of WT genotype that had been exposed to either corticosterone or vehicle. I performed RT-
PCR to measure potential changes in gene expression with and without the administration of 
exogenous GCs. I also measured mitochondrial copy number, and measured changes in tissue 
weight. 
I began by analysing the effect of administration of exogenous GCs on BAT tissue 
weight as ratio to total body weight. I found that there was significant decrease (p<0.01) in the 
BAT weight/body weight ratio in the mice treated with exogenous GC compared to those 
treated with vehicle (Figure 4-8). 
 
 
Figure 4-8 Effect of exposure to exogenous glucocorticoid on BAT mass in brown adipose 
tissue 
The exposure to exogenous GC, CORT leads to a significant increase in the body weight/BAT 
weight ratio. Mice treated with exogenous CORT had a higher body weight/BAT weight ratio 
than those treated with vehicle. Data was analysed using student T-test. * P<0.05, **P<0.01. 
n=7 (vehicle) n=6 (CORT). Error bars represent SEM. 
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Having seen these significant changes in the body weight/BAT weight ratio I investigated the 
possible reasons behind this. I firstly looked to see if there were changes in 11β-HSD1 
expression following GC administration (Figure 4-9). I found that there was a significant 
increase in the expression of 11β-HSD1 in the mice treated with corticosterone (p<0.01) 
compared with those treated with vehicle. Having seen these significant effects on 11β-HSD1 
expression following exogenous GC administration I then investigated the effect of 
endogenous GC administration on glucocorticoid receptor (nr3c1) mRNA expression (Figure 
4.9). I found no changes in nr3c1 mRNA expression in mice treated with corticosterone when 
compared to those treated with vehicle. 
 
Figure 4-9 Effect of exogenous glucocorticoid administration on 11β-HSD1 and nr3c1 
expression in brown adipose tissue 
The exposure to exogenous GC, CORT leads to a significant increase in mRNA expression of 
11β-HSD1 and no change in the mRNA expression of nr2c1. Mice treated with exogenous 
CORT had a higher mRNA expression level of 11β-HSD1 than those treated with vehicle. 
Data was analysed using student T-test. **P<0.01. n=7 (vehicle) n=6 (CORT). Error bars 
represent SEM. 
 
I went on to investigate the effect of GC administration on the expression of BAT 
transcription factors. I analysed changes in the expression of PGC-1α, PRDM16 and PPARγ 
(Figure 4-10). I found no changes in the mRNA expression of any of the transcription factors 
following exposure to exogenous GCs. I then went on to see if there were GC administration 
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related changes in the expression of BAT markers. I analysed the expression of UCP1, 
Cox7a1, Cox8b, and CoxIV (Figure 4-10). I found a significant decrease in the mRNA 
expression of UCP1 (p<0.05) following treatment with corticosterone. 
 
Figure 4-10 Effect of exogenous glucocorticoid administration on PGC-1α, PRDM16, 
PPARγ, UCP1, Cox7a1, Cox8b and CoxIV expression in brown adipose tissue 
The exposure to exogenous GC, CORT lead to a significant decrease in the expression of 
UCP1. Mice treated with exogenous CORT had a significantly lower mRNA expression of 
UCP1 than those treated with vehicle. There was no significant change in the mRNA 
expression of PGC-1α, PRDM16, PPARγ, Cox7a1, Cox8b or CoxIV following exposure to 
CORT. Data was analysed using student T-test. *P<0.05, **P<0.01. n=7 (vehicle) n=6 
(CORT). Error bars represent SEM. 
 
Having noted changes in the expression of UCP1 following GC treatment I then went on to 
see if there were GC administration related changes in the expression genes related to 
mitochondrial biogenesis. I analysed the expression of NRF1 and TFAM and found no 
changes in their expression following GC treatment (Figure 4.11). 
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Figure 4-11 Effect of exposure to exogenous glucocorticoid on NRF1 and TFAM mRNA 
expression in brown adipose tissue 
The exposure to exogenous GC, CORT leads to no change in mRNA expression of NRF1 and 
TRAM. Mice treated with exogenous CORT had the same mRNA expression level of NRF1 
and TFAM as those treated with vehicle. Data was analysed using student T-test.  n=7 
(vehicle) n=6 (CORT). Error bars represent SEM. 
 
Having noted a decrease in the mRNA expression of UCP1 following the administration of 
exogenous GC I investigated possible effects on mitochondrial DNA copy number (Figure 4-
12). I found no change in the mitochondrial copy number following exposure to 
corticosterone.  
 
Figure 4-12 Effect of exogenous glucocorticoid administration on mitochondrial DNA copy 
number in brown adipose tissue 
The exposure to exogenous GC, CORT leads to no change in mitochondrial copy number. 
Mice treated with exogenous CORT had no significant change in mitochondrial copy number 
as those treated with vehicle. Data was analysed using student T-test.  n=3. Error bars 
represent SEM. 
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4.3.3 Effect of 11β-HSD1 knock-out on animals treated with exogenous 
glucocorticoids 
 
Having seen significant changes in mRNA expression of mitochondrial related genes with 
GKO of 11β-HSD1 and also significant changes in the mRNA expression of mitochondrial 
related genes with exogenous GC treatment I wished to test whether GKO of 11β-HSD1 
would protect BAT function from the negative effects of exogenous GC treatment. To test this 
I obtained tissue from WT and GKO genotypes and also those treated with corticosterone. 
The tissue samples were from young (10 week) mice.  
I investigated the effect of GC administration on the expression of BAT transcription 
factors. I analysed changes in the expression of PGC-1α, PRDM16 and PPARγ with GKO in 
mice treated with corticosterone (Figure 4-13). I found a significant increase in the mRNA 
expression of PRDM16 (P<0.01) with GKO in mice treated with corticosterone. 
 
Figure 4-13 Effect of GKO on PGC-1α, PRDM16 and PPARγ expression in samples treated 
with exogenous glucocorticoid in brown adipose tissue 
11β-HSD1 knock-out leads to a significant increase in PRDM16 expression following 
treatment with corticosterone. There was no significant change in the mRNA expression of 
PGC-1α or PPARγ with genotype following treatment with corticosterone. Data was analysed 
using student T-test. *P<0.05, ** P<0.01. n=7 (vehicle) n=6 (cort). Error bars represent 
SEM. 
 
Chapter 4 - 11β-hydroxysteroid dehydrogenase type 1 and brown adipose tissue phenotype 
 
118 
 
I then went on to see if there were GC administration related changes in the expression of 
BAT markers. I analysed the expression of UCP1, Cox7a1, Cox8b, and CoxIV (Figure 4-14). 
I found a significant increase in the mRNA expression of UCP1 (P<0.05), Cox8b (P<0.01), 
and CoxIV (P<0.05) with GKO following treatment with corticosterone. Further to this I 
analysed changes in UCP1 protein expression with GKO following treatment with 
corticosterone (Figure 4-14). I found a significant increase in UCP1 expression with GKO in 
the samples treated with corticosterone (P<0.05). 
 
 
Figure 4-14 Effect of 11β-HSD1 GKO on mRNA expression of UCP1, Cox7a1, Cox8b, and 
CoxIV in mice exposed to exogenous glucocorticoid in brown adipose tissue 
11β-HSD1 knock-out led to a significant increase in UCP1, Cox8b, and CoxIV mRNA 
expression and a significant increase in UCP1 protein expression following treatment with 
corticosterone. There was no significant change in the mRNA expression of Cox7a1 with 
genotype following exposure to corticosterone. Data was analysed using student T-test. 
*P<0.05, ** P<0.01, ***P<0.001. n=7 (vehicle) n=6 (cort).Data was analysed using 
densitometry. *P<0.05, ** P<0.01. n=3. Error bars represent SEM. 
 
I then went on to see if there were GC administration related changes in the expression of 
transcription factors. I analysed the expression of NRF1 and TFAM (Figure 4-15). I found no 
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change in the mRNA expression of either NRF1 or TFAM in the GKOs following treatment 
with corticosterone. 
 
Figure 4-15 Effect of 11β-HSD1 GKO on mRNA expression of NRF1 and TFAM in mice 
exposed to exogenous glucocorticoid in brown adipose tissue 
There was no significant change in the mRNA expression of NRF1 or TFAM with genotype 
following treatment with corticosterone. Data was analysed using student T-test. n=7 
(vehicle) n=6 (cort). Error bars represent SEM. 
 
4.3.4 Effect of glucocorticoid excess on brown adipose tissue in vitro 
Having seen effects following the administration of GCs I wished to investigate this effect 
further. To achieve this I generated primary tissue cultures from intra-scapular BAT from 
wild-type mice aged between 9 and 10 weeks. I analysed the effect of exposure of these 
primary cultures to GC treatment for a four hour period where dexamethasone was added for 
6 hours. I tested the effect of exogenous GC treatment on cells maintained at 37°C. I 
performed; RT-PCR to measure potential changes in gene expression, and 11β-HSD1 activity 
assays to test potential changes in the activity of 11β-HSD1 following GC administration. 
I initially investigated the effect of the addition of exogenous GC on 11β-HSD1 
expression (figure 4.16). I found that there was a significant increase in the expression of 11β-
HSD1 following the administration of GC (p<0.05). However no significant changes in 11β-
HSD1 activity. 
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Figure 4-16 Effect of GC on 11β-HSD1 expression and activity in brown adipose tissue 
The exposure to exogenous GC led to an increase in mRNA expression of 11β-HSD1. Mice 
treated with exogenous GC had a significant increase in mRNA expression of 11β-HSD1 
compared to untreated cells. There was no change in 11β-HSD1 activity following GC 
treatment. Data was analysed using student T-test. *P<0.05, **P<0.01   n=3. Error bars 
represent SEM. 
 
I went on to investigate the effect of exposure to GC on the expression of BAT transcription 
factors. I analysed changes in the expression of PGC-1α, PRDM16 and PPARγ (Figure 4-17). 
I then went on to see if there were GC related changes in the expression of BAT markers. I 
analysed the expression of UCP1, Cox7a1, and Cox8b with and without GC treatment (Figure 
4-17). I found a significant decrease in the expression of Cox8b (P<0.05) when treated with 
exogenous GC. 
 
Figure 4-17 Effect of exogenous GC treatment on the expression of PGC-1α, PRDM16, 
PPARγ, UCP1, Cox7a1, and Cox8b in brown adipose tissue 
The exposure to exogenous GC led to a significant decrease in mRNA expression of Cox8b. 
Data was analysed using student T-test. *P<0.05.  n=3. Error bars represent SEM. 
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Having seen significant changes in genes located within the mitochondrial I went on to see if 
there were GC related changes in the expression of mitochondrial transcription factors. I 
analysed the expression of NRF1 and TFAM (Figure 4-18). I found a significant decrease in 
the mRNA expression of NRF (p<0.05) and TFAM (p<0.01). 
 
Figure 4-18 Effect of exogenous GC treatment on the expression of NRF1 and TFAM in 
brown adipose tissue 
The exposure to exogenous GC led to a decrease in mRNA expression of NRF1 and TFAM 
when compared to untreated cells. Data was analysed using student T-test. *P<0.05, 
**P<0.01.  n=3. Error bars represent SEM. 
 
4.3.5 Effect of 11β-HSD1 knock-out on brown adipose tissue in vivo 
Previous work has highlighted the beneficial effects of 11β-HSD1 knock-out on BAT 
function and also conversely how an increase in 11β-HSD1 can be of detriment to BAT 
function. This led me to analyse the potential beneficial effects of global knock-out of 11β-
HSD1 (GKO) on BAT without exposure to exogenous GCs for a short and a prolonged 
period. I used tissue samples from young (10 weeks) and aged (100 weeks) cohorts, of wild-
type and 11β-HSD1 knock-out genotypes. 
I began by seeing if there was a change in BAT weight/body weight ratio with GKO in 
both the young and aged cohorts (Figure 4.19). I found a significant increase in BAT 
weight/body weight ratio in the aged cohort (p<0.05), however I found no change in BAT 
weight/body weight ratio in the young cohort. 
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Figure 4-19 Effect of 11β-HSD1 knock-out on brown adipose tissue weight in brown adipose 
tissue 
11β-HSD1 knock-out leads to a significant increase in BAT weight/body weight ratio in aged 
mice. Aged mice showed a significantly higher BAT weight/body weight ratio with 11β-HSD1 
KO compared to WT. There was no significant change in BAT weight/body weight ratio in 
young mice between WT and GKO. Data was analysed using student T-test. * P<0.05. n =5 
for WT young, n=9 for GKO young. N = 6 for WT aged, n =6 for GKO aged. Error bars 
represent SEM. 
 
Due to BAT being central to non-shivering thermogenesis and this involves the utilisation of 
mitochondria; I continued my investigations by analysing potential effects of 11β-HSD1 
GKO on markers of mitochondrial function. I began by performing RT-PCR analysis on 
mitochondrial transcription factors which are related to potential improvements in 
mitochondrial function. I analysed changes in the expression of PGC-1α, PRDM16 and 
PPARγ with age (Figure 4.20). I found a significant increase in the mRNA expression of 
PGC-1α (p<0.05), PRDM16 (p<0.05), and PPARγ (p<0.05) with 11β-HSD1 GKO in the 
young cohort, and a significant increase in the mRNA expression of PGC-1α (p<0.001), 
PRDM16 (p<0.05) and PPARγ (p<0.01) with 11β-HSD1 GKO in the aged cohort. 
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Figure 4-20 Changes in mRNA of PGC-1α, PRDM16, and PPARγ between WT and GKO in 
young and aged cohorts in brown adipose tissue 
11β-HSD1 knock-out leads to a significant increase in PGC-1α, PRDM16 and PPARγ 
expression in both young and aged mice. Young and aged mice showed a significantly 
increased PGC-1α, PRDM16, and PPARγ expression with 11β-HSD1 GKO compared to WT. 
Data was analysed using student T-test. * P<0.05, **P<0.01, ***P<0.001. n =5 for WT 
young, n=9 for GKO young. N = 6 for WT aged, n =6 for GKO aged. Error bars represent 
SEM. 
 
Due to the transcription factors being regulators of the expression of mitochondrial genes I 
then went on to see if there were changes in the expression of an array of mitochondrial 
structural genes. I analysed the expression of UCP1, Cox7a1, Cox8b, and CoxIV (Figure 
5.21). I found no change in expression in the young cohort. Within the aged cohort I found 
significant increases in the mRNA expression of Cox7a1 (p<0.01), Cox8b (P<0.01), and 
CoxIV (P<0.05). Further to this I analysed changes in protein concentration of UCP1 via 
western blot analysis (Figure 4.21). I found no change in the protein expression of UCP1 in 
the young cohort, however I found a significant increase in the expression of UCP1 within the 
aged cohort (P<0.05). 
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Figure 4-21 Changes in mRNA of UCP1, Cox7a1, Cox8b, and CoxIV and UCP1 protein 
between WT and GKO in young and aged cohorts in brown adipose tissue 
11β-HSD1 knock-out led to a significant increase in Cox7a1, Cox8b, and CoxIV mRNA 
expression and UCP1 protein expression in aged mice. Aged mice showed a significantly 
increased Cox7a1, Cox8b and CoxIV mRNA expression with 11β-HSD1 GKO compared to 
WT but no significant change in UCP1 expression. Aged mice showed a significant increase 
in UCP1 protein expression with 11β-HSD1 GKO compared to WT. Young mice showed no 
significant change in mRNA UCP1, Cox7a1, Cox8b or CoxIV expression or UCP1 protein 
expression between genotypes. Data was analysed using student T-test. * P<0.05, **P<0.01. 
n =5 for WT young, n=9 for GKO young. N = 6 for WT aged, n =6 for GKO aged. Data was 
analysed using densitometry. * P<0.05. n =3. Error bars represent SEM. 
 
Having seen increases in the expression of mitochondrial genes I investigated possible effects 
of GKO on the expression of genes involved in regulating mitochondrial biogenesis. I 
analysed the expression of NRF1 and TFAM (Figure 4.22). I found that there was a 
significant increase in both NRF1 (p<0.05) and TFAM (p<0.05) with GKO in the young 
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cohort. I found that in the aged cohort there was a significant increase in NRF1 (p<0.05), but 
no change in TFAM. 
 
Figure 4-22 Changes in mRNA of NRF1 and TFAM comparing WT to GKO in young and 
aged cohorts in brown adipose tissue 
11β-HSD1 knock-out leads to a significant increase in NRF1 and TFAM mRNA expression in 
young mice, and a significant increase in NRF1 mRNA expression in aged mice. Young mice 
showed a significantly increased NRF1 and TFAM mRNA expression with 11β-HSD1 GKO 
compared to WT. Aged mice showed a significant increase in NRF1 mRNA expression with 
11β-HSD1 GKO compared to WT. aged mice showed no significant change in TFAM 
expression in the GKO compared to WT. Data was analysed using student T-test. * P<0.05. n 
=5 for WT young, n=9 for GKO young. N = 6 for WT aged, n =6 for GKO aged. Error bars 
represent SEM. 
 
Having noted increases in genes involved mitochondrial function I investigated possible 
effects on mitochondrial copy number. I assessed changes in mitochondrial copy number, and 
performed western blot analysis on mitochondrial complexes (Figure 4-23). I found no 
changes in mitochondrial copy number between WT and GKO in the young cohort, however I 
found a significant increase in mitochondrial copy number in the GKOs compared to the wild-
types in the aged cohort (p<0.05). In addition to this I found a significant increase in protein 
expression of mitochondrial complex 2 (p<0.05) with GKO in the aged tissue samples. 
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Figure 4-23 Changes in mitochondrial copy number and protein concentration of 
mitochondrial complexes comparing WT to GKO in young and aged cohorts in brown 
adipose tissue 
11β-HSD1 knock-out led to significant increase in mitochondrial copy number in aged mice 
(B) but no change in young mice (A). 11β-HSD1 knock-out also led to a significant increase 
in the protein expression of C11-SDHB in aged mice (E, F) but no change in the protein 
expression of CIV-MTCO1 (F, H). In addition there was no change in protein expression of 
C11-SDHB or CIV-MTCO1 in the young mice with 11β-HSD1 knock-out (C, D, G). Data was 
analysed using student T-test. * P<0.05. n =6. Data was analysed using densitometry. * 
P<0.05. n =3. Error bars represent SEM. 
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4.3.6 Effect of 11β-HSD1 knock out on primary cultures of brown adipocytes 
Having seen changes in gene and protein expression following global 11β-HSD1 knock-out I 
wished to take these investigations further by investigating the effect of global knock-out of 
11β-HSD1 on BAT primary culture. I obtained primary brown adipose tissue cultures from 
intrascapular BAT from both 11β-HSD1 global knock-out and wild-type mice genotypes of 
mice aged 10 weeks. 
I investigated the effect of 11β-HSD1 GKO on the expression of PGC-1α, PRDM16 
and PPARγ (Figure 4-24). I found a significant increase in the expression of PGC-1α (p<0.05) 
and PPARγ (p<0.05). I then proceeded to test the effect of 11β-HSD1 knock-out on the 
mRNA expression of UCP1, Cox7a1, and Cox8b (Figure 4.24). I found a significant increase 
in the expression of UCP1 (p<0.05), Cox7a1 (p<0.05), and Cox8b (p<0.05) in the 11β-HSD1 
knock-out mice. 
 
Figure 4-24 Effect of 11β-HSD1 knock-out on the expression of PGC-1α, PRDM16, PPARγ, 
UCP1, Cox7a1 and Cox8b in brown adipose tissue 
11β-HSD1 knock-out led to a significant increase in the mRNA expression of UCP1, Cox7a1, 
Cox8b PGC-1α and PPARγ in primary cultures. There was no significant change in the 
mRNA expression of PPARγ or Cox7a1. Data was analysed using student T-test. * P<0.05. n 
=3. Error bars represent SEM. 
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I went on to investigate the effect of knock-out of 11β-HSD1 on the expression of 
mitochondrial regulators (figure 4.25). I found a significant increase in the expression of 
NRF1 (p<0.05) but no change in the expression of TFAM. 
 
Figure 4-25 Effect of 11β-HSD1 knock-out on the expression of NRF1 and TFAM in brown 
adipose tissue 
11β-HSD1 knock-out leads to a significant increase in NRF1 mRNA expression in primary 
cultures. There was no change in the expression of TFAM. Data was analysed using student 
T-test. * P<0.05. n =3. Error bars represent SEM. 
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4.4 Discussion 
Ageing has been shown to have a negative effect on BAT in humans, where there is a strong 
negative correlation with age and BAT mass which may contribute to thermal dysregulation 
and energy imbalance (Cypress et al 2009). In addition, the metabolic effect of BAT shows a 
decrease with increasing age (Pfannenberg et al 2010). It is thought that the decrease in BAT 
mass in humans seen with age is due to a decreased need for thermogenesis. I investigated the 
effect of age on BAT via young (10 weeks) and aged (100 weeks) WT tissue samples in mice.  
I found a significant increase in BAT weight/body weight ratio with age; which 
contradicts with previous literature which showed a decrease in BAT weight with age 
(Pfannenberg et al 2010). This increase in quantity of BAT with age could lead to a higher 
output from the BAT, leading to positive metabolic effects. However looking purely at tissue 
weight does not assess the quality of the adipose tissue, which may have a larger mass due to 
an increase in lipid quantity, and the function of the BAT may have diminished as a 
consequence of age (Lecoulte et al 2011). 
To further analyse the BAT samples I performed mRNA analysis on an array of genes. 
I found that there was a significant increase in 11β-HSD1 mRNA expression in the aged mice. 
This consequently leads to a higher capacity for local reactivation of GCs in the aged mice via 
the oxo-reductase activity of the 11β-HSD1 enzyme, converting inactive 11-
dehydrocorticosterone to corticosterone (Seckl et al 2001). This potentially higher 
concentration of local active GC could have detrimental effects on the BAT of the aged mice 
due to the negative effects of GC on BAT activity and function, where they suppress BAT 
thermogenesis (Walker et al 1992) (Soumano et al 2000). 
It has previously been shown that 11β-HSD1 expression has a negative effect on BAT 
and therefore I hypothesised that the aged mice would have a decrease in BAT activity and 
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function due their increased exposure to higher intra-cellular levels of GC. I found significant 
increases in the mRNA expression of PRDM16 and PPARγ in the aged mice. This is 
contradictory to what I expected as age has been shown to be a negative regulator of BAT 
function and due to these genes being positively correlated with an increase in BAT function I 
would expect a decrease in their expression with age. 
I hypothesise that the increases in PRDM16 and PPARγ that I showed is due to the 
non-thermoneutral temperatures that the mice have been housed at. All animals used within 
these experiments were housed within non-thermoneutral conditions within the animal house 
(24°C), which is a lower temperature than thermoneutrality (30°C). Normal animal house 
conditions have been shown to lead to chronic thermal stress to mice (Golozoubova et al 
2004). As a consequence of this the aged mice have been exposed to a lifetime at non-
thermalneutral conditions and therefore have activation of non-shivering thermogenesis, and 
an increase in cold-inducible genes. PRDM16 and PPARγ are both cold inducible (Murholm. 
M. 2009). I infer that this lifelong exposure to non-thermoneutrality overrides the previously 
seen and expected negative effects of ageing. In addition these increases in PRDM16 and 
PPARγ with age could explain my observed increase in BAT mass with age as both PRDM16 
and PPARγ contribute to an increase in BAT differentiation and BAT mass (Murholm. M. 
2009; Tzu-Ann. C. 1996). In addition older mice are likely to be less active and therefore have 
a greater require for BAT activity to maintain the correct temperature. 
  I further investigated the effect of age by examining its effect on traditional markers of 
BAT. I found significant increases in the expression of UCP1, Cox7a1, and Cox8b at the 
mRNA level, and also a significant increase in UCP1 expression at the protein level. I 
hypothesise that these increases in expression are a consequence of the non-thermoneutral 
conditions that the mice were housed in, as described earlier. Further these markers are 
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downstream targets of PPARγ and PRDM16 and therefore due to the increases previously 
seen in PPARγ and PRDM16 it would be thought that there would be consequential increases 
in these genes too which is what was seen in my data (Seale et al 2007). In addition to this 
PPARγ has been shown to cooperate with PGC-1α to induce the expression of UCP1 and 
other typical brown adipose markers (Pisani et al 2011; Watanabe et al 2008). 
UCP1 is involved in regulating the energy balance, which was first proposed by 
Rothwell and Stock in 1979, and therefore an increase in its expression could have beneficial 
effects on obesity (Rothwell et al 1979). It has previously been shown that with decreasing 
temperature there is an increase in UCP1, and this supports the hypothesis that due to the 
ageing mice having been exposed to a lifetime of below thermoneutral temperatures there is 
an adaptive response which leads to an increase in UCP1 expression (Van Marken Lichtenbelt 
et al 2009). 
I continued my studies by analysing differences with ageing on the expression of 
NRF1 and transcriptional factor A (TFAM) which are involved in mitochondrial DNA 
transcription and regulation including respiratory subunits and factors involved in the 
replication and transcription of mitochondrial DNA (Chau et al 1992; Scarpulla et al 1997). I 
found significant increases in both NRF1 and TFAM in the aged mice, I again hypothesise 
that this is due to the non-thermoneutral conditions that the mice were housed at, due to the 
expression of NRF1 being rapidly induced by cold-exposure (Puigserver et al 1998). 
NRF1 has been shown to interact with PGC-1α to be involved in the transcriptional 
control of mitochondrial biogenesis during adaptive thermogenesis; therefore its increase in 
expression may correlate with an increase in mitochondria and therefore an increase in the 
potential for non-shivering thermogenesis, which could have beneficial metabolic effects (Wu 
et al 1999).  
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I found that there was a significant increase in mitochondria copy number in the aged 
mice compared to the young, and that there was a significant increase in complex 4 
expression with age. This increase in mitochondrial copy number was expected due to the 
previous data I have generated showing increases in mitochondrial genes and also TFAM and 
NRF1 which are involved in mitochondrial biogenesis and have previously been shown to be 
positively correlated with mitochondrial copy number (Ekstrand et al 2004). 
My findings are contradictory to studies which have shown that with increasing age 
there is a decrease in BAT function, which has been shown in both humans and rodents 
(Pfannenberg et al 2010). I hypothesise that this is due to the non-thermoneutral temperatures 
that the mice were housed at, and that a lifetime exposure to non-thermal temperatures is 
responsible to the increase in BAT markers that I found. This effect of standard animal house 
conditions (18-22°C) and the chronic thermal stress that it produces has been previously 
highlighted by Golozoubova et al 2004, who showed that these mice increase their food intake 
by 50-60%. In addition recent studies within humans have shown that cold exposure leads to 
an increase in BAT (Lichtenbelt et al 2015). I therefore conclude that the constant thermal 
stress incurred from animal house conditions severely effects the animals BAT development 
and function. Overall my ageing studies are supportive of 11β-HSD1 having a regulatory role 
in BAT metabolism, these affects are directionally consistent with young and old, however it 
is the aged cohort which reach statistical significance more often. This may be a consequence 
of the effect of 11β-HSD1 KO having a greater period of time to exert its effects within the 
aged cohort. This is due to 11β-HSD1’s role in the reactivation of active GC and with 
prolonged decrease in reactivated GC being present there is a more striking effect seen. 
I extended my study to look into the effects of exogenous GC administration on BAT. 
GCs have previously been shown to play a crucial role in adipocyte biology, where they are 
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central to the differentiation of pre-adipocytes to mature adipocytes (Hauner. H. 1987). 
Further previous studies have shown that GCs suppress BAT thermogenesis, and that UCP1 
expression negatively correlates with GC concentration (Soumano. K. 2000). 
I found that there was a significant increase in the BAT weight/body weight ratio in 
the mice treated with GC. This data suggests that with an increase in GC availability there is 
an increase in BAT mass. I further analysed the effect of exogenous GC treatment on BAT by 
measuring its effect on 11β-HSD1 expression. I found a significant increase in 11β-HSD1 
expression in tissues from mice treated with corticosterone. This is in agreement with 
previous data which shows that GCs are stimulatory to the expression of 11β-HSD1 (Kaur et 
al 2007). As a consequence of this increase in 11β-HSD1 expression in the GC treated tissues, 
there will be a potential for an increase in the intra-cellular regeneration of active GC, further 
adding to the increase in GC concentration in these mice. 
Having noted these changes I assessed the effect of endogenous GC treatment on the 
expression of an array of BAT markers. I found no changes in the expression of nr3c1, PGC-
1α, PRDM16, PPARγ, Cox7a1, Cox8b, CoxIV, NRF1, or TFAM following treatment with 
corticosterone. However I did find significant decreases in the expression of UCP1. This 
shows that following treatment with exogenous GC there is a detrimental effect on UCP1 
expression within BAT which would lead to a decreased capacity for the tissue to undergo 
non-shivering thermogenesis, due to UCP1 being central to this process in its role in 
uncoupling respiration. Due to this there would be a decrease in BAT function within these 
mice leading to possible obesity and metabolic consequences. 
To further investigate the effect of GC on BAT function I analysed the effect of GC 
administration on terminally differentiated BAT culture. I found that with the addition of GC 
there was a significant increase in the mRNA expression of 11β-HSD1. This is in keeping 
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with my in vivo findings. In addition to this I found a significant decrease in the expression 
Cox8b, NRF1 and TFAM following GC treatment. This was not shown in vivo, however this 
data did show a trend towards a decrease in expression. 
Overall these in vivo and in vitro experiments showed that following exposure to GC, 
there is a significant increase in the expression of 11β-HSD1, which would lead to the 
potential for further increases in active GC regeneration and further to this a decrease in the 
expression of BAT genes is seen which can be used to infer that GCs have a negative effect 
on BAT function. 
Inactive GCs can be reactivated at the pre-receptor level by the 11β-HSD1 enzyme, 
leading to an increase in the local availability of active GC (Seckl et al 2001). When 11β-
HSD1 is over expressed within adipose tissue there is development of full metabolic 
syndrome with visceral obesity, diabetes, dyslipidemia and hypertension (Masuzaki. H. 
2001). Conversely, mice that are deficient in 11β-HSD1 are insulin sensitised and resist the 
adverse effects of a high-fat diet, showing a cardio-protective phenotype. I therefore 
hypothesise that a GKO of 11β-HSD1 will be beneficial to BAT function; I tested the effects 
of 11β-HSD1 in vivo and in vitro. 
I found that within the young cohort there was no change in BAT weight/body weight 
ratio; however in the aged cohort I found a significant increase in BAT weight/body weight 
ratio in the GKO mice. This may be a combined genotype and ageing effect. Despite not 
reaching significance there is a trend towards an increase in BAT weight/body weight ratio in 
the young mice and this increase reaches significance in the aged mice, this therefore 
demonstrates that with a long-term decrease in reactivation of GCs via 11β-HSD1 there is a 
beneficial effect on BAT mass and with age this effect is able to reach significance. 
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I found significant increases in the expression of PGC-1α, PRDM16 and PPARγ in 
both the young and aged mice. In addition I found a significant increase in PGC-1α and 
PPARγ in the GKO primary culture. This is in agreement with my hypothesis that a decrease 
in local GC concentration achieved by the GKO of 11β-HSD1 would lead to an increase in 
BAT gene expression. 
Having seen the increase in expression of PRDM16 I would also expect the increase in 
PGC-1α to be partly as a consequence of this due to PRDM16 inducing its expression. 
PRDM16 also acts as a co regulator to activate PGC-1α and together they drive the molecular 
phenotype of brown fat cells (Seale et al 2007). Further PGC-1α is a positive regulator of 
mitochondrial biogenesis and respiration, adaptive thermogenesis, gluconeogenesis as well as 
many other metabolic processes, therefore an increase in its expression is positive for BAT 
function and may lead to a more desirable phenotype (Handschin and Spiegelman, et al 2006) 
(St-Pierre et al., 2003). In addition an increase in PRDM16 and PPARγ within the GKO aged 
mice could explain why there is an increase in BAT mass with the GKO, as both PRDM16 
and PPARγ contribute to increase in BAT differentiation and BAT mass (Murholm. M. 2009; 
Tzu-Ann et al 1996). Further an increase in expression of PRDM16 has been shown to offer 
protection from obesity due to an increase in energy expenditure, an increase in glucose 
tolerance, and more insulin sensitivity (Seale et al 2014; Montague et al 1998). 
I further investigated the effect of GKO by examining its effect on traditional markers 
of BAT. I found significant increases in the expression of CoxIV, Cox7a1, and Cox8b, at the 
mRNA level in the aged mice, and also a significant increase in UCP1 expression at the 
protein level within the aged cohort. In addition to this I found a significant increase in the 
expression of UCP1, Cox7a1 and Cox8b with GKO in the BAT primary culture experiments. 
I hypothesise that these increases in expression are due to the beneficial effects of decreasing 
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local GC availability in the GKO. In addition previous studies have shown that PGC-1α 
expression levels correlate with that of mitochondrial genes, notably those encoding various 
subunits of the electron transport chain, adaptive thermogenesis, and genes involved in 
oxidative phosphorylation (Leone et al 2005). Also PGC-1α can coactivate the 
PPARγ2/RXRa heterodimer to stimulate the UCP1 promoter (Tiraby et al 2003).     
I continued my studies by analysing differences with GKO on the expression of NRF1 
and TFAM which are involved in mitochondrial biogenesis. I hypothesise that there would be 
an increase in their expression with the GKO, firstly due to the GKO of 11β-HSD1 lowering 
the local GC level and also due to the increases in the genes I have already demonstrated. 
PGC-1α expression has been shown to increase the expression of the nuclear respiratory 
factors (NRFs), and also that PGC-1α increases the expression and acts as a coactivator for 
NRF1 to regulate the expression of mitochondrial transcription factor A, (TFAM), which is 
primarily responsible for the transcription and replication of mitochondrial genes from the 
mitochondrial genome (Wu et al., 1999). I found significant increases in both NRF1 and 
TFAM with GKO in the young mice, and NRF1 with GKO in the aged mice. In addition to 
this I found a significant increase in the expression of NRF1 in the GKO with the primary 
culture experiments. I again hypothesise that this is due to the decrease in GC regeneration in 
the GKO genotype. Both NRF1 and TFAM are involved in mitochondrial biogenesis and it 
can be assumed that an increase in these genes will lead to an increase in mitochondrial 
number and a possible increase in BAT thermogenic function. 
I found that there was a significant increase in mitochondria copy number with GKO 
in the aged mice, and significant increases in mitochondrial complexes 2 and 4 protein 
expression. This increase in mitochondrial copy number was expected due to the previous 
data I have generated showing increases in mitochondrial genes and also NRF1 which is 
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involved in mitochondrial biogenesis and have previously been shown to be positively 
correlated with mitochondrial copy number. I would have expected an increase in 
mitochondrial copy number with GKO in the young mice too; however this was not the case. 
This could be due to these mice being younger (10 weeks) and therefore the effect of the 
GKO has only had a limited amount of time to fully exert its effects on mitochondrial copy 
number within these mice. 
Overall I showed that with GKO of 11β-HSD1 there was an increase in markers of 
overall BAT function and also an increase in BAT mass. This is in keeping with previous 
studies that have shown that GCs are detrimental to BAT function and also that GKO of BAT 
leads to beneficial effects. I hypothesise that the increase in markers of BAT function in the 
GKO mice is due to the consequential decrease in local GC reactivation by the 11β-HSD1 
enzyme. This therefore points to a possible therapeutic role for the targeted disruption of the 
activity of 11β-HSD1 in ameliorating obesity and its metabolic complications. 
Having shown a beneficial effect of GKO of 11β-HSD1 on BAT function in young 
and aged mice, and also the detrimental effect of the addition of exogenous GC on BAT I 
decided to further investigate this by analysing the effect of GKO of 11β-HSD1 on mice 
treated with exogenous GC. This would allow for the mimicking of the effect of people 
treated with exogenous GC as a therapy, and investigate whether a disruption of the 11β-
HSD1 enzyme would be beneficial for patients being treated with exogenous GC. 
I found a significant increase in the mRNA expression of PRDM16, UCP1, Cox8b and 
CoxIV in GKO mice treated with corticosterone. The increase in expression of UCP1 in the 
GKOs will allow for a higher level of non-shivering thermogenesis to take place, and lead to a 
consequential decrease in obesity and metabolic complications, therefore giving the mice the 
potential for a healthier phenotype. The increase in expression of Cox8b and CoxIV show an 
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increase in members of the mitochondrial electron transport chain. Therefore there is an 
increase in the capacity for non-shivering thermogenesis, and it can be inferred from this that 
there is an increase in BAT function in GKO mice. 
I however found no change in the mRNA expression of PGC1α, PPARγ, Cox7a1 
NRF1 or TFAM or in the mitochondrial copy number with GKO following treatment with 
corticosterone. This could be due to the length of treatment with exogenous GC was not 
sufficient enough to cause a significant response. 
It is well established that excess GC and ageing have negative effects on BAT, 
however I have demonstrated that by knocking out 11β-HSD1 and therefore removing the 
local regeneration of active GC I can negate the negative effects of ageing and GCs on BAT. 
As shown in the figure below ageing leads to an increase in 11β-HSD1 expression and the 
consequential increase in active GC regeneration. This increase in active GC leads to negative 
effects on mitochondrial biogenesis, where there is a decrease in UCP1 expression, a decrease 
in mitochondrial gene expression, and a decrease in mitochondrial biogenesis and size. 
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Figure 4-26 Effect of age and chronic glucocorticoid exposure on BAT 
Ageing leads to an increase in 11β-HSD1 activity and a consequential increase in the 
potential for local reactivation of GC. An increase in active GC has negative effects on BAT 
where it impacts upon mitochondrial biogenesis. 
 
However I have demonstrated that knocking out 11β-HSD1 prevents this and my data even 
shows that with age there was a potential improvement in mitochondrial function, however 
this may be exacerbated by the chronic thermal stress the mice were housed in. Overall I have 
shown that 11β-HSD1 represents an exciting possible target for the prevention of GC and age 
induced negative effects on BAT function. Furthermore this opens up the potential of utilising 
BAT as a means to combat obesity. This is of particular importance for translation to humans. 
An increase in BAT mass has been linked with decreases in obesity and with the global 
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epidemic of obesity in humans on the rise it offers an exciting prospect to potential treatment 
of obesity within the human population. 
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5. Chapter 5 - 11β-hydroxysteroid dehydrogenase type 1 and white adipose tissue 
browning 
5.1 Introduction 
11β-HSD1 has been implicated in the pathogenesis of several human disorders including, 
obesity, insulin resistance and hyperglycaemia (Kannisto et al 2004; Baudrand et al 2010). 
11β-HSD1 is responsible for the intracellular regeneration of active GC, and up regulation of 
this activity within adipose appears to be a key contributor to central obesity and metabolic 
dysfunction (Morton et al 2008; Paulmyer-Lacroix et al 2002; Rask et al 2002).  
In addition to this the expression of 11β-HSD1 varies between different adipose 
tissues, there is higher 11β-HSD1 mRNA content in visceral compared to subcutaneous 
adipose depots (Paulmyer-Lacroix et al 2002; Bujalska at al 1997). This may lead to the 
accumulation of the more metabolically disadvantageous visceral adipose tissue, leading to a 
central obese phenotype (Paulmyer-Lacroix et al 2002). The effects of adipose-specific 11β-
HSD1 over-expression are seen more strongly within visceral depots due to higher GR 
concentrations (Morton et al 2004; Rebuffe-Scrive et al 1990). 
Mice deficient in 11β-HSD1 are insulin sensitised and resist the adverse metabolic 
effects of a high-fat diet, showing a cardio-protective phenotype, this has been demonstrated 
in various transgenic models. 11β-HSD1 knock-out mice show resistance to diet-induced 
visceral obesity and diabetes through improved insulin sensitivity (Wamil et al 2011) (Ataab 
et al 2010) (Morton et al 2004). This is due to a reduction in the synthesis and secretion of 
triglycerides and increasing fatty acid oxidation. In addition 11β-HSD1 GKO mice placed on 
a HFD accumulate fat at a higher rate in peripheral areas which are metabolically more 
desirable sites as visceral depots which are metabolically less safe (Morton et al 2004) 
(Wamil et al 2011). Overall a decrease in the level of adipose 11β-HSD1 aids in the 
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production of a protective metabolic phenotype, adding weight to its role as a therapeutic 
target. 
White adipose tissue (WAT) in mice is located predominantly within three areas; 
subcutaneous, mesenteric and gonadal. It functions to store energy in the form of triglycerides 
when there is energy excess, and releases fatty acids when there is an energy deficit, thus 
regulating whole body energy homeostasis. 
Studies have demonstrated that white adipocytes contain two types of cells; pure white 
adipocytes and brite cells. Brite cells have a more brown-like phenotype and have the ability 
to express UCP1, however do not otherwise possess the full molecular characteristics of 
brown adipocytes (Petrovic et al 2009; Guerra et al 1998; Seale et al 2008). These brite cells 
are induced following a given stimulus for example cold exposure, or β-adrenergic receptor 
agonists (Petrovic et al 2009). This has been demonstrated in mice and most recently within 
humans (Kolodny. G. M. et al. 2014). 
Cold-acclimatised pre adipocytes in WAT have slightly more pronounced brown 
characteristics often with large mitochondria (Barbatelli et al 2010). This demonstrates that 
brite cells have the capacity to switch between an energy storage and energy dissipation 
phenotype (Wu et al 2012). Further Young et al 1984 showed similar changes in brite cells 
following cold acclimatisation, and also that in mice maintained at standard animal house 
conditions (23°C) there was the existence of brown fat cells in traditional white fat cell pads 
due to chronic stimulation by cold exposure (Young 1984; Seale et al 2014). Within the 
subcutaneous adipose tissue there was significant expression of PRDM16, UCP1, Cidea, 
Cox8b and Elovl3, showing that under chronic cold exposure there is induction of a brown fat 
like gene programme within WAT (Seale et al 2014). This ability of cells within classical 
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WAT depots to express UCP1 has been recognised for 30 years as first demonstrated by 
Young et al in 1984. 
The white/brown plasticity of adipose tissues might have considerable medical 
implications, since the brown-like phenotype seems to correlate with a reduced propensity for 
developing obesity and diabetes in mice (Murano et al 2009; Bachman et al 2002). Further an 
increase in expression of PGC-1α in WAT may lead to an increase in UCP1 expression and an 
increase in oxidation of fatty acids (Tiraby et al 2003). Further Fisher et al 2012 have shown 
that there is an increase in brite cells within WAT in 11β-HSD1 GKO mice which 
demonstrate a resistance to obesity induced by diet and demonstrate an improvement in 
glucose metabolism. 
Given the data generated in Chapter 4 of this thesis I wanted to assess the impact of 11β-
HSD1 on the ability of WAT to assume a brown/ brite like phenotype, and hypothesise that 
increased exposure to GCs and the activity of 11β-HSD1 with age there will be an inhibitory 
effect. As is seen in BAT in chapter 4. On this basis I hypothesise that loss of 11β-HSD1 and 
the consequential decrease in tissue regeneration of GC there will be beneficial effects on 
WAT cells where they assume a brown phenotype and delay or prevent age associated 
negative effects.  
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5.2 Results 
5.2.1 Effect of ageing on white adipose tissue in vivo 
I wanted to investigate the effect of ageing on WAT. To do this I obtained tissue samples 
from young (10 weeks) and aged (100 weeks) cohorts, of both wild-type (WT) and 11β-HSD1 
global knock-out (GKO) male black 6 mice. I initially analysed the base line effect of ageing 
on these tissues by comparing WT young and aged tissues.  
Initially I analysed potential age related changes in 11β-HSD1 expression, as the 11β-
HSD1 enzyme has previously been shown to be a mediator of WAT function, where it led to 
an increase in WAT mass. I found that there was no change in 11β-HSD1 expression within 
gonadal adipose tissue with age (Figure 5-1). 
 
Figure 5-1 Effect of ageing on 11β-HSD1 mRNA expression in gonadal white adipose tissue 
Ageing lead to no change in the mRNA expression of 11β-HSD1in gonadal adipose.  Data 
was analysed using student T-test. n=11 (young) n=10 (aged). Error bars represent SEM.  
 
I wished to investigate if ageing had an effect on browning/ brite marker within WAT. I 
analysed changes in the expression of PGC-1α, PRDM16 and PPARγ with age. I found no 
significant changes in their expression levels in gonadal adipose tissue (Figure 5-2). Despite 
this I also examined potential age related changes in the expression of genes involved in the 
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mitochondrial electron transport chain. I analysed the expression of UCP1, Cox7a1, Cox8b. I 
found a significant increase in the mRNA expression of UCP1 (p<0.01) with age (Figure 6-2) 
in gonadal adipose tissue. 
 
Figure 5-2 Effect of ageing on PGC-1α, PRDM16, PPARγ, UCP1, Cox7a1 and Cox8b mRNA 
expression in gonadal white adipose tissue 
Ageing lead to no change in the mRNA expression of PGC-1α, PRDM16, PPARγ, Cox7a1, or 
Cox8b. Ageing lead to a significant increase in the mRNA expression of UCP1.Data was 
analysed using student T-test. n=11 (young) n=10 (aged). **p<0.01. Error bars represent 
SEM. 
 
5.2.1 Effect of temperature on white adipose tissue in vitro 
I hypothesised that the increase in expression of UCP1 seen within the aged cohort was a 
consequence of the temperature in which the mice were housed in which is below the level of 
thermoneutrality for mice. In order to test this I generated primary tissue cultures of WAT 
from wild-type mice all aged between 9 and 10 weeks. I analysed the effect of exposure of 
these primary cultures to decreased (25°C) temperatures for a four hour period. I performed 
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RT-PCR and 11β-HSD1 activity assays to measure potential changes in gene expression 
between cells maintained at 37°C and those at 25°C for 4 hours. 
I initially investigated potential effects of colder temperatures on the expression of 
11β-HSD1 within primary WAT culture. I found no change in the mRNA expression of 11β-
HSD1 with a decrease in temperature, and also no change in 11β-HSD1 activity (Figure 5-3).    
 
Figure 5-3 Effect of temperature change on 11β-HSD1 expression and activity in primary 
WAT culture in gonadal white adipose tissue 
A decrease in temperature led to no change in the mRNA expression or activity of 11β-HSD1. 
Primary cultures of both subcutaneous and gonadal adipose tissue maintained at 25°C had 
the same mRNA level and activity as primary cultures maintained at 37°C. Data was analysed 
using student T-test. n=3. Error bars represent SEM. 
 
I went on to investigate the effect of exposure to non-thermoneutral temperature on the 
expression of PGC-1α, PRDM16 and PPARγ with changing temperatures. I found a 
significant increase in the mRNA expression of PGC-1α (p<0.001), PRDM16 (p<0.05), and 
PPARγ (p<0.01) at 25°C in subcutaneous adipose primary culture. I also found a significant 
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increase in the mRNA expression of PGC-1α (p<0.05), and PRDM16 (p<0.01) at 25°C in 
gonadal adipose primary culture (Figure 5-4). 
 
 
Figure 5-4 Effect of temperature on the expression of PGC-1α, PRDM16, and PPARγ 
expression in gonadal white adipose tissue 
A decrease in temperature led to a significant increase in the mRNA of PGC-1α, PRDM16 
and PPARγ in subcutaneous primary adipose tissue culture, it also led to a significant 
increase in the mRNA expression of PGC-1α and PRDM16 in gonadal primary adipose tissue 
culture. There was no significant change in the mRNA expression of PPARγ following a 
decrease in temperature in the gonadal primary adipose tissue culture. Data was analysed 
using student T-test. n=3. *p<0.05, **p<0.01. Error bars represent SEM. 
 
 
I then went on to investigate if there were temperature related changes in the expression of 
brite related genes. I analysed the expression of UCP1, Cox7a1, and Cox8b. I found a 
significant increase in the mRNA expression of UCP1 (p<0.0001), Cox7a1 (p<0.05), and 
Cox8b (p<0.001) within the subcutaneous primary culture and also a significant increase in 
the mRNA expression of UCP1 (p<0.05), Cox7a1 (p<0.05) and Cox8b (p<0.01) in the 
gonadal adipose tissue (Figure 5-5). 
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Figure 5-5 Effect of temperature change on the expression of UCP1, Cox7a1, and Cox8b in 
gonadal  white adipose tissue 
A decrease in temperature led to a significant increase in the mRNA of UCP1, Cox7a1 and 
Cox8b in both subcutaneous and gonadal primary adipose tissue culture. Data was analysed 
using student T-test. n=3. *p<0.05, **p<0.01, ***p<0.001. Error bars represent SEM. 
 
5.2.2 Effect of glucocorticoid excess on white adipose tissue in vitro 
To examine the role of excess GC on WAT function I generated primary tissue cultures of 
mature adipocytes derived from subcutaneous and gonadal WAT from wild-type mice. I 
analysed the effect of exposure of these primary cultures to either GC treatment or vehicle and 
examined the expression of key markers and performed 11β-HSD1 activity assays,. 
I found that there was no change in the mRNA expression of 11β-HSD1 following GC 
addition in subcutaneous adipose primary cultures (Figure 5-6), however I found a significant 
increase in the mRNA expression of 11β-HSD1 within the gonadal adipose primary culture 
(p<0.05) (Figure 5-6). I further went on to see if there were changes in 11β-HSD1 activity 
with exposure to GC. I found no changes in 11β-HSD1 activity following administration of 
GC in either subcutaneous or gonadal primary cultures (Figure 5-6). 
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Figure 5-6 Effect of GC on 11β-HSD1 expression and activity in subcutaneous and gonadal 
adipose in gonadal white adipose tissue 
Exposure to excess GC led to no change in the mRNA expression of 11β-HSD1 in 
subcutaneous primary adipose tissue culture. There was no change in 11β-HSD1 activity 
following administration of exogenous GC in either subcutaneous or gonadal primary 
adipose tissue culture. Data was analysed using the students T-test. N=3. Error bars are 
representative of SEM. 
 
I went on to investigate the effect of exposure to GC on the expression of transcription 
factors. I analysed changes in the expression of PGC-1α, PRDM16 and PPARγ. I found a 
significant decrease in the mRNA expression of PRDM16 (p<0.05), and PPARγ (p<0.05) in 
the subcutaneous primary adipose culture (Figure 5-7). I also found a significant decrease in 
the mRNA expression of PRDM16 (p<0.05) in the gonadal primary adipose culture (Figure 5-
7).  
Chapter 5 - 11β-hydroxysteroid dehydrogenase type 1 and white adipose tissue browning 
 
150 
 
 
Figure 5-7 Effect of endogenous GC treatment on the expression of PGC-1α, PRDM16, and 
PPARγ in subcutaneous and gonadal white adipose tissue  
Exposure to excess GC led to significant decrease in the mRNA expression of PRDM16 and 
PPARγ in subcutaneous primary adipose tissue culture and PRDM16 in gonadal primary 
adipose tissue culture. Data was analysed using student T-test. n=3. *p<0.05. Error bars 
represent SEM. 
 
 
I then went on to see if there were GC related changes in the expression of UCP1, Cox7a1, 
and Cox8b. I found that there was a significant decrease in the mRNA expression of UCP1 
(p<0.05), Cox7a1 (p<0.05) and Coxb8 (p<0.05) following the addition of GC in the 
subcutaneous adipose primary cultures (Figure 5-8). I also found that there was a significant 
decrease in the mRNA expression of UCP1 (p<0.01), Cox7a1 (p<0.05) and Coxb8 (p<0.05) 
following the addition of GC in the gonadal adipose primary cultures (Figure 5-8). 
 
Figure 5-8 Effect of exogenous GC treatment on the expression of UCP1, Cox7a1 and Cox8b 
in subcutaneous and gonadal adipose tissue in white adipose tissue 
Exposure to excess GC led to a significant decrease in the mRNA expression of UCP1, 
Cox7a1 and Cox8b in subcutaneous and gonadal primary adipose tissue culture. Data was 
analysed using student T-test. n=3. *p<0.05, **p<0.01. Error bars represent SEM. 
Chapter 5 - 11β-hydroxysteroid dehydrogenase type 1 and white adipose tissue browning 
 
151 
 
5.2.3 Effect of 11β-HSD1 knock-out on white adipose tissue in vivo 
Previous work has highlighted the beneficial effects of 11β-HSD1 knock-out on WAT 
function and also conversely how an increase in 11β-HSD1 can be of detriment to WAT 
function. In addition my data demonstrated the negative effect of GC administration on WAT, 
therefore I hypothesised that GKO of 11βHSD1 would be beneficial to WAT function. This 
led us to analyse the potential beneficial effects of global knock-out of 11β-HSD1 on WAT 
browning/brite markers in subcutaneous tissue samples from young (10 weeks) and aged (100 
weeks) cohorts, of wild-type and 11β-HSD1 knock-out (GKO) genotypes. 
To do this I measured the expression of markers of browning. I began by performing 
RT-PCR analysis on mitochondrial transcription factors which are related to potential 
improvements in mitochondrial function. I analysed changes in the expression of PGC-1α, 
PRDM16 and PPARγ with age (Figure 5-9). I found no significant increase in the mRNA 
expression of PGC1α PRDM16 and PPARγ in the GKO mice in the young cohort, however I 
found a significant (p<0.05) increase in the mRNA expression of PRDM16 and PPARγ in the 
aged cohort following global GKO of 11β-HSD1 (Figure 5-9). 
 
Figure 5-9 Changes in mRNA of PGC-1α, PRDM16, and PPARγ between WT and GKO in 
young and aged cohorts in gonadal white adipose tissue 
11β-HSD1 knock-out led to a significant increase in PRDM16 and PPARγ mRNA expression 
in aged mice, but no significant change in the mRNA expression of PGC-1α within the aged 
mice. There was no significant change in the mRNA expression of PGC-1α, PRDM16 or 
PPARγ with GKO in the young mice. Data was analysed using student T-test. * P<0.05. n =5 
for WT young, n=9 for GKO young. N = 6 for WT aged, n =6 for GKO aged. Error bars 
represent SEM. 
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Due to the transcription factors being regulators of the expression of mitochondrial genes I 
then went on to see if there were changes in the expression of an array of mitochondrial 
structural genes. I analysed the expression of UCP1, Cox7a1, and Cox8b (figure 5-10). I 
found a significant increase in the mRNA expression of Cox8b (p<0.01) in the GKO of the 
young cohort, and a significant increase in the mRNA expression of Cox7a1 (p<0.01) and 
Cox8b (p<0.05) in the GKO of the aged cohort (Figure 5-10). 
 
Figure 5-10 Changes in mRNA of UCP1, Cox7a1, Cox8b, and CoxIV between WT and GKO 
in young and aged cohorts in gonadal white adipose tissue 
11β-HSD1 knock-out leads to a significant increase in Cox8b mRNA expression in young 
mice, and a significant increase in Cox7a1 and Cox8b mRNA expression in aged mice. There 
was no significant change in the mRNA expression of UCP1, or Cox7a1 with GKO in the 
young mice, and there was no significant change in the mRNA expression of UCP1 with KI in 
the aged mice. Data was analysed using student T-test. * P<0.05, *p<0.01. n =5 for WT 
young, n=9 for GKO young. N = 6 for WT aged, n =6 for GKO aged. Error bars represent 
SEM. 
5.2.4 Effect of 11β-HSD1 knock-out on white adipose tissue in vitro 
To further examine if 11β-HSD1 mediates the effect of the observed GC suppression of WAT 
browning markers I investigated primary white adipose tissue cultures from subcutaneous and 
gonadal WAT from both global knock-out 11β-HSD1 and wild-type mice. 
I investigated the effect of GKO on the expression of PGC-1α, PRDM16 and PPARγ. 
I found a significant increase in the mRNA expression of PGC-1α (p<0.01), PPARγ (p<0.05) 
in the primary subcutaneous culture (Figure 5-11). I also found a significant increase in the 
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mRNA expression of PGC-1α (p<0.05), PRDM16 (p<0.05), and PPARγ (p<0.05) in the 
primary gonadal culture (Figure 5-11). 
 
Figure 5-11 Effect of 11β-HSD1 knock-out on the expression of PGC-1α, PRDM16, and 
PPARγ in primary subcutaneous and gonadal adipose tissue in white adipose tissue 
Knock-out of 11β-HSD1 led to a significant increase in the mRNA expression of PGC-1α and 
PPARγ expression in subcutaneous primary adipose tissue culture, and a significant increase 
in PGC-1α, PRDM16, and PPARγ expression in gonadal primary adipose tissue culture. Data 
was analysed using student T-test. n=3. *p<0.05, **p<0.01. Error bars represent SEM. 
 
 
I then proceeded to test the effect of 11β-HSD1 knock-out on the mRNA expression of UCP1, 
Cox7a1, and Cox8b. I found that there was a significant increase in the mRNA expression of 
Cox8b (p<0.01) and UCP1 (p<0.01) in the subcutaneous primary culture with the GKO 
(figure 5-12). I also found that there was a significant increase in the mRNA expression of 
UCP1 (p<0.01) and Cox8b (p<0.05) in the gonadal primary culture, with the GKO (figure 5-
12). 
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Figure 5-12 Effect of 11β-HSD1 knock-out on the expression of UCP1, Cox7a1 and Cox8b in 
subcutaneous and gonadal primary culture in white adipose tissue 
Knock-out of 11β-HSD1 led to significant increase in UCP1 and Cox8b expression at in 
subcutaneous primary adipose tissue culture and a significant increase in UCP1 and Cox7a1 
expression at in gonadal primary adipose tissue culture. Data was analysed using student T-
test. n=3. *p<0.05, **p<0.01. Error bars represent SEM. 
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5.3 Discussion 
Age has a detrimental effect on WAT function due to substantial changes in fat tissue 
metabolic function. These include declines in insulin, lipolytic, and fatty acid responsiveness 
(Das et al., 2004). Ageing has previously been shown to lead to a redistribution of fat between 
different fat depots, especially during middle age where fat redistributes from subcutaneous to 
visceral adipose depots (Meunier et al 1971). Visceral adipose accumulation has been shown 
to increase the risk of cardiometabolic diseases, therefore prevention of this redistribution of 
adipose tissue with age is desirable (Wajchenberg et al 2000). 
I found that there was no change in the mRNA expression of 11β-HSD1 within 
gonadal WAT with age. Previous studies in pre and post-menopausal women have shown that 
there is an increase in 11β-HSD1 expression within WAT following the menopause 
(Andersson et al 2009), however it can not be said if these changes were menopause or ageing 
related. Due to there being no significant change in the mRNA expression of 11β-HSD1 with 
age it can be inferred that this would mean that there would be no alteration in the quantity of 
reactivated GC availability at the tissue level, as 11β-HSD1 is responsible for the tissue 
specific regeneration of active GC (Seckl et al 2001). This inference however is limited as 
often there is not a clear correlation between mRNA and protein expression and thus activity 
(Kendrick et al 2014). This is due to post-translational regulation, including co-factor binding, 
and phosphorylation. Despite this in other results where protein levels and 11β-HSD1 activity 
are measured alongside mRNA expression, there appears to be correlation. 
I proceeded to see if there were changes in transcriptional factors and mitochondrial 
component expression. I found that there was a significant increase in the mRNA expression 
of UCP1 with age; however I found no significant changes in the expression of the other 
genes screened, however I did see a trend towards their increase. This increase was 
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unexpected given results from previous studies as increases in the expression of these genes is 
related to improvements in function, which is contradictory to studies showing decreased 
function with age. 
UCP1 is the main protein involved in non-shivering thermogenesis, where it 
uncouples the electron transport chain from the production of ATP to the production of heat 
(Houstek et al 1978). Non-shivering thermogenesis is triggered by exposure to cold 
temperatures; this therefore implies that the increased production of UCP1 with age has been 
triggered by chronic cold exposure (Himms-Hagen et al 1984). The mice were kept in 
standard animal house conditions (22°C) which is below the standard thermoneutral 
temperatures for mice (37°C). I therefore hypothesise that the increase in expression in UCP1 
is cold driven. This increase in thermogenic genes following mice being housed in animal 
house conditions has been shown by Young et al, who also showed an increase in brite cells 
when mice were housed in standard animal conditions. This increase in non-shivering 
thermogenesis seen with age may be of benefit to the mouse due to following cold exposure 
there is mobilisation of fatty acids from WAT which may lead to weight loss and a healthier 
phenotype (Deiulis et al 2010). Previous studies by Nedergaard and Cannon et al 2013 have 
showed an induction of 100 fold increase in the expression of UCP1. This is far higher than 
the induction I observed however my increase still reached significance. Due to the induction 
of UCP1 expression still being <20% of those seen in classical BAT depots it has been 
questioned whether there is enough UCP1 present to mediate significant thermogenesis 
(Walden et al 2012; Nedergaard and Cannon et al 2013; Shabalina et al 2010). However 
Nedergaard et al have shown that the UCP1 within WAT is thermogenically functional 
however BAT would still predominate in thermogenesis. It can therefore be concluded that 
with a chronic lifetime exposure to below thermoneutral temperatures there is an increase in 
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themo-regulated gene expression, demonstrated here by the increase in mRNA expression of 
UCP1. 
To test my hypothesis that it is temperature which has caused the alteration in gene 
expression with age I generated primary cultures of WAT from both subcutaneous and 
gonadal adipose depots. I found no change in the 11β-HSD1 mRNA expression or 11β-HSD1 
oxo-reductase activity with changing temperatures. Therefore there would be no change in the 
intercellular regeneration of GC. I can therefore say that any changes seen in gene expression 
will be as a consequence of the temperature change.  
I investigated the effect of cold on the expression of brite markers within the WAT 
primary cultures. I found a significant increase in the mRNA expression of PGC-1α, 
PRDM16, PPARγ, UCP1, Cox7a1 and Cox8b with colder temperatures in the subcutaneous 
primary adipose line and a significant increase in the mRNA expression of PGC-1α, 
PRDM16, UCP1, Cox7a1 and Cox8b with colder temperatures in the gonadal primary 
adipose line, therefore showing a more brown like phenotype following cold exposure. This is 
in keeping with previous studies which have shown an increase in the expression of 
thermogenic genes, mitochondrial genes, and transcriptional regulators following cold 
exposure (Wu et al 2012; Barbatelli et al 2010; Walden et al 2012). In addition this change 
has been shown to be more striking within subcutaneous as opposed to visceral adipose which 
is what I showed (Barbatelli et al 2010; Lee et al 2012). This increase in thermogenic and 
mitochondrial genes is linked with an increase in the incidence of brite adipocytes within the 
WAT (Barbatelli et al 2010). A process which is termed browning. These increases in mRNA 
expression following cold exposure confirm my hypothesis that it was the chronic cold 
exposure which triggered the increase in UCP1 in the aged mice. 
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Certain genes are influential in the development of brite adipocytes. Firstly PRDM16 
has been shown to be key in the differentiation of most brite genes including UCP1, Cox8b, 
and PPARγ (Seale et al 2014). I have demonstrated an increase in expression of PRDM16 and 
also its previously demonstrated target genes. In addition PPARγ has been shown to allow 
preadipocyte cultures to acquire brown–like characteristics (Petrovic et al 2010; Seale et al 
2007), this activation is achieved along with PGC-1α which coactivates the PPARγ2/RXRa 
heterodimer to stimulate brown adipocyte markers including UCP1 (Tiraby et al 2003). In 
addition PPARγ has been shown to induce the expression of UCP1 and also stimulate 
mitochondrial biogenesis and uncoupled cellular respiration (Seale et al 2007). 
Therefore this potential increase in the expression of brite cells seen following cold 
exposure may have considerable medical implications as the brown-like phenotype 
demonstrated in my studies correlates with a reduced propensity for the development of 
obesity and diabetes in mice (Murano et al 2009; Bachman et al 2002). Further Tsukiyama-
Kohora et al 2001 have shown that when there is an increase in brite cells within WAT there 
is resistance to diet induced obesity and improved glucose metabolism. These results 
following cold stimulation within primary cultures is in agreement with my hypothesis that 
the effect I saw with ageing on the expression of UCP1 and other genes is due to a chronic 
lifetime exposure to cold temperatures within an animal house setting. The increases in 
mRNA I observed from the primary culture studies are far more striking than those I found 
with my ageing study. This may be due to the cold exposure that was experienced by the 
primary cultures was more intense than that experienced by the mice, and also that the mice 
within the animal house are often group housed with bedding which can allow them access to 
additional heat other than the ambient temperature of the animal house. Further this study 
exposes WAT directly to cold stimulus, however when this study is converted to look at 
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potential in vivo effects it may be argued that the effects of cold would not be as great, as the 
WAT within an in vivo model would not be directly exposed and therefore may not be 
exposed to the same degree of cold, and as a consequence the dramatic effects seen within this 
study may not be fully converted. However a study by Huttunen et al demonstrated an 
increase in BAT in outdoor workers which was hypothesised to be an effect of cold exposure. 
Further to ageing and temperature another factor that effects WAT is GCs. GCs can be 
reactivated at the pre-receptor level by 11β-HSD1 (Seckl et al 2001), leading to an increase in 
the local availability of active GC. GCs have also been shown to suppress thermogenesis 
(Walker et al 1992). Studies have shown that an increase in 11β-HSD1 activity WAT leads to 
the development of MS with visceral obesity, diabetes, dyslipidemia and hypertension 
(Masuzaki et al 2001).I tested the effects of exogenous GC administration on primary cultures 
of WAT and also the effect of GKO of 11β-HSD1 on WAT primary culture and WAT.  
Following exogenous GC administration I found no change in the expression of 11β-
HSD1 and also no change in 11β-HSD1 activity in subcutaneous adipose tissue. This is 
contradictory to previous studies which have shown that GC increases the expression of 11β-
HSD1 (Low et al 1994), however there was a significant increase in the mRNA expression of 
11β-HSD1 in gonadal adipose tissue following GC treatment. If the GC had been left on the 
primary culture for a longer period of time the change may have reached significance in 
subcutaneous adipose. 
I went on to test the effect of GC administration on genetic markers. I found a 
significant decrease in the mRNA expression of PGC-1α, PPARγ, PRDM16, UCP1, Cox7a1 
and Cox8b within the subcutaneous primary culture. In addition I found a significant decrease 
in the mRNA expression of PRDM16, PPARγ, UCP1, Cox7a1 and Cox8b within the gonadal 
primary culture. These results clearly demonstrate the negative effect GCs have on WAT and 
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how they decrease the amount of browning within the WAT and lead to a stronger WAT 
phenotype. This has the potential to be detrimental to the mice as it leads to a decrease in the 
degree of browning, and therefore changes the WAT from an energy expending to an energy 
storing depot. 
To try to counteract the negative effects of GC on WAT I have tested the effect of 
GKO of 11β-HSD1 in both subcutaneous and gonadal adipose tissue. I found a significant 
increase in the mRNA expression of Cox8b within the young cohort and a significant increase 
in the expression of PRDM16, PPARγ, Cox7a1 and Cox8b within the aged cohort. The 
increase in significance seen within the aged cohort compared to the young cohort may be due 
to the increased amount of time that these mice were exposed to a decrease in local GC 
regeneration and therefore the GKO of 11β-HSD1 had a longer time to exert significant 
effects on the WAT.  
I increased my study into the effects of GKO of 11β-HSD1 by generating primary 
WAT cultures of subcutaneous and gonadal adipose tissue of both WT and GKO genotype. 
Within the subcutaneous primary adipose tissue culture I found a significant increase in the 
mRNA expression of PGC-1α PPARγ, UCP1 and Cox8b within the GKOs. Within the 
gonadal primary adipose tissue culture I found a significant increase in the mRNA expression 
of PGC-1α, PRDM16, PPARγ, UCP1 and Cox7a1 within the GKOs. This increase in gene 
expression with GKO suggests an increase in browning.  
Previous studies have shown the benefit of 11β-HSD1 GKO on WAT where they have 
demonstrated resistance to diet induced visceral obesity and diabetes through improved liver 
and adipose function. In addition over expression of 11β-HSD1 within adipose tissue has been 
shown to lead to obesity, dyslipidemia and insulin resistance (Masuzaki et al 2001). In 
addition, the brown like phenotype I have demonstrated with GKO of 11β-HSD1 has been 
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shown to correlate with reduced propensity for developing obesity and diabetes in mice 
(Murano et al 2009) (Bachman et al 2002). These results demonstrate an increased degree of 
browning seen with GKO of 11β-HSD1 and that manipulation of 11β-HSD1 is a potential 
therapeutic target for a myriad of diseases. 
Overall I have demonstrated that cold exposure leads to an increase of browning of WAT 
which could confer a beneficial phenotype. In addition to this I have investigated the effect of 
GKO of 11β-HSD1 and the consequential decrease in local regeneration of active GC. I have 
demonstrated that following GKO there is an improved genetic profile which implies a more 
brown like phenotype. The potential increase in brite seen following GKO and cold exposure 
has potential in combating a myriad of diseases. Therefore 11β-HSD1 represents a promising 
therapeutic target. 
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6. Chapter 6 - Conclusions and further studies 
6.1 Adipose specific knock-out of 11β-hydroxysteroid dehydrogenase type 1 
When in excess GCs have been shown to lead to the development of Cushing’s syndrome, 
metabolic syndrome and type 2 diabetes (Fardet. L. 2007). In addition GCs can also be 
regenerated at the tissue specific level by 11β-HSD1 (Koteleytsev et al 1997). Animal models 
incorporating a GKO of 11β-HSD1 have shown protection from glucose intolerance, 
hyperinsulinemia, hepatic steotosis, adiposity, hypertension, myopathy, and Cushing’s 
syndrome (Morton. N. M 2001). In contrast to this over expression of 11β-HSD1 has been 
shown to lead to weight gain (predominantly visceral), dyslipidemia, hyperglycaemia, 
hypertension and insulin resistance (Masuzaki. H. 2003). Further increased 11β-HSD1 
activity selectively in adipose tissue results in the development of full metabolic syndrome 
with visceral obesity, diabetes adyslipidemia and hypertension (Masuzaki. H. 2001). Together 
these data suggest that adipose 11β-HSD1 plays a key role in the development of the adverse 
metabolic profile of GC excess, leading to the potential for adipose 11β-HSD1 inhibition as a 
potential treatment for Cushing’s syndrome and metabolic complications within humans. 
I showed that GKO of 11β-HSD1 conferred a protective phenotype following GC 
excess and I wished to attempt to elucidate the tissue responsible for this effect. I generated a 
novel mouse model which contained an adipose-specific deletion of 11β-HSD1 (FKO) 
utilising cre flox technology. The KO was confirmed using DNA, RNA and 11β-HSD1 oxo-
reductase activity assays. 
I wished to test my model to see if it had protective effects against exposure to excess 
GC. This is due to GC being widely prescribed in medical practice, and this leads to many 
adverse effects and long term GC therapy can lead to suppression of the HPA axis (Krasner et 
al 1999), insulin resistance (Lansang et al 2011) and diabetes (Lansang et al 2011) within 
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humans. This effect of GCs is amplified by 11β-HSD1 which regulates intracellular GC 
metabolism at the pre-receptor level (Rabbitt et al 2002), via its oxo-reductase activity 
increasing intracellular GC levels by converting circulating inert GC to active GC (Tomlinson 
et al 2001; Napolitano et al 1998). Further recent data in our lab has shown that global KO of 
11β-HSD1 leads to improved glucose tolerance, insulin sensitivity, and improved systolic 
blood pressure.  
With my adipose specific knock-out of 11β-HSD1 I showed that these mice were not 
protected from adiposity, decreased lean body mass, glucose intolerance, hyperimsulinemia or 
reduced grip strength following CORT treatment. This therefore highlights the role played by 
11β-HSD1 within other tissues. The tissues where 11β-HSD1 is most highly abundant are 
adipose, liver, kidney and lung. These tissues are therefore the primary suspects in 
contributing to the effects of GC excess still shown in my FKO model which are protected 
from in the GKO model. I hypothesise that the 11β-HSD1 present in these tissues reactivates 
GC to levels significant enough to ameliorate the proactive effect of 11β-HSD1 KO in 
adipose. Further the reactivated GC may be able to travel to other tissues apart from those 
where it is reactivated and therefore exert its effects more widely. This may consequently 
mean that tissue specific KO of 11β-HSD1 may not be sufficient to ameliorate all of the side 
effects of GC excess and it may prove necessary to KO 11β-HSD1 globally in order to fully 
achieve protection. 
However these mice were protected from hepatic TAG accumulation, increased serum 
free fatty acids, hepatic steotosis and increased adipose expression of hormone sensitive lipase 
(HSL), adipose triglyceride lipase (ATGL), liver X receptor a (LXRa), and liver X receptor b 
(LXRb). These effects were not seen in the LKO mice which suggests that increased 
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intracellular GC availability within adipose tissue as opposed to the liver is central to the 
beneficial effects seen in the GKO. 
This demonstrates the protective role adipose specific KO of 11β-HSD1 has on the 
liver by protecting from hepatic TAG accumulation and hepatic steotosis. Further it implies 
that the KO of 11β-HSD1 specifically within adipose tissue has a central role in the regulation 
of energy stores, as HSL and ATGL are involved in the breakdown of triglycerides (Kershaw 
et al 2006; Zimmermann et al 2004).In addition adipose specific KO of 11β-HSD1 confers 
protection by preventing an increase in expression of LXRa or LXRb which breakdown stored 
triglycerides, and as a consequence increase free fatty acid levels. However adipose specific 
knock-out of 11β-HSD1 does not recapitulate the full beneficial profile demonstrated 
following global KO of 11β-HSD1 and therefore this highlights the role of other tissue in this 
process. 
This study highlights the contributory effect of excess GC on the development of MS 
and its related disorders, and offers a potential therapy in the form of 11β-HSD1 inhibition. 
There are currently a wide range of 11β-HSD1 inhibitors including BVT.2733 which lead to a 
decreased the level of cortisol generated in the liver and adipose tissue, and decrease tissue-
specific gluconeogenesis and fatty acid metabolism (Harno et al 2010; Liu et al 2013). 
There is however a need for selectivity of these inhibitors in order to remove the 
negative effects linked with non-selective binding to 11β-HSD2, leading to over activation of 
MRs, thus causing  hypokalemia and hypernatremia, which in turn would lead to hypertension 
(Lepsin et al 2011). 
The further development of specific 11β-HSD1 inhibitors offers a novel therapeutic 
for the treatment of GC excess within man and a potential counteractive to the negative 
effects on health of prescribed GCs. 
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6.1.1 Further studies 
In order to elucidate the tissues responsible for the full list of beneficial effects seen with 
global KO of β-HSD1, further studies could include the generation of other tissue specific 
KOs of 11β-HSD1 and a repeat of the tests conducted here to produce a full document of 
individual tissue contributions to the beneficial phenotype conferred with global KO of 11β-
HSD1. Further, additional gene expression studies could be conducted to within the adipose 
tissue to clarify consistency between the models. 
6.1.2 Limitations of the study 
I showed that there was protection in both the global and adipose-tissue specific knock-out for 
liver fat accumulation, steatosis, and serum NEFA level. I hypothesise that the protection 
from increased lipolytic gene expression in adipose tissue explains some of the protective 
effects observed for the adipose tissue specific knock-out, however I did not conduct similar 
gene expression studies within the adipose tissue (or liver for CD36) of the global knock-out 
which would serve to clarify if this is genuine consistency between models. In order to add 
further weight to my conclusions this study would prove beneficial. 
6.2 Effect of 11β-hydroxysteroid dehydrogenase type 1 activity on brown adipose tissue 
BAT is the main site for adaptive thermogenesis and responds to fluctuations in 
environmental factors, for example cold and diet, by increasing energy expenditure through 
thermogenesis. Following exposure to cold BAT uses lipids and carbohydrates to generate 
heat by using UCP1 to uncouple electron transport from oxidative phosphorylation, thus 
playing an active role in energy expenditure and fatty acid oxidation (Cannon. B. 2008).  
With its role in energy expenditure BAT has a central role in the regulation body fat 
stores and may have potential in opposing obesity and diabetes within humans due to its vast 
metabolic capacity (Enerback. S. 2010), further evidence to support this is that mice deficient 
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in BAT develop obesity with insulin resistance and other metabolic abnormalities typical of 
obesity (Lowell. B. B. 1993; Hamann. A. 1995). However many factors have a negative 
impact on BAT, two main players are GCs and ageing, where increased GC exposure and 
increased ageing lead to a decrease in BAT function. Age is strongly negatively correlated 
with BAT mass, and the metabolic effect of BAT, by comparing its relationship to BMI, 
decreases with age (Tam et al 2012). Ageing also affects BAT tissue where there is a decrease 
in BAT over time and this may contribute to thermal dysregulation and energy imbalance 
(Heaton et al, 1972; Cypress et al 2009). The effect of GC is further increased via the 11β-
HSD1 enzyme, which converts inactive cortisone to active cortisol. Increasing age has been 
shown to have negative effects on BAT and may contribute to thermal dysregulation and 
energy imbalance. Increasing age shows a strongly negative correlation with BAT mass and 
BAT’s metabolic effect, further there is a higher incidence in the increase of BAT following 
cold exposure in a young rather than an aged cohort (Pfannenberg et al; Saito et al 2009). 
I initially tested the effect of age on BAT and showed that with ageing there is as 
significant increase in BAT weight/body weigh ratio, mRNA expression of 11β-HSD1, 
PRDM16, PPARγ, UCP1, Cox7a1, Cox8b, NRF1 and TFAM, the protein expression of 
UCP1, mitochondrial copy number and the protein expression of mitochondrial electron 
transport chain complex 4. These increases in markers of BAT function are contradictory to 
previous studies that have shown ageing to have a negative effect on BAT function 
(Pfannenberg et al 2010). However I conclude that these increases are a consequence of 
animal conditions (22°C) which are lower than thermoneutral temperatures for the mouse 
(37°C). This has previously been highlighted by Golozoubova et al 2004. I therefore conclude 
that the constant thermal stress incurred from animal house conditions severely effects the 
Chapter 6 - Conclusions and further studies 
 
167 
 
animals BAT development and function and leads to an increased capacity for non-shivering 
thermogenesis.  
In addition I investigated the role of GC on BAT I did this by exposing BAT primary 
culture to GC and also by testing the effect of GKO of 11β-HSD1 on BAT genetic markers. 
GCs have previously been shown to play a crucial role in adipocyte biology, where they are 
central to the differentiation of pre-adipocytes to mature adipocytes (Hauner. H. 1987). In 
addition previous studies have shown that GCs suppress BAT thermogenesis, and that UCP1 
expression negatively correlates with GC concentration (Soumano. K. 2000). Further to this 
when 11β-HSD1 is over expressed within adipose tissue there is development of full 
metabolic syndrome with visceral obesity, diabetes, dyslipidemia and hypertension 
(Masuzaki. H. 2001). Conversely, mice that are deficient in 11β-HSD1 are insulin sensitised 
and resist the adverse effects of a high-fat diet, showing a cardio-protective phenotype. I 
therefore hypothesise that a GKO of 11β-HSD1 will be beneficial to BAT function. To test 
this I measured the effects of KO of 11β-HSD1 on various markers of BAT function. 
I found that with 11β-HSD1 GKO there is a significant increase in the mRNA 
expression of PGC-1α, PRDM16, PPARγ, UCP1, Cox7a1, Cox8b, CoxIV, and NRF1 a 
significant increase in the protein expression of UCP1, a significant increase in mitochondrial 
copy number and a significant increase in the protein expression of mitochondrial electron 
transport chain complexes 2 and 4 with GKO in aged mice. I also found a significant increase 
in the mRNA expression of PGC-1α, PRDM16, PPARγ, UCP1, Cox7a1, Cox8b, and NRF1 in 
KO with BAT primary culture following GKO. Therefore overall I found that with GKO of 
11β-HSD1 there is an increase in markers of overall BAT function. This is in keeping with 
previous studies that have shown that GCs are detrimental to BAT function and also that 
GKO of 11β-HSD1 leads to beneficial effects. I hypothesise that the increase in markers of 
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BAT function in the GKO mice is due to the consequential decrease in local GC reactivation 
by the 11β-HSD1 enzyme. This therefore points to a possible therapeutic role for the targeted 
disruption of the activity of 11β-HSD1 in ameliorating obesity and its metabolic 
complications. 
Further to this I analysed the effect of exogenous GC administration on BAT. This is 
of primary importance for the conversion of the study into humans as it attempts to mimic the 
effect of GC treatment within humans. I found that there was a significant increase in 11β-
HSD1 expression following GC administration which would lead to an increased capacity for 
reactivation of GC at the tissue specific level. I further found that there was a significant 
decrease in mRNA expression of UCP1 in the BAT tissue of mice treated with exogenous 
GC. This was mirrored in the primary BAT culture experiments which showed a significant 
decrease in the mRNA expression of UCP1 following treatment with exogenous GC. In 
addition to this there was a significant decrease in the mRNA expression of Cox8b, NRF1 and 
TFAM in primary BAT culture following treatment with exogenous GC. Overall utilising in 
vivo and in vitro experiments I showed that following exposure to GC, there is a negative 
effect on BAT function which is further exacerbated by the significant increase in the 
expression of 11β-HSD1, which would lead to the potential for further increases in active GC 
regeneration and further to this a decrease in the expression of BAT genes. This can be 
inferred to show that with exposure to exogenous GCs there is a decrease in BAT function 
and therefore highlights GCs as a negative effector on BAT. 
These studies clearly demonstrate the negative effect of GC on BAT and that a GKO 
of 11β-HSD1 has a positive effect on BAT. Due to BAT being linked to a decrease in obesity 
it would be beneficial to have increased concentrations of BAT within the body. Therefore a 
potential 11β-HSD1 targeted inhibitor (discussed above) which would lead to a decrease in 
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the local reactivation of GC could offer a therapeutic. Having a potential target for the 
prevention of obesity is of huge current importance due to the global rise in obesity and its 
related complications. 
6.2.1 Further studies 
To further investigate this area I could perform tests on mitochondrial function. This could be 
performed using Seahorse technology where the oxygen consumption rate is measured. This 
would be beneficial as I have currently demonstrated that there is an increase in mitochondrial 
copy number and mRNA expression of gene, however have not tested how well these 
mitochondria are functioning. By performing mitochondrial function tests it would allow us to 
say whether the interventions are truly of benefit to the adipose tissue function. In addition to 
this I could perform lipid quantification studies on the adipose tissue tested to see if the 
structure/content of the tissue has been improved. In addition to this I could expand my cold 
stress studies on the cell culture models by performing experiments at an array of differing 
temperatures and for differing durations in order to ascertain the optimum cold exposure for 
BAT function. In addition to this I could perform histological studies to see if the structure of 
the BAT is altered by the changing temperature. This could allow us to see if there is an 
increase in mitochondrial number and mitochondrial size. Further I could investigate if long 
term exposure to cold prevent the age associated negative effects on BAT structure. 
6.2.2 Limitations of the study 
The mice used within this study were all housed within standard animal house conditions 
which are below thermoneutral conditions. This places a background cold stress on the mice 
which may impact on the results. In order to combat these experiments could be repeated at 
thermoneutral temperatures.  In addition to this a large chunk of the data is centred on mRNA 
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measurements, which do not necessary mirror protein expression or activity. Further studies 
could be conducted to address this as discussed earlier with Seahorse technology. 
 
6.3 Effect of 11β-hydroxysteroid dehydrogenase type 1 activity on white adipose tissue 
11β-HSD1 is responsible for the intracellular regeneration of active GC, and up regulation of 
this activity within adipose appears to be a key contributor to central obesity and metabolic 
dysfunction in both men and women (Morton. N. M. 2008; Paulmyer-Lacroix. O. 2002; Rask. 
E. 2002). This is further emphasised by studies on mice which are deficient in 11β-HSD1 
where these mice are insulin sensitised and resist the adverse metabolic effects of a high-fat 
diet, showing a cardio-protective phenotype (Wamil. M. 2011; Ataab. C. A. 2010) and 
diabetes through improved insulin sensitivity (Morton. N. M. 2004). 
Studies have demonstrated that white adipocytes contain two types of cells; pure white 
adipocytes and brite cells. Brite cells have a more brown-like phenotype and have the ability 
to express UCP1, however otherwise do not posses the full molecular characteristics of brown 
adipocytes (Petrovic. N. 2009). These brite cells are induced following a given stimulus for 
example cold exposure, or β-adrenergic receptor agonists (Petrovic. N. 2009). 
The white/brown plasticity of adipose tissues might have considerable medical 
implications, since the brown-like phenotype seems to correlate with a reduced propensity for 
developing obesity and diabetes in mice (Bachman. E. S. 2002). Further an increase in 
expression of PGC-1α within WAT may lead to the induction of the expression of UCP1 and 
the oxidation of fatty acids, which together result in a reduction in adipose mass (Tiraby. C. 
2003). Further Tsukiyama-Kohora et al 2001 have shown that there is an increase in brite 
cells within WAT in GKO strains that show resistance to diet induced obesity and improved 
glucose metabolism. 
Chapter 6 - Conclusions and further studies 
 
171 
 
I showed that with age there is a significant increase in the mRNA expression of 
UCP1, I hypothesised that this increase in UCP1 with age is a consequence of the non-
thermoneutral temperatures in which the mice were housed. This would lead to activation of 
non-shivering thermogenesis (Himms-Hagen. J. 1984) and a consequential increase in UCP1 
quantity as previously demonstrated by Young et al. This increase in non-shivering 
thermogenesis seen with age may be of benefit to the mouse due to the mobilisation of fatty 
acids from WAT which may lead to weight loss and a healthier phenotype (Deiulis. J. A. 
2010). I hypothesise that this increase in UCP1 represents and increase in the quantity of brite 
cells present. 
This increase in the expression of brite cells seen following cold exposure may have 
considerable medical implications as the brown-like phenotype demonstrated in my studies 
correlates with a reduced propensity for the development of obesity and diabetes in mice 
(Murano et al 2009; Bachman et al 2002). Further Tsukiyama-Kohora et al 2001 have shown 
that with an increase in brite cells within the WAT there is resistance to diet induced obesity 
and improved glucose metabolism.  
Another effector on adipose are GCs. GCs can be reactivated at the pre-receptor level 
by the 11β-HSD1 enzyme, leading to an increase in the local availability of active GC. (Seckl 
et al 2001) I tested the effects of exogenous GC administration to primary cultures of WAT 
and also the effect of GKO of 11β-HSD1 on WAT primary culture and WAT.  
I found a significant decrease in the mRNA expression of PPARγ, PRDM16, UCP1, 
Cox7a1 and Cox8b within the subcutaneous and gonadal primary culture. These results 
clearly demonstrate the negative effect GCs have on WAT and how they decrease the amount 
of browning within the WAT and lead to a stronger WAT phenotype. This has the potential to 
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be detrimental to the mice as it leads to a decrease in the degree of browning, and therefore 
changes the WAT from an energy expending to an energy storing depot. 
To try to counteract the negative effects of GC on WAT I have tested the effect of 
GKO of 11β-HSD1 in both WAT and subcutaneous and gonadal primary adipose tissue 
culture. Within the WAT I found a significant increase in the expression of PRDM16, 
PPARγ, Cox7a1 and Cox8b with GKO. In addition I found a significant increase in the 
mRNA expression of PGC-1α PPARγ, and UCP1 within the KOs in both subcutaneous and 
gonadal primary cultures. This increase in gene expression with GKO suggests that there is an 
increase in browning within the GKO cohort. Previous studies have shown the benefit of 11β-
HSD1 GKO on WAT where they have resistance to diet induced visceral obesity and diabetes 
through improved liver and adipose function. In addition over expression of 11β-HSD1 within 
adipose tissue has been shown to lead to obesity, dyslipidemia and insulin resistance 
(Masuzaki et al 2001). In addition the brown like phenotype I have demonstrated with GKO 
of 11β-HSD1 has been shown to correlate with reduced propensity for developing obesity and 
diabetes in mice (Murano et al 2009; Bachman et al 2002). 
Overall I showed that an excess of GC has negative effects on WAT and that GKO of 
11β-HSD1 and the consequential decrease in local reactivation of GC protects against these 
negative effects of excess GC. This therefore points the possible role of 11β-HSD1 in the 
treatment and prevention of disorders related to GC excess. 
These studies mirror those seen previously clearly demonstrating the negative effect of 
GC and that a GKO of 11β-HSD1 has a positive effect. Therefore a potential 11β-HSD1 
targeted inhibitor (discussed above) which would lead to a decrease in the local reactivation 
of GC could offer a therapeutic. Further to this if the effects seen with the decrease in 
temperatures could be replicated within humans by potentially stimulating the same pathways 
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artificially this could be of huge benefit to treat obesity and its associated complications by 
increasing brite cells and as seen above, BAT cells. 
6.3.1 Further studies 
I could expand this work by testing mitochondrial function. This could be performed using 
Seahorse technology where the oxygen consumption rate is measured. This would be 
beneficial as it would allow us to measure how well the adipose tissue is functioning. By 
performing mitochondrial function tests it would allow us to say whether the interventions are 
truly of benefit to the adipose tissue function. In addition to this I could perform lipid 
quantification studies on the adipose tissue tested to see if the structure/content of the tissue 
has been improved. In addition to this I could expand my cold stress studies on the cell culture 
models by performing experiments at an array of differing temperatures and for differing 
durations in order to ascertain the optimum cold exposure for WAT. In addition to this I could 
perform histological studies to see if the structure of the WAT is altered by the changing 
temperature. In addition I could expand my study to differing WAT depots to investigate if 
there are differing levels of effects in different WAT depots. 
 Further studies could also include investigating the pathways which are stimulated 
following the cold exposure and investigate whether these pathways could be stimulated 
artificially. 
6.3.2 Limitations of study 
As highlighted within the discussion there is an inference that 11β-HSD1 activity correlates 
with mRNA expression, and therefore no change in mRNA expression is assumed to reflect 
no change in 11β-HSD1. This assumption may be incorrect as often there is no true 
correlation between mRNA expression and activity. To improve this study and add further 
weight to the results further studies measuring protein concentration and 11β-HSD1 activity 
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would be beneficial. Further the mice studied were all housed within standard animal house 
conditions which are below thermoneutral conditions. This induces a cold stress on the mice 
which may affect the results. To assess the affect of this the experiments could be repeated at 
thermoneutral temperatures.   
A further limitation to this study is that temperature changes in a cell culture model were used 
to infer the in vivo effects of a decrease in temperature. Within an in vivo model the cold 
temperature would not have direct access to the adipose tissue and therefore potentially would 
not be cooled to the extreme as what is seen in the study. This would lead to potentially 
exaggerated results in our model as to what would be seen in vivo. This limitation leads to 
potential further studies examining the effects of a decrease in temperature on an in vivo 
model in an attempt to reproduce the effects demonstrated in this study. 
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